#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder
#Text=Dopamine type 2 and type 3 receptors (D2R/D3R) appear critical to addictive disorders.
1-1	0-8	Regional	_
1-2	9-12	and	_
1-3	13-25	source-based	_
1-4	26-34	patterns	_
1-5	35-37	of	_
1-6	38-39	[	_
1-7	39-42	11C	_
1-8	42-43	]	_
1-9	43-44	-	_
1-10	44-45	(	_
1-11	45-46	+	_
1-12	46-47	)	_
1-13	47-48	-	_
1-14	48-52	PHNO	_
1-15	53-60	binding	_
1-16	61-70	potential	_
1-17	71-77	reveal	_
1-18	78-88	concurrent	_
1-19	89-100	alterations	_
1-20	101-103	in	_
1-21	104-112	dopamine	_
1-22	113-115	D2	_
1-23	116-119	and	_
1-24	120-122	D3	_
1-25	123-131	receptor	_
1-26	132-144	availability	_
1-27	145-147	in	_
1-28	148-159	cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]
1-29	160-168	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]
1-30	169-177	Dopamine	_
1-31	178-182	type	_
1-32	183-184	2	_
1-33	185-188	and	_
1-34	189-193	type	_
1-35	194-195	3	_
1-36	196-205	receptors	_
1-37	206-207	(	_
1-38	207-210	D2R	_
1-39	210-211	/	_
1-40	211-214	D3R	_
1-41	214-215	)	_
1-42	216-222	appear	_
1-43	223-231	critical	_
1-44	232-234	to	_
1-45	235-244	addictive	_
1-46	245-254	disorders	_
1-47	254-255	.	_

#Text=Cocaine-use disorder (CUD) is associated with lower D2R availability and greater D3R availability in regions primarily expressing D2R or D3R concentrations, respectively.
2-1	256-267	Cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
2-2	268-276	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
2-3	277-278	(	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
2-4	278-281	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
2-5	281-282	)	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]
2-6	283-285	is	_
2-7	286-296	associated	_
2-8	297-301	with	_
2-9	302-307	lower	_
2-10	308-311	D2R	_
2-11	312-324	availability	_
2-12	325-328	and	_
2-13	329-336	greater	_
2-14	337-340	D3R	_
2-15	341-353	availability	_
2-16	354-356	in	_
2-17	357-364	regions	_
2-18	365-374	primarily	_
2-19	375-385	expressing	_
2-20	386-389	D2R	_
2-21	390-392	or	_
2-22	393-396	D3R	_
2-23	397-411	concentrations	_
2-24	411-412	,	_
2-25	413-425	respectively	_
2-26	425-426	.	_

#Text=However, these CUD-related alterations in D2R and D3R have not been concurrently detected using available dopaminergic radioligands.
3-1	427-434	However	_
3-2	434-435	,	_
3-3	436-441	these	_
3-4	442-453	CUD-related	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
3-5	454-465	alterations	_
3-6	466-468	in	_
3-7	469-472	D2R	_
3-8	473-476	and	_
3-9	477-480	D3R	_
3-10	481-485	have	_
3-11	486-489	not	_
3-12	490-494	been	_
3-13	495-507	concurrently	_
3-14	508-516	detected	_
3-15	517-522	using	_
3-16	523-532	available	_
3-17	533-545	dopaminergic	_
3-18	546-558	radioligands	_
3-19	558-559	.	_

#Text=Furthermore, receptor availability in regions of mixed D2R/D3R concentration in CUD remains unclear.
4-1	560-571	Furthermore	_
4-2	571-572	,	_
4-3	573-581	receptor	_
4-4	582-594	availability	_
4-5	595-597	in	_
4-6	598-605	regions	_
4-7	606-608	of	_
4-8	609-614	mixed	_
4-9	615-618	D2R	_
4-10	618-619	/	_
4-11	619-622	D3R	_
4-12	623-636	concentration	_
4-13	637-639	in	_
4-14	640-643	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-15	644-651	remains	_
4-16	652-659	unclear	_
4-17	659-660	.	_

#Text=The current study aimed to extend investigations of CUD-related alterations in D2R and D3R availability using regional and source-based analyses of [11C]-(+)-PHNO positron emission tomography (PET) of 26 individuals with CUD and 26 matched healthy comparison (HC) participants.
5-1	661-664	The	_
5-2	665-672	current	_
5-3	673-678	study	_
5-4	679-684	aimed	_
5-5	685-687	to	_
5-6	688-694	extend	_
5-7	695-709	investigations	_
5-8	710-712	of	_
5-9	713-724	CUD-related	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
5-10	725-736	alterations	_
5-11	737-739	in	_
5-12	740-743	D2R	_
5-13	744-747	and	_
5-14	748-751	D3R	_
5-15	752-764	availability	_
5-16	765-770	using	_
5-17	771-779	regional	_
5-18	780-783	and	_
5-19	784-796	source-based	_
5-20	797-805	analyses	_
5-21	806-808	of	_
5-22	809-810	[	_
5-23	810-813	11C	_
5-24	813-814	]	_
5-25	814-815	-	_
5-26	815-816	(	_
5-27	816-817	+	_
5-28	817-818	)	_
5-29	818-819	-	_
5-30	819-823	PHNO	_
5-31	824-832	positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[3]
5-32	833-841	emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[3]
5-33	842-852	tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[3]
5-34	853-854	(	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[3]
5-35	854-857	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[3]
5-36	857-858	)	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[3]
5-37	859-861	of	_
5-38	862-864	26	_
5-39	865-876	individuals	_
5-40	877-881	with	_
5-41	882-885	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
5-42	886-889	and	_
5-43	890-892	26	_
5-44	893-900	matched	_
5-45	901-908	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
5-46	909-919	comparison	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
5-47	920-921	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
5-48	921-923	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
5-49	923-924	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
5-50	925-937	participants	_
5-51	937-938	.	_

#Text=Regional analysis detected greater binding potential (BPND) in CUD in the midbrain, consistent with prior [11C]-(+)-PHNO research, and lower BPND in CUD in the dorsal striatum, consistent with research using non-selective D2R/D3R radiotracers.
6-1	939-947	Regional	_
6-2	948-956	analysis	_
6-3	957-965	detected	_
6-4	966-973	greater	_
6-5	974-981	binding	_
6-6	982-991	potential	_
6-7	992-993	(	_
6-8	993-997	BPND	_
6-9	997-998	)	_
6-10	999-1001	in	_
6-11	1002-1005	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
6-12	1006-1008	in	_
6-13	1009-1012	the	_
6-14	1013-1021	midbrain	_
6-15	1021-1022	,	_
6-16	1023-1033	consistent	_
6-17	1034-1038	with	_
6-18	1039-1044	prior	_
6-19	1045-1046	[	_
6-20	1046-1049	11C	_
6-21	1049-1050	]	_
6-22	1050-1051	-	_
6-23	1051-1052	(	_
6-24	1052-1053	+	_
6-25	1053-1054	)	_
6-26	1054-1055	-	_
6-27	1055-1059	PHNO	_
6-28	1060-1068	research	_
6-29	1068-1069	,	_
6-30	1070-1073	and	_
6-31	1074-1079	lower	_
6-32	1080-1084	BPND	_
6-33	1085-1087	in	_
6-34	1088-1091	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
6-35	1092-1094	in	_
6-36	1095-1098	the	_
6-37	1099-1105	dorsal	_
6-38	1106-1114	striatum	_
6-39	1114-1115	,	_
6-40	1116-1126	consistent	_
6-41	1127-1131	with	_
6-42	1132-1140	research	_
6-43	1141-1146	using	_
6-44	1147-1160	non-selective	_
6-45	1161-1164	D2R	_
6-46	1164-1165	/	_
6-47	1165-1168	D3R	_
6-48	1169-1181	radiotracers	_
6-49	1181-1182	.	_

#Text=Exploratory independent component analysis (ICA) identified three sources of BPND (striatopallidal, pallidonigral, and mesoaccumbens sources) that represent systems of brain regions displaying coherent variation in receptor availability.
7-1	1183-1194	Exploratory	_
7-2	1195-1206	independent	_
7-3	1207-1216	component	_
7-4	1217-1225	analysis	_
7-5	1226-1227	(	_
7-6	1227-1230	ICA	_
7-7	1230-1231	)	_
7-8	1232-1242	identified	_
7-9	1243-1248	three	_
7-10	1249-1256	sources	_
7-11	1257-1259	of	_
7-12	1260-1264	BPND	_
7-13	1265-1266	(	_
7-14	1266-1281	striatopallidal	_
7-15	1281-1282	,	_
7-16	1283-1296	pallidonigral	_
7-17	1296-1297	,	_
7-18	1298-1301	and	_
7-19	1302-1315	mesoaccumbens	_
7-20	1316-1323	sources	_
7-21	1323-1324	)	_
7-22	1325-1329	that	_
7-23	1330-1339	represent	_
7-24	1340-1347	systems	_
7-25	1348-1350	of	_
7-26	1351-1356	brain	_
7-27	1357-1364	regions	_
7-28	1365-1375	displaying	_
7-29	1376-1384	coherent	_
7-30	1385-1394	variation	_
7-31	1395-1397	in	_
7-32	1398-1406	receptor	_
7-33	1407-1419	availability	_
7-34	1419-1420	.	_

#Text=The striatopallidal source was associated with estimates of regional D2R-related proportions of BPND (calculated using independent reports of [11C]-(+)-PHNO receptor binding fractions), was lower in intensity in CUD and negatively associated with years of cocaine use.
8-1	1421-1424	The	_
8-2	1425-1440	striatopallidal	_
8-3	1441-1447	source	_
8-4	1448-1451	was	_
8-5	1452-1462	associated	_
8-6	1463-1467	with	_
8-7	1468-1477	estimates	_
8-8	1478-1480	of	_
8-9	1481-1489	regional	_
8-10	1490-1501	D2R-related	_
8-11	1502-1513	proportions	_
8-12	1514-1516	of	_
8-13	1517-1521	BPND	_
8-14	1522-1523	(	_
8-15	1523-1533	calculated	_
8-16	1534-1539	using	_
8-17	1540-1551	independent	_
8-18	1552-1559	reports	_
8-19	1560-1562	of	_
8-20	1563-1564	[	_
8-21	1564-1567	11C	_
8-22	1567-1568	]	_
8-23	1568-1569	-	_
8-24	1569-1570	(	_
8-25	1570-1571	+	_
8-26	1571-1572	)	_
8-27	1572-1573	-	_
8-28	1573-1577	PHNO	_
8-29	1578-1586	receptor	_
8-30	1587-1594	binding	_
8-31	1595-1604	fractions	_
8-32	1604-1605	)	_
8-33	1605-1606	,	_
8-34	1607-1610	was	_
8-35	1611-1616	lower	_
8-36	1617-1619	in	_
8-37	1620-1629	intensity	_
8-38	1630-1632	in	_
8-39	1633-1636	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
8-40	1637-1640	and	_
8-41	1641-1651	negatively	_
8-42	1652-1662	associated	_
8-43	1663-1667	with	_
8-44	1668-1673	years	_
8-45	1674-1676	of	_
8-46	1677-1684	cocaine	_
8-47	1685-1688	use	_
8-48	1688-1689	.	_

#Text=By comparison, the pallidonigral source was associated with estimates of regional D3R distribution, was greater in intensity in CUD and positively associated with years of cocaine use.
9-1	1690-1692	By	_
9-2	1693-1703	comparison	_
9-3	1703-1704	,	_
9-4	1705-1708	the	_
9-5	1709-1722	pallidonigral	_
9-6	1723-1729	source	_
9-7	1730-1733	was	_
9-8	1734-1744	associated	_
9-9	1745-1749	with	_
9-10	1750-1759	estimates	_
9-11	1760-1762	of	_
9-12	1763-1771	regional	_
9-13	1772-1775	D3R	_
9-14	1776-1788	distribution	_
9-15	1788-1789	,	_
9-16	1790-1793	was	_
9-17	1794-1801	greater	_
9-18	1802-1804	in	_
9-19	1805-1814	intensity	_
9-20	1815-1817	in	_
9-21	1818-1821	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
9-22	1822-1825	and	_
9-23	1826-1836	positively	_
9-24	1837-1847	associated	_
9-25	1848-1852	with	_
9-26	1853-1858	years	_
9-27	1859-1861	of	_
9-28	1862-1869	cocaine	_
9-29	1870-1873	use	_
9-30	1873-1874	.	_

#Text=The current study extends previous D2R/D3R research in CUD, demonstrating both lower BPND in the D2R-rich dorsal striatum and greater BPND in the D3R-rich midbrain using a single radiotracer.
10-1	1875-1878	The	_
10-2	1879-1886	current	_
10-3	1887-1892	study	_
10-4	1893-1900	extends	_
10-5	1901-1909	previous	_
10-6	1910-1913	D2R	_
10-7	1913-1914	/	_
10-8	1914-1917	D3R	_
10-9	1918-1926	research	_
10-10	1927-1929	in	_
10-11	1930-1933	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
10-12	1933-1934	,	_
10-13	1935-1948	demonstrating	_
10-14	1949-1953	both	_
10-15	1954-1959	lower	_
10-16	1960-1964	BPND	_
10-17	1965-1967	in	_
10-18	1968-1971	the	_
10-19	1972-1980	D2R-rich	_
10-20	1981-1987	dorsal	_
10-21	1988-1996	striatum	_
10-22	1997-2000	and	_
10-23	2001-2008	greater	_
10-24	2009-2013	BPND	_
10-25	2014-2016	in	_
10-26	2017-2020	the	_
10-27	2021-2029	D3R-rich	_
10-28	2030-2038	midbrain	_
10-29	2039-2044	using	_
10-30	2045-2046	a	_
10-31	2047-2053	single	_
10-32	2054-2065	radiotracer	_
10-33	2065-2066	.	_

#Text=In addition, exploratory ICA identified sources of [11C]-(+)-PHNO BPND that were correlated with regional estimates of D2R-related and D3R-related proportions of BPND, were consistent with regional differences in CUD, and suggest receptor alterations in CUD may also be present in regions of mixed D2R/D3R concentration.
#Text=1.
11-1	2067-2069	In	_
11-2	2070-2078	addition	_
11-3	2078-2079	,	_
11-4	2080-2091	exploratory	_
11-5	2092-2095	ICA	_
11-6	2096-2106	identified	_
11-7	2107-2114	sources	_
11-8	2115-2117	of	_
11-9	2118-2119	[	_
11-10	2119-2122	11C	_
11-11	2122-2123	]	_
11-12	2123-2124	-	_
11-13	2124-2125	(	_
11-14	2125-2126	+	_
11-15	2126-2127	)	_
11-16	2127-2128	-	_
11-17	2128-2132	PHNO	_
11-18	2133-2137	BPND	_
11-19	2138-2142	that	_
11-20	2143-2147	were	_
11-21	2148-2158	correlated	_
11-22	2159-2163	with	_
11-23	2164-2172	regional	_
11-24	2173-2182	estimates	_
11-25	2183-2185	of	_
11-26	2186-2197	D2R-related	_
11-27	2198-2201	and	_
11-28	2202-2213	D3R-related	_
11-29	2214-2225	proportions	_
11-30	2226-2228	of	_
11-31	2229-2233	BPND	_
11-32	2233-2234	,	_
11-33	2235-2239	were	_
11-34	2240-2250	consistent	_
11-35	2251-2255	with	_
11-36	2256-2264	regional	_
11-37	2265-2276	differences	_
11-38	2277-2279	in	_
11-39	2280-2283	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-40	2283-2284	,	_
11-41	2285-2288	and	_
11-42	2289-2296	suggest	_
11-43	2297-2305	receptor	_
11-44	2306-2317	alterations	_
11-45	2318-2320	in	_
11-46	2321-2324	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
11-47	2325-2328	may	_
11-48	2329-2333	also	_
11-49	2334-2336	be	_
11-50	2337-2344	present	_
11-51	2345-2347	in	_
11-52	2348-2355	regions	_
11-53	2356-2358	of	_
11-54	2359-2364	mixed	_
11-55	2365-2368	D2R	_
11-56	2368-2369	/	_
11-57	2369-2372	D3R	_
11-58	2373-2386	concentration	_
11-59	2386-2387	.	_
11-60	2388-2389	1	_
11-61	2389-2390	.	_

#Text=Introduction
#Text=Individuals with cocaine-use disorder (CUD) exhibit alterations in subcortical dopamine including alterations in receptor availability, blunted dopamine release and reduced dopamine transport mechanisms.
12-1	2391-2403	Introduction	_
12-2	2404-2415	Individuals	_
12-3	2416-2420	with	_
12-4	2421-2432	cocaine-use	_
12-5	2433-2441	disorder	_
12-6	2442-2443	(	_
12-7	2443-2446	CUD	_
12-8	2446-2447	)	_
12-9	2448-2455	exhibit	_
12-10	2456-2467	alterations	_
12-11	2468-2470	in	_
12-12	2471-2482	subcortical	_
12-13	2483-2491	dopamine	_
12-14	2492-2501	including	_
12-15	2502-2513	alterations	_
12-16	2514-2516	in	_
12-17	2517-2525	receptor	_
12-18	2526-2538	availability	_
12-19	2538-2539	,	_
12-20	2540-2547	blunted	_
12-21	2548-2556	dopamine	_
12-22	2557-2564	release	_
12-23	2565-2568	and	_
12-24	2569-2576	reduced	_
12-25	2577-2585	dopamine	_
12-26	2586-2595	transport	_
12-27	2596-2606	mechanisms	_
12-28	2606-2607	.	_

#Text=However, dopaminergic pharmacotherapies for stimulant-related addictions have displayed limited efficacy to date (see), thus a greater understanding of dopamine-related alterations in CUD may improve targeted interventions for addictions.
13-1	2608-2615	However	_
13-2	2615-2616	,	_
13-3	2617-2629	dopaminergic	_
13-4	2630-2647	pharmacotherapies	_
13-5	2648-2651	for	_
13-6	2652-2669	stimulant-related	_
13-7	2670-2680	addictions	_
13-8	2681-2685	have	_
13-9	2686-2695	displayed	_
13-10	2696-2703	limited	_
13-11	2704-2712	efficacy	_
13-12	2713-2715	to	_
13-13	2716-2720	date	_
13-14	2721-2722	(	_
13-15	2722-2725	see	_
13-16	2725-2726	)	_
13-17	2726-2727	,	_
13-18	2728-2732	thus	_
13-19	2733-2734	a	_
13-20	2735-2742	greater	_
13-21	2743-2756	understanding	_
13-22	2757-2759	of	_
13-23	2760-2776	dopamine-related	_
13-24	2777-2788	alterations	_
13-25	2789-2791	in	_
13-26	2792-2795	CUD	_
13-27	2796-2799	may	_
13-28	2800-2807	improve	_
13-29	2808-2816	targeted	_
13-30	2817-2830	interventions	_
13-31	2831-2834	for	_
13-32	2835-2845	addictions	_
13-33	2845-2846	.	_

#Text=Alterations in dopamine type-2 and type-3 receptors (D2R/D3R) are associated with CUD and other substance-use disorders, suggesting related neurobiological mechanisms that may hold potential as targets in treating addictions.
14-1	2847-2858	Alterations	_
14-2	2859-2861	in	_
14-3	2862-2870	dopamine	_
14-4	2871-2875	type	_
14-5	2875-2876	-	_
14-6	2876-2877	2	_
14-7	2878-2881	and	_
14-8	2882-2886	type	_
14-9	2886-2887	-	_
14-10	2887-2888	3	_
14-11	2889-2898	receptors	_
14-12	2899-2900	(	_
14-13	2900-2903	D2R	_
14-14	2903-2904	/	_
14-15	2904-2907	D3R	_
14-16	2907-2908	)	_
14-17	2909-2912	are	_
14-18	2913-2923	associated	_
14-19	2924-2928	with	_
14-20	2929-2932	CUD	_
14-21	2933-2936	and	_
14-22	2937-2942	other	_
14-23	2943-2956	substance-use	_
14-24	2957-2966	disorders	_
14-25	2966-2967	,	_
14-26	2968-2978	suggesting	_
14-27	2979-2986	related	_
14-28	2987-3002	neurobiological	_
14-29	3003-3013	mechanisms	_
14-30	3014-3018	that	_
14-31	3019-3022	may	_
14-32	3023-3027	hold	_
14-33	3028-3037	potential	_
14-34	3038-3040	as	_
14-35	3041-3048	targets	_
14-36	3049-3051	in	_
14-37	3052-3060	treating	_
14-38	3061-3071	addictions	_
14-39	3071-3072	.	_

#Text=Specifically, D2Rs and D3Rs are implicated in the habitual and compulsive behaviors associated with the persistence of chronic drug use and relapse.
15-1	3073-3085	Specifically	_
15-2	3085-3086	,	_
15-3	3087-3091	D2Rs	_
15-4	3092-3095	and	_
15-5	3096-3100	D3Rs	_
15-6	3101-3104	are	_
15-7	3105-3115	implicated	_
15-8	3116-3118	in	_
15-9	3119-3122	the	_
15-10	3123-3131	habitual	_
15-11	3132-3135	and	_
15-12	3136-3146	compulsive	_
15-13	3147-3156	behaviors	_
15-14	3157-3167	associated	_
15-15	3168-3172	with	_
15-16	3173-3176	the	_
15-17	3177-3188	persistence	_
15-18	3189-3191	of	_
15-19	3192-3199	chronic	_
15-20	3200-3204	drug	_
15-21	3205-3208	use	_
15-22	3209-3212	and	_
15-23	3213-3220	relapse	_
15-24	3220-3221	.	_

#Text=Animal models demonstrate functional dissociation of D2R and D3R systems, suggesting these dopamine receptor subtypes may provide distinct contributions to addictive processes.
16-1	3222-3228	Animal	_
16-2	3229-3235	models	_
16-3	3236-3247	demonstrate	_
16-4	3248-3258	functional	_
16-5	3259-3271	dissociation	_
16-6	3272-3274	of	_
16-7	3275-3278	D2R	_
16-8	3279-3282	and	_
16-9	3283-3286	D3R	_
16-10	3287-3294	systems	_
16-11	3294-3295	,	_
16-12	3296-3306	suggesting	_
16-13	3307-3312	these	_
16-14	3313-3321	dopamine	_
16-15	3322-3330	receptor	_
16-16	3331-3339	subtypes	_
16-17	3340-3343	may	_
16-18	3344-3351	provide	_
16-19	3352-3360	distinct	_
16-20	3361-3374	contributions	_
16-21	3375-3377	to	_
16-22	3378-3387	addictive	_
16-23	3388-3397	processes	_
16-24	3397-3398	.	_

#Text=Research using dopamine-antagonist radioligands with equal affinities for D2R and D3Rs (e.g., [11C]raclopride) indicate lower receptor availability in D2R-rich striatal regions of individuals with CUD.
17-1	3399-3407	Research	_
17-2	3408-3413	using	_
17-3	3414-3433	dopamine-antagonist	_
17-4	3434-3446	radioligands	_
17-5	3447-3451	with	_
17-6	3452-3457	equal	_
17-7	3458-3468	affinities	_
17-8	3469-3472	for	_
17-9	3473-3476	D2R	_
17-10	3477-3480	and	_
17-11	3481-3485	D3Rs	_
17-12	3486-3487	(	_
17-13	3487-3490	e.g	_
17-14	3490-3491	.	_
17-15	3491-3492	,	_
17-16	3493-3494	[	_
17-17	3494-3497	11C	_
17-18	3497-3498	]	_
17-19	3498-3508	raclopride	_
17-20	3508-3509	)	_
17-21	3510-3518	indicate	_
17-22	3519-3524	lower	_
17-23	3525-3533	receptor	_
17-24	3534-3546	availability	_
17-25	3547-3549	in	_
17-26	3550-3558	D2R-rich	_
17-27	3559-3567	striatal	_
17-28	3568-3575	regions	_
17-29	3576-3578	of	_
17-30	3579-3590	individuals	_
17-31	3591-3595	with	_
17-32	3596-3599	CUD	_
17-33	3599-3600	.	_

#Text=By comparison, research using the D3R-preferring dopamine-agonist radioligand [11C]-(+)-PHNO in CUD and stimulant addiction indicate increased receptor availability in the D3R-rich midbrain.
18-1	3601-3603	By	_
18-2	3604-3614	comparison	_
18-3	3614-3615	,	_
18-4	3616-3624	research	_
18-5	3625-3630	using	_
18-6	3631-3634	the	_
18-7	3635-3649	D3R-preferring	_
18-8	3650-3666	dopamine-agonist	_
18-9	3667-3678	radioligand	_
18-10	3679-3680	[	_
18-11	3680-3683	11C	_
18-12	3683-3684	]	_
18-13	3684-3685	-	_
18-14	3685-3686	(	_
18-15	3686-3687	+	_
18-16	3687-3688	)	_
18-17	3688-3689	-	_
18-18	3689-3693	PHNO	_
18-19	3694-3696	in	_
18-20	3697-3700	CUD	_
18-21	3701-3704	and	_
18-22	3705-3714	stimulant	_
18-23	3715-3724	addiction	_
18-24	3725-3733	indicate	_
18-25	3734-3743	increased	_
18-26	3744-3752	receptor	_
18-27	3753-3765	availability	_
18-28	3766-3768	in	_
18-29	3769-3772	the	_
18-30	3773-3781	D3R-rich	_
18-31	3782-3790	midbrain	_
18-32	3790-3791	.	_

#Text=These concurrently upregulated and downregulated dopamine systems in CUD may undermine dopaminergic therapies for cocaine addiction.
19-1	3792-3797	These	_
19-2	3798-3810	concurrently	_
19-3	3811-3822	upregulated	_
19-4	3823-3826	and	_
19-5	3827-3840	downregulated	_
19-6	3841-3849	dopamine	_
19-7	3850-3857	systems	_
19-8	3858-3860	in	_
19-9	3861-3864	CUD	_
19-10	3865-3868	may	_
19-11	3869-3878	undermine	_
19-12	3879-3891	dopaminergic	_
19-13	3892-3901	therapies	_
19-14	3902-3905	for	_
19-15	3906-3913	cocaine	_
19-16	3914-3923	addiction	_
19-17	3923-3924	.	_

#Text=Adding to this complexity, D2R and D3R are both expressed in structures central to addiction (e.g., midbrain, ventral striatum, pallidum), and assessing potential alterations of specific receptor subtypes in these regions is challenging.
20-1	3925-3931	Adding	_
20-2	3932-3934	to	_
20-3	3935-3939	this	_
20-4	3940-3950	complexity	_
20-5	3950-3951	,	_
20-6	3952-3955	D2R	_
20-7	3956-3959	and	_
20-8	3960-3963	D3R	_
20-9	3964-3967	are	_
20-10	3968-3972	both	_
20-11	3973-3982	expressed	_
20-12	3983-3985	in	_
20-13	3986-3996	structures	_
20-14	3997-4004	central	_
20-15	4005-4007	to	_
20-16	4008-4017	addiction	_
20-17	4018-4019	(	_
20-18	4019-4022	e.g	_
20-19	4022-4023	.	_
20-20	4023-4024	,	_
20-21	4025-4033	midbrain	_
20-22	4033-4034	,	_
20-23	4035-4042	ventral	_
20-24	4043-4051	striatum	_
20-25	4051-4052	,	_
20-26	4053-4061	pallidum	_
20-27	4061-4062	)	_
20-28	4062-4063	,	_
20-29	4064-4067	and	_
20-30	4068-4077	assessing	_
20-31	4078-4087	potential	_
20-32	4088-4099	alterations	_
20-33	4100-4102	of	_
20-34	4103-4111	specific	_
20-35	4112-4120	receptor	_
20-36	4121-4129	subtypes	_
20-37	4130-4132	in	_
20-38	4133-4138	these	_
20-39	4139-4146	regions	_
20-40	4147-4149	is	_
20-41	4150-4161	challenging	_
20-42	4161-4162	.	_

#Text=Regional binding of [11C]-(+)-PHNO reflects local concentrations of both D2Rs and D3Rs, allowing for simultaneous imaging of D2R/D3R not possible using other D2-like receptor radioligands.
21-1	4163-4171	Regional	_
21-2	4172-4179	binding	_
21-3	4180-4182	of	_
21-4	4183-4184	[	_
21-5	4184-4187	11C	_
21-6	4187-4188	]	_
21-7	4188-4189	-	_
21-8	4189-4190	(	_
21-9	4190-4191	+	_
21-10	4191-4192	)	_
21-11	4192-4193	-	_
21-12	4193-4197	PHNO	_
21-13	4198-4206	reflects	_
21-14	4207-4212	local	_
21-15	4213-4227	concentrations	_
21-16	4228-4230	of	_
21-17	4231-4235	both	_
21-18	4236-4240	D2Rs	_
21-19	4241-4244	and	_
21-20	4245-4249	D3Rs	_
21-21	4249-4250	,	_
21-22	4251-4259	allowing	_
21-23	4260-4263	for	_
21-24	4264-4276	simultaneous	_
21-25	4277-4284	imaging	_
21-26	4285-4287	of	_
21-27	4288-4291	D2R	_
21-28	4291-4292	/	_
21-29	4292-4295	D3R	_
21-30	4296-4299	not	_
21-31	4300-4308	possible	_
21-32	4309-4314	using	_
21-33	4315-4320	other	_
21-34	4321-4323	D2	_
21-35	4323-4324	-	_
21-36	4324-4328	like	_
21-37	4329-4337	receptor	_
21-38	4338-4350	radioligands	_
21-39	4350-4351	.	_

#Text=To date however, [11C]-(+)-PHNO research of CUD has not replicated findings of lower receptor availability in the D2R-rich dorsal striatum, or detected alterations in mixed-D2R/D3R regions.
22-1	4352-4354	To	_
22-2	4355-4359	date	_
22-3	4360-4367	however	_
22-4	4367-4368	,	_
22-5	4369-4370	[	_
22-6	4370-4373	11C	_
22-7	4373-4374	]	_
22-8	4374-4375	-	_
22-9	4375-4376	(	_
22-10	4376-4377	+	_
22-11	4377-4378	)	_
22-12	4378-4379	-	_
22-13	4379-4383	PHNO	_
22-14	4384-4392	research	_
22-15	4393-4395	of	_
22-16	4396-4399	CUD	_
22-17	4400-4403	has	_
22-18	4404-4407	not	_
22-19	4408-4418	replicated	_
22-20	4419-4427	findings	_
22-21	4428-4430	of	_
22-22	4431-4436	lower	_
22-23	4437-4445	receptor	_
22-24	4446-4458	availability	_
22-25	4459-4461	in	_
22-26	4462-4465	the	_
22-27	4466-4474	D2R-rich	_
22-28	4475-4481	dorsal	_
22-29	4482-4490	striatum	_
22-30	4490-4491	,	_
22-31	4492-4494	or	_
22-32	4495-4503	detected	_
22-33	4504-4515	alterations	_
22-34	4516-4518	in	_
22-35	4519-4528	mixed-D2R	_
22-36	4528-4529	/	_
22-37	4529-4532	D3R	_
22-38	4533-4540	regions	_
22-39	4540-4541	.	_

#Text=However, these results of non-altered D2R-like availability in the striatum in CUD are consistent with research using alternative dopamine-agonist radioligands with equal affinities for D2R/D3R (e.g., [11C]NPA).
23-1	4542-4549	However	_
23-2	4549-4550	,	_
23-3	4551-4556	these	_
23-4	4557-4564	results	_
23-5	4565-4567	of	_
23-6	4568-4579	non-altered	_
23-7	4580-4588	D2R-like	_
23-8	4589-4601	availability	_
23-9	4602-4604	in	_
23-10	4605-4608	the	_
23-11	4609-4617	striatum	_
23-12	4618-4620	in	_
23-13	4621-4624	CUD	_
23-14	4625-4628	are	_
23-15	4629-4639	consistent	_
23-16	4640-4644	with	_
23-17	4645-4653	research	_
23-18	4654-4659	using	_
23-19	4660-4671	alternative	_
23-20	4672-4688	dopamine-agonist	_
23-21	4689-4701	radioligands	_
23-22	4702-4706	with	_
23-23	4707-4712	equal	_
23-24	4713-4723	affinities	_
23-25	4724-4727	for	_
23-26	4728-4731	D2R	_
23-27	4731-4732	/	_
23-28	4732-4735	D3R	_
23-29	4736-4737	(	_
23-30	4737-4740	e.g	_
23-31	4740-4741	.	_
23-32	4741-4742	,	_
23-33	4743-4744	[	_
23-34	4744-4747	11C	_
23-35	4747-4748	]	_
23-36	4748-4751	NPA	_
23-37	4751-4752	)	_
23-38	4752-4753	.	_

#Text=The current study aimed to further examine D2R and D3R alterations in the midbrain, striatum and other subcortical structures (e.g., globus pallidus, ventral pallidum and hypothalamus) in CUD using [11C]-(+)-PHNO positron emission tomography (PET) imaging.
24-1	4754-4757	The	_
24-2	4758-4765	current	_
24-3	4766-4771	study	_
24-4	4772-4777	aimed	_
24-5	4778-4780	to	_
24-6	4781-4788	further	_
24-7	4789-4796	examine	_
24-8	4797-4800	D2R	_
24-9	4801-4804	and	_
24-10	4805-4808	D3R	_
24-11	4809-4820	alterations	_
24-12	4821-4823	in	_
24-13	4824-4827	the	_
24-14	4828-4836	midbrain	_
24-15	4836-4837	,	_
24-16	4838-4846	striatum	_
24-17	4847-4850	and	_
24-18	4851-4856	other	_
24-19	4857-4868	subcortical	_
24-20	4869-4879	structures	_
24-21	4880-4881	(	_
24-22	4881-4884	e.g	_
24-23	4884-4885	.	_
24-24	4885-4886	,	_
24-25	4887-4893	globus	_
24-26	4894-4902	pallidus	_
24-27	4902-4903	,	_
24-28	4904-4911	ventral	_
24-29	4912-4920	pallidum	_
24-30	4921-4924	and	_
24-31	4925-4937	hypothalamus	_
24-32	4937-4938	)	_
24-33	4939-4941	in	_
24-34	4942-4945	CUD	_
24-35	4946-4951	using	_
24-36	4952-4953	[	_
24-37	4953-4956	11C	_
24-38	4956-4957	]	_
24-39	4957-4958	-	_
24-40	4958-4959	(	_
24-41	4959-4960	+	_
24-42	4960-4961	)	_
24-43	4961-4962	-	_
24-44	4962-4966	PHNO	_
24-45	4967-4975	positron	_
24-46	4976-4984	emission	_
24-47	4985-4995	tomography	_
24-48	4996-4997	(	_
24-49	4997-5000	PET	_
24-50	5000-5001	)	_
24-51	5002-5009	imaging	_
24-52	5009-5010	.	_

#Text=Investigation of regional [11C]-(+)-PHNO BPND was conducted on individuals with CUD and matched healthy comparison (HC) participants.
25-1	5011-5024	Investigation	_
25-2	5025-5027	of	_
25-3	5028-5036	regional	_
25-4	5037-5038	[	_
25-5	5038-5041	11C	_
25-6	5041-5042	]	_
25-7	5042-5043	-	_
25-8	5043-5044	(	_
25-9	5044-5045	+	_
25-10	5045-5046	)	_
25-11	5046-5047	-	_
25-12	5047-5051	PHNO	_
25-13	5052-5056	BPND	_
25-14	5057-5060	was	_
25-15	5061-5070	conducted	_
25-16	5071-5073	on	_
25-17	5074-5085	individuals	_
25-18	5086-5090	with	_
25-19	5091-5094	CUD	_
25-20	5095-5098	and	_
25-21	5099-5106	matched	_
25-22	5107-5114	healthy	_
25-23	5115-5125	comparison	_
25-24	5126-5127	(	_
25-25	5127-5129	HC	_
25-26	5129-5130	)	_
25-27	5131-5143	participants	_
25-28	5143-5144	.	_

#Text=In addition, exploratory spatial independent component analysis (ICA) was performed on [11C]-(+)-PHNO BPND data to examine D2R and D3R using a source-based approach.
26-1	5145-5147	In	_
26-2	5148-5156	addition	_
26-3	5156-5157	,	_
26-4	5158-5169	exploratory	_
26-5	5170-5177	spatial	_
26-6	5178-5189	independent	_
26-7	5190-5199	component	_
26-8	5200-5208	analysis	_
26-9	5209-5210	(	_
26-10	5210-5213	ICA	_
26-11	5213-5214	)	_
26-12	5215-5218	was	_
26-13	5219-5228	performed	_
26-14	5229-5231	on	_
26-15	5232-5233	[	_
26-16	5233-5236	11C	_
26-17	5236-5237	]	_
26-18	5237-5238	-	_
26-19	5238-5239	(	_
26-20	5239-5240	+	_
26-21	5240-5241	)	_
26-22	5241-5242	-	_
26-23	5242-5246	PHNO	_
26-24	5247-5251	BPND	_
26-25	5252-5256	data	_
26-26	5257-5259	to	_
26-27	5260-5267	examine	_
26-28	5268-5271	D2R	_
26-29	5272-5275	and	_
26-30	5276-5279	D3R	_
26-31	5280-5285	using	_
26-32	5286-5287	a	_
26-33	5288-5300	source-based	_
26-34	5301-5309	approach	_
26-35	5309-5310	.	_

#Text=ICA is a data-driven computational procedure that decomposes or ‘un-mixes’ a measured signal into its maximal spatially independent ‘sources’.
27-1	5311-5314	ICA	_
27-2	5315-5317	is	_
27-3	5318-5319	a	_
27-4	5320-5331	data-driven	_
27-5	5332-5345	computational	_
27-6	5346-5355	procedure	_
27-7	5356-5360	that	_
27-8	5361-5371	decomposes	_
27-9	5372-5374	or	_
27-10	5375-5376	‘	_
27-11	5376-5384	un-mixes	_
27-12	5384-5385	’	_
27-13	5386-5387	a	_
27-14	5388-5396	measured	_
27-15	5397-5403	signal	_
27-16	5404-5408	into	_
27-17	5409-5412	its	_
27-18	5413-5420	maximal	_
27-19	5421-5430	spatially	_
27-20	5431-5442	independent	_
27-21	5443-5444	‘	_
27-22	5444-5451	sources	_
27-23	5451-5452	’	_
27-24	5452-5453	.	_

#Text=While [11C]-(+)-PHNO exhibits an estimated 20- to 50-fold selectivity in vivo for D3Rs relative to D2Rs, local BPND reflects a weighted sum of D2R/D3R concentrations.
28-1	5454-5459	While	_
28-2	5460-5461	[	_
28-3	5461-5464	11C	_
28-4	5464-5465	]	_
28-5	5465-5466	-	_
28-6	5466-5467	(	_
28-7	5467-5468	+	_
28-8	5468-5469	)	_
28-9	5469-5470	-	_
28-10	5470-5474	PHNO	_
28-11	5475-5483	exhibits	_
28-12	5484-5486	an	_
28-13	5487-5496	estimated	_
28-14	5497-5499	20	_
28-15	5499-5500	-	_
28-16	5501-5503	to	_
28-17	5504-5506	50	_
28-18	5506-5507	-	_
28-19	5507-5511	fold	_
28-20	5512-5523	selectivity	_
28-21	5524-5526	in	_
28-22	5527-5531	vivo	_
28-23	5532-5535	for	_
28-24	5536-5540	D3Rs	_
28-25	5541-5549	relative	_
28-26	5550-5552	to	_
28-27	5553-5557	D2Rs	_
28-28	5557-5558	,	_
28-29	5559-5564	local	_
28-30	5565-5569	BPND	_
28-31	5570-5578	reflects	_
28-32	5579-5580	a	_
28-33	5581-5589	weighted	_
28-34	5590-5593	sum	_
28-35	5594-5596	of	_
28-36	5597-5600	D2R	_
28-37	5600-5601	/	_
28-38	5601-5604	D3R	_
28-39	5605-5619	concentrations	_
28-40	5619-5620	.	_

#Text=That is, [11C]-(+)-PHNO BPND primarily reflects D3R availability in D3-rich regions (e.g., substantia nigra), D2R availability in D2-rich regions (e.g., dorsal striatum), and an aggregate of D2R and D3R availability in mixed D2R/D3R regions (e.g. ventral striatum).
29-1	5621-5625	That	_
29-2	5626-5628	is	_
29-3	5628-5629	,	_
29-4	5630-5631	[	_
29-5	5631-5634	11C	_
29-6	5634-5635	]	_
29-7	5635-5636	-	_
29-8	5636-5637	(	_
29-9	5637-5638	+	_
29-10	5638-5639	)	_
29-11	5639-5640	-	_
29-12	5640-5644	PHNO	_
29-13	5645-5649	BPND	_
29-14	5650-5659	primarily	_
29-15	5660-5668	reflects	_
29-16	5669-5672	D3R	_
29-17	5673-5685	availability	_
29-18	5686-5688	in	_
29-19	5689-5691	D3	_
29-20	5691-5692	-	_
29-21	5692-5696	rich	_
29-22	5697-5704	regions	_
29-23	5705-5706	(	_
29-24	5706-5709	e.g	_
29-25	5709-5710	.	_
29-26	5710-5711	,	_
29-27	5712-5722	substantia	_
29-28	5723-5728	nigra	_
29-29	5728-5729	)	_
29-30	5729-5730	,	_
29-31	5731-5734	D2R	_
29-32	5735-5747	availability	_
29-33	5748-5750	in	_
29-34	5751-5753	D2	_
29-35	5753-5754	-	_
29-36	5754-5758	rich	_
29-37	5759-5766	regions	_
29-38	5767-5768	(	_
29-39	5768-5771	e.g	_
29-40	5771-5772	.	_
29-41	5772-5773	,	_
29-42	5774-5780	dorsal	_
29-43	5781-5789	striatum	_
29-44	5789-5790	)	_
29-45	5790-5791	,	_
29-46	5792-5795	and	_
29-47	5796-5798	an	_
29-48	5799-5808	aggregate	_
29-49	5809-5811	of	_
29-50	5812-5815	D2R	_
29-51	5816-5819	and	_
29-52	5820-5823	D3R	_
29-53	5824-5836	availability	_
29-54	5837-5839	in	_
29-55	5840-5845	mixed	_
29-56	5846-5849	D2R	_
29-57	5849-5850	/	_
29-58	5850-5853	D3R	_
29-59	5854-5861	regions	_
29-60	5862-5863	(	_
29-61	5863-5866	e.g	_
29-62	5866-5867	.	_
29-63	5868-5875	ventral	_
29-64	5876-5884	striatum	_
29-65	5884-5885	)	_
29-66	5885-5886	.	_

#Text=This unique mixed-signal nature of [11C]-(+)-PHNO strongly motivates the utility of source-based analyses like ICA to un-mix the D2R and D3R components of BPND and examine distinct sources of receptor availability.
30-1	5887-5891	This	_
30-2	5892-5898	unique	_
30-3	5899-5911	mixed-signal	_
30-4	5912-5918	nature	_
30-5	5919-5921	of	_
30-6	5922-5923	[	_
30-7	5923-5926	11C	_
30-8	5926-5927	]	_
30-9	5927-5928	-	_
30-10	5928-5929	(	_
30-11	5929-5930	+	_
30-12	5930-5931	)	_
30-13	5931-5932	-	_
30-14	5932-5936	PHNO	_
30-15	5937-5945	strongly	_
30-16	5946-5955	motivates	_
30-17	5956-5959	the	_
30-18	5960-5967	utility	_
30-19	5968-5970	of	_
30-20	5971-5983	source-based	_
30-21	5984-5992	analyses	_
30-22	5993-5997	like	_
30-23	5998-6001	ICA	_
30-24	6002-6004	to	_
30-25	6005-6011	un-mix	_
30-26	6012-6015	the	_
30-27	6016-6019	D2R	_
30-28	6020-6023	and	_
30-29	6024-6027	D3R	_
30-30	6028-6038	components	_
30-31	6039-6041	of	_
30-32	6042-6046	BPND	_
30-33	6047-6050	and	_
30-34	6051-6058	examine	_
30-35	6059-6067	distinct	_
30-36	6068-6075	sources	_
30-37	6076-6078	of	_
30-38	6079-6087	receptor	_
30-39	6088-6100	availability	_
30-40	6100-6101	.	_

#Text=We hypothesized that CUD-related reductions in D2R availability in the dorsal striatum would be detectable using [11C]-(+)-PHNO in a large sample, and that CUD-related increases in D3R availability in the midbrain would be confirmed.
31-1	6102-6104	We	_
31-2	6105-6117	hypothesized	_
31-3	6118-6122	that	_
31-4	6123-6134	CUD-related	_
31-5	6135-6145	reductions	_
31-6	6146-6148	in	_
31-7	6149-6152	D2R	_
31-8	6153-6165	availability	_
31-9	6166-6168	in	_
31-10	6169-6172	the	_
31-11	6173-6179	dorsal	_
31-12	6180-6188	striatum	_
31-13	6189-6194	would	_
31-14	6195-6197	be	_
31-15	6198-6208	detectable	_
31-16	6209-6214	using	_
31-17	6215-6216	[	_
31-18	6216-6219	11C	_
31-19	6219-6220	]	_
31-20	6220-6221	-	_
31-21	6221-6222	(	_
31-22	6222-6223	+	_
31-23	6223-6224	)	_
31-24	6224-6225	-	_
31-25	6225-6229	PHNO	_
31-26	6230-6232	in	_
31-27	6233-6234	a	_
31-28	6235-6240	large	_
31-29	6241-6247	sample	_
31-30	6247-6248	,	_
31-31	6249-6252	and	_
31-32	6253-6257	that	_
31-33	6258-6269	CUD-related	_
31-34	6270-6279	increases	_
31-35	6280-6282	in	_
31-36	6283-6286	D3R	_
31-37	6287-6299	availability	_
31-38	6300-6302	in	_
31-39	6303-6306	the	_
31-40	6307-6315	midbrain	_
31-41	6316-6321	would	_
31-42	6322-6324	be	_
31-43	6325-6334	confirmed	_
31-44	6334-6335	.	_

#Text=We also hypothesized that the exploratory ICA would identify sources of [11C]-(+)-PHNO BPND consistent with estimates of regional proportions of D2R-related and D3R-related BPND, with mixed-D2R/D3R regions incorporated into multiple sources.
32-1	6336-6338	We	_
32-2	6339-6343	also	_
32-3	6344-6356	hypothesized	_
32-4	6357-6361	that	_
32-5	6362-6365	the	_
32-6	6366-6377	exploratory	_
32-7	6378-6381	ICA	_
32-8	6382-6387	would	_
32-9	6388-6396	identify	_
32-10	6397-6404	sources	_
32-11	6405-6407	of	_
32-12	6408-6409	[	_
32-13	6409-6412	11C	_
32-14	6412-6413	]	_
32-15	6413-6414	-	_
32-16	6414-6415	(	_
32-17	6415-6416	+	_
32-18	6416-6417	)	_
32-19	6417-6418	-	_
32-20	6418-6422	PHNO	_
32-21	6423-6427	BPND	_
32-22	6428-6438	consistent	_
32-23	6439-6443	with	_
32-24	6444-6453	estimates	_
32-25	6454-6456	of	_
32-26	6457-6465	regional	_
32-27	6466-6477	proportions	_
32-28	6478-6480	of	_
32-29	6481-6492	D2R-related	_
32-30	6493-6496	and	_
32-31	6497-6508	D3R-related	_
32-32	6509-6513	BPND	_
32-33	6513-6514	,	_
32-34	6515-6519	with	_
32-35	6520-6529	mixed-D2R	_
32-36	6529-6530	/	_
32-37	6530-6533	D3R	_
32-38	6534-6541	regions	_
32-39	6542-6554	incorporated	_
32-40	6555-6559	into	_
32-41	6560-6568	multiple	_
32-42	6569-6576	sources	_
32-43	6576-6577	.	_

#Text=Consistent with research demonstrating regional differences in D2R and D3R in CUD, we hypothesized that individuals with CUD would exhibit increased intensity of sources that include D3-rich regions and reduced intensity of sources that include D2-rich regions.
33-1	6578-6588	Consistent	_
33-2	6589-6593	with	_
33-3	6594-6602	research	_
33-4	6603-6616	demonstrating	_
33-5	6617-6625	regional	_
33-6	6626-6637	differences	_
33-7	6638-6640	in	_
33-8	6641-6644	D2R	_
33-9	6645-6648	and	_
33-10	6649-6652	D3R	_
33-11	6653-6655	in	_
33-12	6656-6659	CUD	_
33-13	6659-6660	,	_
33-14	6661-6663	we	_
33-15	6664-6676	hypothesized	_
33-16	6677-6681	that	_
33-17	6682-6693	individuals	_
33-18	6694-6698	with	_
33-19	6699-6702	CUD	_
33-20	6703-6708	would	_
33-21	6709-6716	exhibit	_
33-22	6717-6726	increased	_
33-23	6727-6736	intensity	_
33-24	6737-6739	of	_
33-25	6740-6747	sources	_
33-26	6748-6752	that	_
33-27	6753-6760	include	_
33-28	6761-6763	D3	_
33-29	6763-6764	-	_
33-30	6764-6768	rich	_
33-31	6769-6776	regions	_
33-32	6777-6780	and	_
33-33	6781-6788	reduced	_
33-34	6789-6798	intensity	_
33-35	6799-6801	of	_
33-36	6802-6809	sources	_
33-37	6810-6814	that	_
33-38	6815-6822	include	_
33-39	6823-6825	D2	_
33-40	6825-6826	-	_
33-41	6826-6830	rich	_
33-42	6831-6838	regions	_
33-43	6838-6839	.	_

#Text=Finally, we examined relationships between regional BPND and source intensities with duration of cocaine use.
#Text=2.
34-1	6840-6847	Finally	_
34-2	6847-6848	,	_
34-3	6849-6851	we	_
34-4	6852-6860	examined	_
34-5	6861-6874	relationships	_
34-6	6875-6882	between	_
34-7	6883-6891	regional	_
34-8	6892-6896	BPND	_
34-9	6897-6900	and	_
34-10	6901-6907	source	_
34-11	6908-6919	intensities	_
34-12	6920-6924	with	_
34-13	6925-6933	duration	_
34-14	6934-6936	of	_
34-15	6937-6944	cocaine	_
34-16	6945-6948	use	_
34-17	6948-6949	.	_
34-18	6950-6951	2	_
34-19	6951-6952	.	_

#Text=Methods and Materials
#Text=2.1.
35-1	6953-6960	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
35-2	6961-6964	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
35-3	6965-6974	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
35-4	6975-6978	2.1	_
35-5	6978-6979	.	_

#Text=Participants
#Text=Participants were 26 non-treatment seeking individuals with CUD and 26 age- and gender-matched HC participants, most of whom (22 CUD and 21 HC) were included in previous reports (Table 1).
36-1	6980-6992	Participants	_
36-2	6993-7005	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-3	7006-7010	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-4	7011-7013	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-5	7014-7027	non-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-6	7028-7035	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-7	7036-7047	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-8	7048-7052	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-9	7053-7056	CUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[7]
36-10	7057-7060	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-11	7061-7063	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-12	7064-7067	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-13	7067-7068	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-14	7069-7072	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-15	7073-7087	gender-matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-16	7088-7090	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]
36-17	7091-7103	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-18	7103-7104	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-19	7105-7109	most	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-20	7110-7112	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-21	7113-7117	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-22	7118-7119	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-23	7119-7121	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-24	7122-7125	CUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[9]
36-25	7126-7129	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-26	7130-7132	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-27	7133-7135	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]
36-28	7135-7136	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-29	7137-7141	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-30	7142-7150	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-31	7151-7153	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-32	7154-7162	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-33	7163-7170	reports	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-34	7171-7172	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-35	7172-7177	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-36	7178-7179	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-37	7179-7180	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
36-38	7180-7181	.	_

#Text=Physical exams with medical history, routine laboratory studies, pregnancy tests and electrocardiograms (ECGs) were performed to assess medical health eligibility criteria.
37-1	7182-7190	Physical	_
37-2	7191-7196	exams	_
37-3	7197-7201	with	_
37-4	7202-7209	medical	_
37-5	7210-7217	history	_
37-6	7217-7218	,	_
37-7	7219-7226	routine	_
37-8	7227-7237	laboratory	_
37-9	7238-7245	studies	_
37-10	7245-7246	,	_
37-11	7247-7256	pregnancy	_
37-12	7257-7262	tests	_
37-13	7263-7266	and	_
37-14	7267-7285	electrocardiograms	http://www.case.edu/ProvCaRe/provcare#Electrocardiograph[11]
37-15	7286-7287	(	http://www.case.edu/ProvCaRe/provcare#Electrocardiograph[11]
37-16	7287-7291	ECGs	http://www.case.edu/ProvCaRe/provcare#Electrocardiograph[11]
37-17	7291-7292	)	http://www.case.edu/ProvCaRe/provcare#Electrocardiograph[11]
37-18	7293-7297	were	_
37-19	7298-7307	performed	_
37-20	7308-7310	to	_
37-21	7311-7317	assess	_
37-22	7318-7325	medical	_
37-23	7326-7332	health	_
37-24	7333-7344	eligibility	_
37-25	7345-7353	criteria	_
37-26	7353-7354	.	_

#Text=Urine toxicology screening for a range of drugs (including cocaine, amphetamines, marijuana, opiates, benzodiazepines, barbiturates) were performed to confirm cocaine-use status in CUD participants and the absence of other recent drug use in both CUD and HC participants.
38-1	7355-7360	Urine	_
38-2	7361-7371	toxicology	_
38-3	7372-7381	screening	_
38-4	7382-7385	for	_
38-5	7386-7387	a	_
38-6	7388-7393	range	_
38-7	7394-7396	of	_
38-8	7397-7402	drugs	_
38-9	7403-7404	(	_
38-10	7404-7413	including	_
38-11	7414-7421	cocaine	_
38-12	7421-7422	,	_
38-13	7423-7435	amphetamines	_
38-14	7435-7436	,	_
38-15	7437-7446	marijuana	_
38-16	7446-7447	,	_
38-17	7448-7455	opiates	_
38-18	7455-7456	,	_
38-19	7457-7472	benzodiazepines	_
38-20	7472-7473	,	_
38-21	7474-7486	barbiturates	_
38-22	7486-7487	)	_
38-23	7488-7492	were	_
38-24	7493-7502	performed	_
38-25	7503-7505	to	_
38-26	7506-7513	confirm	_
38-27	7514-7525	cocaine-use	_
38-28	7526-7532	status	_
38-29	7533-7535	in	_
38-30	7536-7539	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
38-31	7540-7552	participants	_
38-32	7553-7556	and	_
38-33	7557-7560	the	_
38-34	7561-7568	absence	_
38-35	7569-7571	of	_
38-36	7572-7577	other	_
38-37	7578-7584	recent	_
38-38	7585-7589	drug	_
38-39	7590-7593	use	_
38-40	7594-7596	in	_
38-41	7597-7601	both	_
38-42	7602-7605	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
38-43	7606-7609	and	_
38-44	7610-7612	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
38-45	7613-7625	participants	_
38-46	7625-7626	.	_

#Text=Participants were assessed for DSM-IV diagnoses using clinical interviews (SCID; MINI).
39-1	7627-7639	Participants	_
39-2	7640-7644	were	_
39-3	7645-7653	assessed	_
39-4	7654-7657	for	_
39-5	7658-7664	DSM-IV	_
39-6	7665-7674	diagnoses	_
39-7	7675-7680	using	_
39-8	7681-7689	clinical	_
39-9	7690-7700	interviews	_
39-10	7701-7702	(	_
39-11	7702-7706	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
39-12	7706-7707	;	_
39-13	7708-7712	MINI	_
39-14	7712-7713	)	_
39-15	7713-7714	.	_

#Text=Participants meeting criteria for cocaine dependence (i.e., presenting with 3 or more criteria) were included in the CUD sample.
40-1	7715-7727	Participants	_
40-2	7728-7735	meeting	_
40-3	7736-7744	criteria	_
40-4	7745-7748	for	_
40-5	7749-7756	cocaine	_
40-6	7757-7767	dependence	_
40-7	7768-7769	(	_
40-8	7769-7772	i.e	_
40-9	7772-7773	.	_
40-10	7773-7774	,	_
40-11	7775-7785	presenting	_
40-12	7786-7790	with	_
40-13	7791-7792	3	_
40-14	7793-7795	or	_
40-15	7796-7800	more	_
40-16	7801-7809	criteria	_
40-17	7809-7810	)	_
40-18	7811-7815	were	_
40-19	7816-7824	included	_
40-20	7825-7827	in	_
40-21	7828-7831	the	_
40-22	7832-7835	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
40-23	7836-7842	sample	_
40-24	7842-7843	.	_

#Text=Exclusion criteria included the presence or history of a general medical illness or psychotic disorder, pregnancy or breast feeding, or any condition that would interfere with the ability to participate in PET or MRI protocols (e.g., claustrophobia, metallic implants).
41-1	7844-7853	Exclusion	_
41-2	7854-7862	criteria	_
41-3	7863-7871	included	_
41-4	7872-7875	the	_
41-5	7876-7884	presence	_
41-6	7885-7887	or	_
41-7	7888-7895	history	_
41-8	7896-7898	of	_
41-9	7899-7900	a	_
41-10	7901-7908	general	_
41-11	7909-7916	medical	_
41-12	7917-7924	illness	_
41-13	7925-7927	or	_
41-14	7928-7937	psychotic	_
41-15	7938-7946	disorder	_
41-16	7946-7947	,	_
41-17	7948-7957	pregnancy	_
41-18	7958-7960	or	_
41-19	7961-7967	breast	_
41-20	7968-7975	feeding	_
41-21	7975-7976	,	_
41-22	7977-7979	or	_
41-23	7980-7983	any	_
41-24	7984-7993	condition	_
41-25	7994-7998	that	_
41-26	7999-8004	would	_
41-27	8005-8014	interfere	_
41-28	8015-8019	with	_
41-29	8020-8023	the	_
41-30	8024-8031	ability	_
41-31	8032-8034	to	_
41-32	8035-8046	participate	_
41-33	8047-8049	in	_
41-34	8050-8053	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
41-35	8054-8056	or	_
41-36	8057-8060	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument
41-37	8061-8070	protocols	_
41-38	8071-8072	(	_
41-39	8072-8075	e.g	_
41-40	8075-8076	.	_
41-41	8076-8077	,	_
41-42	8078-8092	claustrophobia	_
41-43	8092-8093	,	_
41-44	8094-8102	metallic	_
41-45	8103-8111	implants	_
41-46	8111-8112	)	_
41-47	8112-8113	.	_

#Text=All study procedures were approved by the Yale Human Investigation, Yale University Radiation Safety, Yale-New Haven Hospital Radioactive Drug Research, and Yale MRI Safety Committees, and participants provided written informed consent.
#Text=2.2.
42-1	8114-8117	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-2	8118-8123	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-3	8124-8134	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-4	8135-8139	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-5	8140-8148	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-6	8149-8151	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-7	8152-8155	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-8	8156-8160	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-9	8161-8166	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-10	8167-8180	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-11	8180-8181	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-12	8182-8186	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-13	8187-8197	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-14	8198-8207	Radiation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-15	8208-8214	Safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-16	8214-8215	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-17	8216-8224	Yale-New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-18	8225-8230	Haven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-19	8231-8239	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-20	8240-8251	Radioactive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-21	8252-8256	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-22	8257-8265	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-23	8265-8266	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-24	8267-8270	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-25	8271-8275	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-26	8276-8279	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-27	8280-8286	Safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-28	8287-8297	Committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-29	8297-8298	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-30	8299-8302	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-31	8303-8315	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-32	8316-8324	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-33	8325-8332	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-34	8333-8341	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-35	8342-8349	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
42-36	8349-8350	.	_
42-37	8351-8354	2.2	_
42-38	8354-8355	.	_

#Text=Radiochemistry and image acquisition
#Text=[11C]-(+)-PHNO was prepared as previously described.
43-1	8356-8370	Radiochemistry	_
43-2	8371-8374	and	_
43-3	8375-8380	image	_
43-4	8381-8392	acquisition	_
43-5	8393-8394	[	_
43-6	8394-8397	11C	_
43-7	8397-8398	]	_
43-8	8398-8399	-	_
43-9	8399-8400	(	_
43-10	8400-8401	+	_
43-11	8401-8402	)	_
43-12	8402-8403	-	_
43-13	8403-8407	PHNO	_
43-14	8408-8411	was	_
43-15	8412-8420	prepared	_
43-16	8421-8423	as	_
43-17	8424-8434	previously	_
43-18	8435-8444	described	_
43-19	8444-8445	.	_

#Text=Radioactive dose, specific activity and injected mass for CUD and HC groups are listed in Table 1.
44-1	8446-8457	Radioactive	_
44-2	8458-8462	dose	_
44-3	8462-8463	,	_
44-4	8464-8472	specific	_
44-5	8473-8481	activity	_
44-6	8482-8485	and	_
44-7	8486-8494	injected	_
44-8	8495-8499	mass	_
44-9	8500-8503	for	_
44-10	8504-8507	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
44-11	8508-8511	and	_
44-12	8512-8514	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
44-13	8515-8521	groups	_
44-14	8522-8525	are	_
44-15	8526-8532	listed	_
44-16	8533-8535	in	_
44-17	8536-8541	Table	_
44-18	8542-8543	1	_
44-19	8543-8544	.	_

#Text=PET imaging was performed on a Siemens high-resolution research tomograph (HRRT; Siemens/CTI, Knoxville, TN, USA).
45-1	8545-8548	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
45-2	8549-8556	imaging	_
45-3	8557-8560	was	_
45-4	8561-8570	performed	_
45-5	8571-8573	on	_
45-6	8574-8575	a	_
45-7	8576-8583	Siemens	_
45-8	8584-8599	high-resolution	_
45-9	8600-8608	research	_
45-10	8609-8618	tomograph	_
45-11	8619-8620	(	_
45-12	8620-8624	HRRT	_
45-13	8624-8625	;	_
45-14	8626-8633	Siemens	_
45-15	8633-8634	/	_
45-16	8634-8637	CTI	_
45-17	8637-8638	,	_
45-18	8639-8648	Knoxville	_
45-19	8648-8649	,	_
45-20	8650-8652	TN	_
45-21	8652-8653	,	_
45-22	8654-8657	USA	_
45-23	8657-8658	)	_
45-24	8658-8659	.	_

#Text=A transmission scan was obtained before the emission scan.
46-1	8660-8661	A	_
46-2	8662-8674	transmission	_
46-3	8675-8679	scan	_
46-4	8680-8683	was	_
46-5	8684-8692	obtained	_
46-6	8693-8699	before	_
46-7	8700-8703	the	_
46-8	8704-8712	emission	_
46-9	8713-8717	scan	_
46-10	8717-8718	.	_

#Text=PET scans (slices=207, slice separation=1.2mm, reconstructed image resolution ~3 mm) were acquired for 120 min at rest.
47-1	8719-8722	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
47-2	8723-8728	scans	_
47-3	8729-8730	(	_
47-4	8730-8736	slices	_
47-5	8736-8737	=	_
47-6	8737-8740	207	_
47-7	8740-8741	,	_
47-8	8742-8747	slice	_
47-9	8748-8758	separation	_
47-10	8758-8759	=	_
47-11	8759-8764	1.2mm	_
47-12	8764-8765	,	_
47-13	8766-8779	reconstructed	_
47-14	8780-8785	image	_
47-15	8786-8796	resolution	_
47-16	8797-8798	~	_
47-17	8798-8799	3	_
47-18	8800-8802	mm	_
47-19	8802-8803	)	_
47-20	8804-8808	were	_
47-21	8809-8817	acquired	_
47-22	8818-8821	for	_
47-23	8822-8825	120	_
47-24	8826-8829	min	_
47-25	8830-8832	at	_
47-26	8833-8837	rest	_
47-27	8837-8838	.	_

#Text=Head motion was measured using an optical detector (Vicra, NDI Systems, Waterloo, Ontario, Canada).
48-1	8839-8843	Head	_
48-2	8844-8850	motion	_
48-3	8851-8854	was	_
48-4	8855-8863	measured	_
48-5	8864-8869	using	_
48-6	8870-8872	an	_
48-7	8873-8880	optical	_
48-8	8881-8889	detector	_
48-9	8890-8891	(	_
48-10	8891-8896	Vicra	_
48-11	8896-8897	,	_
48-12	8898-8901	NDI	_
48-13	8902-8909	Systems	_
48-14	8909-8910	,	_
48-15	8911-8919	Waterloo	_
48-16	8919-8920	,	_
48-17	8921-8928	Ontario	_
48-18	8928-8929	,	_
48-19	8930-8936	Canada	_
48-20	8936-8937	)	_
48-21	8937-8938	.	_

#Text=MR images were collected on a Siemens 3T Trio system (Siemens Medical Solutions, Malvern, PA) using a magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (repeat time (TR)/echo time (TE)=2530/3.34, flip angle=7°, in-plane resolution=0.98×0.98 mm, matrix=256×256, slice thickness=1mm, slices=176).
#Text=2.3.
49-1	8939-8941	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
49-2	8942-8948	images	_
49-3	8949-8953	were	_
49-4	8954-8963	collected	_
49-5	8964-8966	on	_
49-6	8967-8968	a	_
49-7	8969-8976	Siemens	_
49-8	8977-8979	3T	_
49-9	8980-8984	Trio	_
49-10	8985-8991	system	_
49-11	8992-8993	(	_
49-12	8993-9000	Siemens	_
49-13	9001-9008	Medical	_
49-14	9009-9018	Solutions	_
49-15	9018-9019	,	_
49-16	9020-9027	Malvern	_
49-17	9027-9028	,	_
49-18	9029-9031	PA	_
49-19	9031-9032	)	_
49-20	9033-9038	using	_
49-21	9039-9040	a	_
49-22	9041-9054	magnetization	_
49-23	9055-9063	prepared	_
49-24	9064-9069	rapid	_
49-25	9070-9081	acquisition	_
49-26	9082-9090	gradient	_
49-27	9091-9095	echo	_
49-28	9096-9097	(	_
49-29	9097-9103	MPRAGE	_
49-30	9103-9104	)	_
49-31	9105-9113	sequence	_
49-32	9114-9115	(	_
49-33	9115-9121	repeat	_
49-34	9122-9126	time	_
49-35	9127-9128	(	_
49-36	9128-9130	TR	_
49-37	9130-9131	)	_
49-38	9131-9132	/	_
49-39	9132-9136	echo	_
49-40	9137-9141	time	_
49-41	9142-9143	(	_
49-42	9143-9145	TE	_
49-43	9145-9146	)	_
49-44	9146-9147	=	_
49-45	9147-9151	2530	_
49-46	9151-9152	/	_
49-47	9152-9156	3.34	_
49-48	9156-9157	,	_
49-49	9158-9162	flip	_
49-50	9163-9168	angle	_
49-51	9168-9169	=	_
49-52	9169-9170	7	_
49-53	9170-9171	°	_
49-54	9171-9172	,	_
49-55	9173-9181	in-plane	_
49-56	9182-9192	resolution	_
49-57	9192-9193	=	_
49-58	9193-9197	0.98	_
49-59	9197-9198	×	_
49-60	9198-9202	0.98	_
49-61	9203-9205	mm	_
49-62	9205-9206	,	_
49-63	9207-9213	matrix	_
49-64	9213-9214	=	_
49-65	9214-9217	256	_
49-66	9217-9218	×	_
49-67	9218-9221	256	_
49-68	9221-9222	,	_
49-69	9223-9228	slice	_
49-70	9229-9238	thickness	_
49-71	9238-9239	=	_
49-72	9239-9242	1mm	_
49-73	9242-9243	,	_
49-74	9244-9250	slices	_
49-75	9250-9251	=	_
49-76	9251-9254	176	_
49-77	9254-9255	)	_
49-78	9255-9256	.	_
49-79	9257-9260	2.3	_
49-80	9260-9261	.	_

#Text=Image processing
#Text=Dynamic PET data (frame timing: 6×30s; 3×60s; 2×120s; 22×300s) were reconstructed with corrections (attenuation, normalization, scatter, randoms, deadtime and motion) using the MOLAR algorithm.
50-1	9262-9267	Image	_
50-2	9268-9278	processing	_
50-3	9279-9286	Dynamic	_
50-4	9287-9290	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
50-5	9291-9295	data	_
50-6	9296-9297	(	_
50-7	9297-9302	frame	_
50-8	9303-9309	timing	_
50-9	9309-9310	:	_
50-10	9311-9312	6	_
50-11	9312-9313	×	_
50-12	9313-9316	30s	_
50-13	9316-9317	;	_
50-14	9318-9319	3	_
50-15	9319-9320	×	_
50-16	9320-9323	60s	_
50-17	9323-9324	;	_
50-18	9325-9326	2	_
50-19	9326-9327	×	_
50-20	9327-9331	120s	_
50-21	9331-9332	;	_
50-22	9333-9335	22	_
50-23	9335-9336	×	_
50-24	9336-9340	300s	_
50-25	9340-9341	)	_
50-26	9342-9346	were	_
50-27	9347-9360	reconstructed	_
50-28	9361-9365	with	_
50-29	9366-9377	corrections	_
50-30	9378-9379	(	_
50-31	9379-9390	attenuation	_
50-32	9390-9391	,	_
50-33	9392-9405	normalization	_
50-34	9405-9406	,	_
50-35	9407-9414	scatter	_
50-36	9414-9415	,	_
50-37	9416-9423	randoms	_
50-38	9423-9424	,	_
50-39	9425-9433	deadtime	_
50-40	9434-9437	and	_
50-41	9438-9444	motion	_
50-42	9444-9445	)	_
50-43	9446-9451	using	_
50-44	9452-9455	the	_
50-45	9456-9461	MOLAR	_
50-46	9462-9471	algorithm	_
50-47	9471-9472	.	_

#Text=Parametric images of [11C]-(+)-PHNO BPND were computed using a simplified reference tissue model (SRTM2) with the cerebellum as reference.
51-1	9473-9483	Parametric	_
51-2	9484-9490	images	_
51-3	9491-9493	of	_
51-4	9494-9495	[	_
51-5	9495-9498	11C	_
51-6	9498-9499	]	_
51-7	9499-9500	-	_
51-8	9500-9501	(	_
51-9	9501-9502	+	_
51-10	9502-9503	)	_
51-11	9503-9504	-	_
51-12	9504-9508	PHNO	_
51-13	9509-9513	BPND	_
51-14	9514-9518	were	_
51-15	9519-9527	computed	_
51-16	9528-9533	using	_
51-17	9534-9535	a	_
51-18	9536-9546	simplified	_
51-19	9547-9556	reference	_
51-20	9557-9563	tissue	_
51-21	9564-9569	model	_
51-22	9570-9571	(	_
51-23	9571-9576	SRTM2	_
51-24	9576-9577	)	_
51-25	9578-9582	with	_
51-26	9583-9586	the	_
51-27	9587-9597	cerebellum	_
51-28	9598-9600	as	_
51-29	9601-9610	reference	_
51-30	9610-9611	.	_

#Text=Registration of individual images into MNI152 space was performed using SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK).
52-1	9612-9624	Registration	_
52-2	9625-9627	of	_
52-3	9628-9638	individual	_
52-4	9639-9645	images	_
52-5	9646-9650	into	_
52-6	9651-9657	MNI152	_
52-7	9658-9663	space	_
52-8	9664-9667	was	_
52-9	9668-9677	performed	_
52-10	9678-9683	using	_
52-11	9684-9689	SPM12	_
52-12	9690-9691	(	_
52-13	9691-9699	Wellcome	_
52-14	9700-9705	Trust	_
52-15	9706-9712	Centre	_
52-16	9713-9716	for	_
52-17	9717-9729	Neuroimaging	_
52-18	9729-9730	,	_
52-19	9731-9737	London	_
52-20	9737-9738	,	_
52-21	9739-9741	UK	_
52-22	9741-9742	)	_
52-23	9742-9743	.	_

#Text=A summed [11C]-(+)-PHNO uptake (0–10 min post-injection) image was created from the motion-corrected PET data and rigid-body registered to the subject's MR image.
53-1	9744-9745	A	_
53-2	9746-9752	summed	_
53-3	9753-9754	[	_
53-4	9754-9757	11C	_
53-5	9757-9758	]	_
53-6	9758-9759	-	_
53-7	9759-9760	(	_
53-8	9760-9761	+	_
53-9	9761-9762	)	_
53-10	9762-9763	-	_
53-11	9763-9767	PHNO	_
53-12	9768-9774	uptake	_
53-13	9775-9776	(	_
53-14	9776-9777	0	_
53-15	9777-9778	–	_
53-16	9778-9780	10	_
53-17	9781-9784	min	_
53-18	9785-9799	post-injection	_
53-19	9799-9800	)	_
53-20	9801-9806	image	_
53-21	9807-9810	was	_
53-22	9811-9818	created	_
53-23	9819-9823	from	_
53-24	9824-9827	the	_
53-25	9828-9844	motion-corrected	_
53-26	9845-9848	PET	_
53-27	9849-9853	data	_
53-28	9854-9857	and	_
53-29	9858-9868	rigid-body	_
53-30	9869-9879	registered	_
53-31	9880-9882	to	_
53-32	9883-9886	the	_
53-33	9887-9896	subject's	_
53-34	9897-9899	MR	_
53-35	9900-9905	image	_
53-36	9905-9906	.	_

#Text=Nonlinear registration of the MR image to MNI152 space was determined using optimized unified segmentation.
54-1	9907-9916	Nonlinear	_
54-2	9917-9929	registration	_
54-3	9930-9932	of	_
54-4	9933-9936	the	_
54-5	9937-9939	MR	_
54-6	9940-9945	image	_
54-7	9946-9948	to	_
54-8	9949-9955	MNI152	_
54-9	9956-9961	space	_
54-10	9962-9965	was	_
54-11	9966-9976	determined	_
54-12	9977-9982	using	_
54-13	9983-9992	optimized	_
54-14	9993-10000	unified	_
54-15	10001-10013	segmentation	_
54-16	10013-10014	.	_

#Text=The combined rigid-body and nonlinear registrations were applied to the parametric BPND, and smoothed with a 4mm FWHM Gaussian kernel.
#Text=2.4.
55-1	10015-10018	The	_
55-2	10019-10027	combined	_
55-3	10028-10038	rigid-body	_
55-4	10039-10042	and	_
55-5	10043-10052	nonlinear	_
55-6	10053-10066	registrations	_
55-7	10067-10071	were	_
55-8	10072-10079	applied	_
55-9	10080-10082	to	_
55-10	10083-10086	the	_
55-11	10087-10097	parametric	_
55-12	10098-10102	BPND	_
55-13	10102-10103	,	_
55-14	10104-10107	and	_
55-15	10108-10116	smoothed	_
55-16	10117-10121	with	_
55-17	10122-10123	a	_
55-18	10124-10127	4mm	_
55-19	10128-10132	FWHM	_
55-20	10133-10141	Gaussian	_
55-21	10142-10148	kernel	_
55-22	10148-10149	.	_
55-23	10150-10153	2.4	_
55-24	10153-10154	.	_

#Text=Analyses of regional [11C]-(+)-PHNO BPND
#Text=Seven regions of interest (ROIs) were examined: dorsal caudate (DCA), dorsal putamen (DPU), globus pallidus (GP), hypothalamus (HY), substantia nigra (SN), ventral pallidum (VP), and ventral striatum (VS).
56-1	10155-10163	Analyses	_
56-2	10164-10166	of	_
56-3	10167-10175	regional	_
56-4	10176-10177	[	_
56-5	10177-10180	11C	_
56-6	10180-10181	]	_
56-7	10181-10182	-	_
56-8	10182-10183	(	_
56-9	10183-10184	+	_
56-10	10184-10185	)	_
56-11	10185-10186	-	_
56-12	10186-10190	PHNO	_
56-13	10191-10195	BPND	_
56-14	10196-10201	Seven	_
56-15	10202-10209	regions	_
56-16	10210-10212	of	_
56-17	10213-10221	interest	_
56-18	10222-10223	(	_
56-19	10223-10227	ROIs	_
56-20	10227-10228	)	_
56-21	10229-10233	were	_
56-22	10234-10242	examined	_
56-23	10242-10243	:	_
56-24	10244-10250	dorsal	_
56-25	10251-10258	caudate	_
56-26	10259-10260	(	_
56-27	10260-10263	DCA	_
56-28	10263-10264	)	_
56-29	10264-10265	,	_
56-30	10266-10272	dorsal	_
56-31	10273-10280	putamen	_
56-32	10281-10282	(	_
56-33	10282-10285	DPU	_
56-34	10285-10286	)	_
56-35	10286-10287	,	_
56-36	10288-10294	globus	_
56-37	10295-10303	pallidus	_
56-38	10304-10305	(	_
56-39	10305-10307	GP	_
56-40	10307-10308	)	_
56-41	10308-10309	,	_
56-42	10310-10322	hypothalamus	_
56-43	10323-10324	(	_
56-44	10324-10326	HY	_
56-45	10326-10327	)	_
56-46	10327-10328	,	_
56-47	10329-10339	substantia	_
56-48	10340-10345	nigra	_
56-49	10346-10347	(	_
56-50	10347-10349	SN	_
56-51	10349-10350	)	_
56-52	10350-10351	,	_
56-53	10352-10359	ventral	_
56-54	10360-10368	pallidum	_
56-55	10369-10370	(	_
56-56	10370-10372	VP	_
56-57	10372-10373	)	_
56-58	10373-10374	,	_
56-59	10375-10378	and	_
56-60	10379-10386	ventral	_
56-61	10387-10395	striatum	_
56-62	10396-10397	(	_
56-63	10397-10399	VS	_
56-64	10399-10400	)	_
56-65	10400-10401	.	_

#Text=ROIs were defined using previously described guidelines.
57-1	10402-10406	ROIs	_
57-2	10407-10411	were	_
57-3	10412-10419	defined	_
57-4	10420-10425	using	_
57-5	10426-10436	previously	_
57-6	10437-10446	described	_
57-7	10447-10457	guidelines	_
57-8	10457-10458	.	_

#Text=DCA, DPU and VS ROIs were obtained from FSL (Oxford Centre for Functional MRI of the Brain, Oxford, UK).
58-1	10459-10462	DCA	_
58-2	10462-10463	,	_
58-3	10464-10467	DPU	_
58-4	10468-10471	and	_
58-5	10472-10474	VS	_
58-6	10475-10479	ROIs	_
58-7	10480-10484	were	_
58-8	10485-10493	obtained	_
58-9	10494-10498	from	_
58-10	10499-10502	FSL	_
58-11	10503-10504	(	_
58-12	10504-10510	Oxford	_
58-13	10511-10517	Centre	_
58-14	10518-10521	for	_
58-15	10522-10532	Functional	_
58-16	10533-10536	MRI	_
58-17	10537-10539	of	_
58-18	10540-10543	the	_
58-19	10544-10549	Brain	_
58-20	10549-10550	,	_
58-21	10551-10557	Oxford	_
58-22	10557-10558	,	_
58-23	10559-10561	UK	_
58-24	10561-10562	)	_
58-25	10562-10563	.	_

#Text=GP, HY, and VP ROIs were manually drawn on the ICBM-MNI52 template (Montreal Neurological Institute, Montreal, Canada).
59-1	10564-10566	GP	_
59-2	10566-10567	,	_
59-3	10568-10570	HY	_
59-4	10570-10571	,	_
59-5	10572-10575	and	_
59-6	10576-10578	VP	_
59-7	10579-10583	ROIs	_
59-8	10584-10588	were	_
59-9	10589-10597	manually	_
59-10	10598-10603	drawn	_
59-11	10604-10606	on	_
59-12	10607-10610	the	_
59-13	10611-10621	ICBM-MNI52	_
59-14	10622-10630	template	_
59-15	10631-10632	(	_
59-16	10632-10640	Montreal	_
59-17	10641-10653	Neurological	_
59-18	10654-10663	Institute	_
59-19	10663-10664	,	_
59-20	10665-10673	Montreal	_
59-21	10673-10674	,	_
59-22	10675-10681	Canada	_
59-23	10681-10682	)	_
59-24	10682-10683	.	_

#Text=The SN ROI was manually defined on a group-average parametric [11C]-(+)-PHNO BPND image from an independent sample.
60-1	10684-10687	The	_
60-2	10688-10690	SN	_
60-3	10691-10694	ROI	_
60-4	10695-10698	was	_
60-5	10699-10707	manually	_
60-6	10708-10715	defined	_
60-7	10716-10718	on	_
60-8	10719-10720	a	_
60-9	10721-10734	group-average	_
60-10	10735-10745	parametric	_
60-11	10746-10747	[	_
60-12	10747-10750	11C	_
60-13	10750-10751	]	_
60-14	10751-10752	-	_
60-15	10752-10753	(	_
60-16	10753-10754	+	_
60-17	10754-10755	)	_
60-18	10755-10756	-	_
60-19	10756-10760	PHNO	_
60-20	10761-10765	BPND	_
60-21	10766-10771	image	_
60-22	10772-10776	from	_
60-23	10777-10779	an	_
60-24	10780-10791	independent	_
60-25	10792-10798	sample	_
60-26	10798-10799	.	_

#Text=Regional [11C]-(+)-PHNO BPND was determined from the individual smoothed parametric BPND images in standard space.
61-1	10800-10808	Regional	_
61-2	10809-10810	[	_
61-3	10810-10813	11C	_
61-4	10813-10814	]	_
61-5	10814-10815	-	_
61-6	10815-10816	(	_
61-7	10816-10817	+	_
61-8	10817-10818	)	_
61-9	10818-10819	-	_
61-10	10819-10823	PHNO	_
61-11	10824-10828	BPND	_
61-12	10829-10832	was	_
61-13	10833-10843	determined	_
61-14	10844-10848	from	_
61-15	10849-10852	the	_
61-16	10853-10863	individual	_
61-17	10864-10872	smoothed	_
61-18	10873-10883	parametric	_
61-19	10884-10888	BPND	_
61-20	10889-10895	images	_
61-21	10896-10898	in	_
61-22	10899-10907	standard	_
61-23	10908-10913	space	_
61-24	10913-10914	.	_

#Text=ROI volumes were calculated by inverse transformation of template regions into individual native space.
62-1	10915-10918	ROI	_
62-2	10919-10926	volumes	_
62-3	10927-10931	were	_
62-4	10932-10942	calculated	_
62-5	10943-10945	by	_
62-6	10946-10953	inverse	_
62-7	10954-10968	transformation	_
62-8	10969-10971	of	_
62-9	10972-10980	template	_
62-10	10981-10988	regions	_
62-11	10989-10993	into	_
62-12	10994-11004	individual	_
62-13	11005-11011	native	_
62-14	11012-11017	space	_
62-15	11017-11018	.	_

#Text=A confirmatory whole-brain, between-group analysis was performed on BPND images using a two-sample t-test in SPM12 with a relative threshold mask (0.8; displayed in Figure 1).
63-1	11019-11020	A	_
63-2	11021-11033	confirmatory	_
63-3	11034-11045	whole-brain	_
63-4	11045-11046	,	_
63-5	11047-11060	between-group	_
63-6	11061-11069	analysis	_
63-7	11070-11073	was	_
63-8	11074-11083	performed	_
63-9	11084-11086	on	_
63-10	11087-11091	BPND	_
63-11	11092-11098	images	_
63-12	11099-11104	using	_
63-13	11105-11106	a	_
63-14	11107-11117	two-sample	_
63-15	11118-11124	t-test	_
63-16	11125-11127	in	_
63-17	11128-11133	SPM12	_
63-18	11134-11138	with	_
63-19	11139-11140	a	_
63-20	11141-11149	relative	_
63-21	11150-11159	threshold	_
63-22	11160-11164	mask	_
63-23	11165-11166	(	_
63-24	11166-11169	0.8	_
63-25	11169-11170	;	_
63-26	11171-11180	displayed	_
63-27	11181-11183	in	_
63-28	11184-11190	Figure	_
63-29	11191-11192	1	_
63-30	11192-11193	)	_
63-31	11193-11194	.	_

#Text=Due to the relatively low BPND signal (less than 0.5) in the thalamic and amygdala regions included in previous reports, substantial portions of these structures did not survive threshold masking and thus were excluded from ROI analyses.
64-1	11195-11198	Due	_
64-2	11199-11201	to	_
64-3	11202-11205	the	_
64-4	11206-11216	relatively	_
64-5	11217-11220	low	_
64-6	11221-11225	BPND	_
64-7	11226-11232	signal	_
64-8	11233-11234	(	_
64-9	11234-11238	less	_
64-10	11239-11243	than	_
64-11	11244-11247	0.5	_
64-12	11247-11248	)	_
64-13	11249-11251	in	_
64-14	11252-11255	the	_
64-15	11256-11264	thalamic	_
64-16	11265-11268	and	_
64-17	11269-11277	amygdala	_
64-18	11278-11285	regions	_
64-19	11286-11294	included	_
64-20	11295-11297	in	_
64-21	11298-11306	previous	_
64-22	11307-11314	reports	_
64-23	11314-11315	,	_
64-24	11316-11327	substantial	_
64-25	11328-11336	portions	_
64-26	11337-11339	of	_
64-27	11340-11345	these	_
64-28	11346-11356	structures	_
64-29	11357-11360	did	_
64-30	11361-11364	not	_
64-31	11365-11372	survive	_
64-32	11373-11382	threshold	_
64-33	11383-11390	masking	_
64-34	11391-11394	and	_
64-35	11395-11399	thus	_
64-36	11400-11404	were	_
64-37	11405-11413	excluded	_
64-38	11414-11418	from	_
64-39	11419-11422	ROI	_
64-40	11423-11431	analyses	_
64-41	11431-11432	.	_

#Text=Group differences were explored at an uncorrected significance level of p<0.005, and cluster extent (k) >20 contiguous voxels.
#Text=2.5.
65-1	11433-11438	Group	_
65-2	11439-11450	differences	_
65-3	11451-11455	were	_
65-4	11456-11464	explored	_
65-5	11465-11467	at	_
65-6	11468-11470	an	_
65-7	11471-11482	uncorrected	_
65-8	11483-11495	significance	_
65-9	11496-11501	level	_
65-10	11502-11504	of	_
65-11	11505-11506	p	_
65-12	11506-11507	<	_
65-13	11507-11512	0.005	_
65-14	11512-11513	,	_
65-15	11514-11517	and	_
65-16	11518-11525	cluster	_
65-17	11526-11532	extent	_
65-18	11533-11534	(	_
65-19	11534-11535	k	_
65-20	11535-11536	)	_
65-21	11537-11538	>	_
65-22	11538-11540	20	_
65-23	11541-11551	contiguous	_
65-24	11552-11558	voxels	_
65-25	11558-11559	.	_
65-26	11560-11563	2.5	_
65-27	11563-11564	.	_

#Text=Independent component analysis (ICA)
#Text=Exploratory ICA was performed on parametric images of [11C]-(+)-PHNO BPND using the source-based morphometry (SBM) module of the Group ICA of fMRI Toolbox (GIFT v2.0e; http://mialab.mrn.org/software/gift).
66-1	11565-11576	Independent	_
66-2	11577-11586	component	_
66-3	11587-11595	analysis	_
66-4	11596-11597	(	_
66-5	11597-11600	ICA	_
66-6	11600-11601	)	_
66-7	11602-11613	Exploratory	_
66-8	11614-11617	ICA	_
66-9	11618-11621	was	_
66-10	11622-11631	performed	_
66-11	11632-11634	on	_
66-12	11635-11645	parametric	_
66-13	11646-11652	images	_
66-14	11653-11655	of	_
66-15	11656-11657	[	_
66-16	11657-11660	11C	_
66-17	11660-11661	]	_
66-18	11661-11662	-	_
66-19	11662-11663	(	_
66-20	11663-11664	+	_
66-21	11664-11665	)	_
66-22	11665-11666	-	_
66-23	11666-11670	PHNO	_
66-24	11671-11675	BPND	_
66-25	11676-11681	using	_
66-26	11682-11685	the	_
66-27	11686-11698	source-based	_
66-28	11699-11710	morphometry	_
66-29	11711-11712	(	_
66-30	11712-11715	SBM	_
66-31	11715-11716	)	_
66-32	11717-11723	module	_
66-33	11724-11726	of	_
66-34	11727-11730	the	_
66-35	11731-11736	Group	_
66-36	11737-11740	ICA	_
66-37	11741-11743	of	_
66-38	11744-11748	fMRI	_
66-39	11749-11756	Toolbox	_
66-40	11757-11758	(	_
66-41	11758-11762	GIFT	_
66-42	11763-11768	v2.0e	_
66-43	11768-11769	;	_
66-44	11770-11774	http	_
66-45	11774-11775	:	_
66-46	11775-11776	/	_
66-47	11776-11777	/	_
66-48	11777-11791	mialab.mrn.org	_
66-49	11791-11792	/	_
66-50	11792-11800	software	_
66-51	11800-11801	/	_
66-52	11801-11805	gift	_
66-53	11805-11806	)	_
66-54	11806-11807	.	_

#Text=Using higher order statistics, ICA identifies maximally independent vectors that comprise an unknown linear mixture (A) of mostly non-Gaussian sources (s) that generate a random variable (x).
67-1	11808-11813	Using	_
67-2	11814-11820	higher	_
67-3	11821-11826	order	_
67-4	11827-11837	statistics	_
67-5	11837-11838	,	_
67-6	11839-11842	ICA	_
67-7	11843-11853	identifies	_
67-8	11854-11863	maximally	_
67-9	11864-11875	independent	_
67-10	11876-11883	vectors	_
67-11	11884-11888	that	_
67-12	11889-11897	comprise	_
67-13	11898-11900	an	_
67-14	11901-11908	unknown	_
67-15	11909-11915	linear	_
67-16	11916-11923	mixture	_
67-17	11924-11925	(	_
67-18	11925-11926	A	_
67-19	11926-11927	)	_
67-20	11928-11930	of	_
67-21	11931-11937	mostly	_
67-22	11938-11950	non-Gaussian	_
67-23	11951-11958	sources	_
67-24	11959-11960	(	_
67-25	11960-11961	s	_
67-26	11961-11962	)	_
67-27	11963-11967	that	_
67-28	11968-11976	generate	_
67-29	11977-11978	a	_
67-30	11979-11985	random	_
67-31	11986-11994	variable	_
67-32	11995-11996	(	_
67-33	11996-11997	x	_
67-34	11997-11998	)	_
67-35	11998-11999	.	_

#Text=Given x = As, ICA solves for y =Wx, or the estimated un-mixing matrix (W) of approximated source maps (y).
68-1	12000-12005	Given	_
68-2	12006-12007	x	_
68-3	12008-12009	=	_
68-4	12010-12012	As	_
68-5	12012-12013	,	_
68-6	12014-12017	ICA	_
68-7	12018-12024	solves	_
68-8	12025-12028	for	_
68-9	12029-12030	y	_
68-10	12031-12032	=	_
68-11	12032-12034	Wx	_
68-12	12034-12035	,	_
68-13	12036-12038	or	_
68-14	12039-12042	the	_
68-15	12043-12052	estimated	_
68-16	12053-12062	un-mixing	_
68-17	12063-12069	matrix	_
68-18	12070-12071	(	_
68-19	12071-12072	W	_
68-20	12072-12073	)	_
68-21	12074-12076	of	_
68-22	12077-12089	approximated	_
68-23	12090-12096	source	_
68-24	12097-12101	maps	_
68-25	12102-12103	(	_
68-26	12103-12104	y	_
68-27	12104-12105	)	_
68-28	12105-12106	.	_

#Text=Parametric images of all 52 participants were entered into the ICA to allow direct comparison of source loadings.
69-1	12107-12117	Parametric	_
69-2	12118-12124	images	_
69-3	12125-12127	of	_
69-4	12128-12131	all	_
69-5	12132-12134	52	_
69-6	12135-12147	participants	_
69-7	12148-12152	were	_
69-8	12153-12160	entered	_
69-9	12161-12165	into	_
69-10	12166-12169	the	_
69-11	12170-12173	ICA	_
69-12	12174-12176	to	_
69-13	12177-12182	allow	_
69-14	12183-12189	direct	_
69-15	12190-12200	comparison	_
69-16	12201-12203	of	_
69-17	12204-12210	source	_
69-18	12211-12219	loadings	_
69-19	12219-12220	.	_

#Text=The analysis was constrained to data within the relative threshold mask determined in the GLM analysis (described above), and with no prior information as to group membership.
70-1	12221-12224	The	_
70-2	12225-12233	analysis	_
70-3	12234-12237	was	_
70-4	12238-12249	constrained	_
70-5	12250-12252	to	_
70-6	12253-12257	data	_
70-7	12258-12264	within	_
70-8	12265-12268	the	_
70-9	12269-12277	relative	_
70-10	12278-12287	threshold	_
70-11	12288-12292	mask	_
70-12	12293-12303	determined	_
70-13	12304-12306	in	_
70-14	12307-12310	the	_
70-15	12311-12314	GLM	_
70-16	12315-12323	analysis	_
70-17	12324-12325	(	_
70-18	12325-12334	described	_
70-19	12335-12340	above	_
70-20	12340-12341	)	_
70-21	12341-12342	,	_
70-22	12343-12346	and	_
70-23	12347-12351	with	_
70-24	12352-12354	no	_
70-25	12355-12360	prior	_
70-26	12361-12372	information	_
70-27	12373-12375	as	_
70-28	12376-12378	to	_
70-29	12379-12384	group	_
70-30	12385-12395	membership	_
70-31	12395-12396	.	_

#Text=A modified minimum-description-length (MDL) criterion estimated the dimensionality of the dataset to consist of three sources which were extracted from the aggregate dataset using a neural-network algorithm designed to minimize mutual information of source outputs (InfoMax).
71-1	12397-12398	A	_
71-2	12399-12407	modified	_
71-3	12408-12434	minimum-description-length	_
71-4	12435-12436	(	_
71-5	12436-12439	MDL	_
71-6	12439-12440	)	_
71-7	12441-12450	criterion	_
71-8	12451-12460	estimated	_
71-9	12461-12464	the	_
71-10	12465-12479	dimensionality	_
71-11	12480-12482	of	_
71-12	12483-12486	the	_
71-13	12487-12494	dataset	_
71-14	12495-12497	to	_
71-15	12498-12505	consist	_
71-16	12506-12508	of	_
71-17	12509-12514	three	_
71-18	12515-12522	sources	_
71-19	12523-12528	which	_
71-20	12529-12533	were	_
71-21	12534-12543	extracted	_
71-22	12544-12548	from	_
71-23	12549-12552	the	_
71-24	12553-12562	aggregate	_
71-25	12563-12570	dataset	_
71-26	12571-12576	using	_
71-27	12577-12578	a	_
71-28	12579-12593	neural-network	_
71-29	12594-12603	algorithm	_
71-30	12604-12612	designed	_
71-31	12613-12615	to	_
71-32	12616-12624	minimize	_
71-33	12625-12631	mutual	_
71-34	12632-12643	information	_
71-35	12644-12646	of	_
71-36	12647-12653	source	_
71-37	12654-12661	outputs	_
71-38	12662-12663	(	_
71-39	12663-12670	InfoMax	_
71-40	12670-12671	)	_
71-41	12671-12672	.	_

#Text=Output from the ICA included the spatial source maps (yM;M =1,2,3) and subject ICA-loading values (Ã; 1M,i;i = 1, …, 52), where Ã denotes the estimate of the unknown mixing matrix A (i.e. the inverse of ICA-derived un-mixing matrix W).
72-1	12673-12679	Output	_
72-2	12680-12684	from	_
72-3	12685-12688	the	_
72-4	12689-12692	ICA	_
72-5	12693-12701	included	_
72-6	12702-12705	the	_
72-7	12706-12713	spatial	_
72-8	12714-12720	source	_
72-9	12721-12725	maps	_
72-10	12726-12727	(	_
72-11	12727-12729	yM	_
72-12	12729-12730	;	_
72-13	12730-12731	M	_
72-14	12732-12733	=	_
72-15	12733-12738	1,2,3	_
72-16	12738-12739	)	_
72-17	12740-12743	and	_
72-18	12744-12751	subject	_
72-19	12752-12763	ICA-loading	_
72-20	12764-12770	values	_
72-21	12771-12772	(	_
72-22	12772-12773	Ã	_
72-23	12773-12774	;	_
72-24	12775-12777	1M	_
72-25	12777-12778	,	_
72-26	12778-12779	i	_
72-27	12779-12780	;	_
72-28	12780-12781	i	_
72-29	12782-12783	=	_
72-30	12784-12785	1	_
72-31	12785-12786	,	_
72-32	12787-12788	…	_
72-33	12788-12789	,	_
72-34	12790-12792	52	_
72-35	12792-12793	)	_
72-36	12793-12794	,	_
72-37	12795-12800	where	_
72-38	12801-12802	Ã	_
72-39	12803-12810	denotes	_
72-40	12811-12814	the	_
72-41	12815-12823	estimate	_
72-42	12824-12826	of	_
72-43	12827-12830	the	_
72-44	12831-12838	unknown	_
72-45	12839-12845	mixing	_
72-46	12846-12852	matrix	_
72-47	12853-12854	A	_
72-48	12855-12856	(	_
72-49	12856-12859	i.e	_
72-50	12859-12860	.	_
72-51	12861-12864	the	_
72-52	12865-12872	inverse	_
72-53	12873-12875	of	_
72-54	12876-12887	ICA-derived	_
72-55	12888-12897	un-mixing	_
72-56	12898-12904	matrix	_
72-57	12905-12906	W	_
72-58	12906-12907	)	_
72-59	12907-12908	.	_

#Text=Note that applications of ICA to biomedical images typically employ principal component analysis (PCA) for data reduction prior to ICA; thus, subject ICA-loadings also incorporate the PCA-reduction factor (R) and are more accurately characterized as (R × Ã), but for convenience, we use Ã to represent the final subject ICA-loading parameters.
73-1	12909-12913	Note	_
73-2	12914-12918	that	_
73-3	12919-12931	applications	_
73-4	12932-12934	of	_
73-5	12935-12938	ICA	_
73-6	12939-12941	to	_
73-7	12942-12952	biomedical	_
73-8	12953-12959	images	_
73-9	12960-12969	typically	_
73-10	12970-12976	employ	_
73-11	12977-12986	principal	_
73-12	12987-12996	component	_
73-13	12997-13005	analysis	_
73-14	13006-13007	(	_
73-15	13007-13010	PCA	_
73-16	13010-13011	)	_
73-17	13012-13015	for	_
73-18	13016-13020	data	_
73-19	13021-13030	reduction	_
73-20	13031-13036	prior	_
73-21	13037-13039	to	_
73-22	13040-13043	ICA	_
73-23	13043-13044	;	_
73-24	13045-13049	thus	_
73-25	13049-13050	,	_
73-26	13051-13058	subject	_
73-27	13059-13071	ICA-loadings	_
73-28	13072-13076	also	_
73-29	13077-13088	incorporate	_
73-30	13089-13092	the	_
73-31	13093-13106	PCA-reduction	_
73-32	13107-13113	factor	_
73-33	13114-13115	(	_
73-34	13115-13116	R	_
73-35	13116-13117	)	_
73-36	13118-13121	and	_
73-37	13122-13125	are	_
73-38	13126-13130	more	_
73-39	13131-13141	accurately	_
73-40	13142-13155	characterized	_
73-41	13156-13158	as	_
73-42	13159-13160	(	_
73-43	13160-13161	R	_
73-44	13162-13163	×	_
73-45	13164-13165	Ã	_
73-46	13165-13166	)	_
73-47	13166-13167	,	_
73-48	13168-13171	but	_
73-49	13172-13175	for	_
73-50	13176-13187	convenience	_
73-51	13187-13188	,	_
73-52	13189-13191	we	_
73-53	13192-13195	use	_
73-54	13196-13197	Ã	_
73-55	13198-13200	to	_
73-56	13201-13210	represent	_
73-57	13211-13214	the	_
73-58	13215-13220	final	_
73-59	13221-13228	subject	_
73-60	13229-13240	ICA-loading	_
73-61	13241-13251	parameters	_
73-62	13251-13252	.	_

#Text=The subject ICA-loading values represent the source ‘intensity’ or relative strength to which each subject’s BPND data contained a given source.
74-1	13253-13256	The	_
74-2	13257-13264	subject	_
74-3	13265-13276	ICA-loading	_
74-4	13277-13283	values	_
74-5	13284-13293	represent	_
74-6	13294-13297	the	_
74-7	13298-13304	source	_
74-8	13305-13306	‘	_
74-9	13306-13315	intensity	_
74-10	13315-13316	’	_
74-11	13317-13319	or	_
74-12	13320-13328	relative	_
74-13	13329-13337	strength	_
74-14	13338-13340	to	_
74-15	13341-13346	which	_
74-16	13347-13351	each	_
74-17	13352-13359	subject	_
74-18	13359-13360	’	_
74-19	13360-13361	s	_
74-20	13362-13366	BPND	_
74-21	13367-13371	data	_
74-22	13372-13381	contained	_
74-23	13382-13383	a	_
74-24	13384-13389	given	_
74-25	13390-13396	source	_
74-26	13396-13397	.	_

#Text=The spatial source maps were ‘intensity-scaled’ such that (yM × Ã) reflects the relative contribution of each source to the aggregate BPND signal, where ÃM,iis the average subject intensity for source M, and: where x̃ is the approximate reconstruction of the original data x, and x̄ is the global mean BPND value (1.56) removed prior to ICA extraction.
75-1	13398-13401	The	_
75-2	13402-13409	spatial	_
75-3	13410-13416	source	_
75-4	13417-13421	maps	_
75-5	13422-13426	were	_
75-6	13427-13428	‘	_
75-7	13428-13444	intensity-scaled	_
75-8	13444-13445	’	_
75-9	13446-13450	such	_
75-10	13451-13455	that	_
75-11	13456-13457	(	_
75-12	13457-13459	yM	_
75-13	13460-13461	×	_
75-14	13462-13463	Ã	_
75-15	13463-13464	)	_
75-16	13465-13473	reflects	_
75-17	13474-13477	the	_
75-18	13478-13486	relative	_
75-19	13487-13499	contribution	_
75-20	13500-13502	of	_
75-21	13503-13507	each	_
75-22	13508-13514	source	_
75-23	13515-13517	to	_
75-24	13518-13521	the	_
75-25	13522-13531	aggregate	_
75-26	13532-13536	BPND	_
75-27	13537-13543	signal	_
75-28	13543-13544	,	_
75-29	13545-13550	where	_
75-30	13551-13553	ÃM	_
75-31	13553-13554	,	_
75-32	13554-13557	iis	_
75-33	13558-13561	the	_
75-34	13562-13569	average	_
75-35	13570-13577	subject	_
75-36	13578-13587	intensity	_
75-37	13588-13591	for	_
75-38	13592-13598	source	_
75-39	13599-13600	M	_
75-40	13600-13601	,	_
75-41	13602-13605	and	_
75-42	13605-13606	:	_
75-43	13607-13612	where	_
75-44	13613-13615	x̃	_
75-45	13616-13618	is	_
75-46	13619-13622	the	_
75-47	13623-13634	approximate	_
75-48	13635-13649	reconstruction	_
75-49	13650-13652	of	_
75-50	13653-13656	the	_
75-51	13657-13665	original	_
75-52	13666-13670	data	_
75-53	13671-13672	x	_
75-54	13672-13673	,	_
75-55	13674-13677	and	_
75-56	13678-13680	x̄	_
75-57	13681-13683	is	_
75-58	13684-13687	the	_
75-59	13688-13694	global	_
75-60	13695-13699	mean	_
75-61	13700-13704	BPND	_
75-62	13705-13710	value	_
75-63	13711-13712	(	_
75-64	13712-13716	1.56	_
75-65	13716-13717	)	_
75-66	13718-13725	removed	_
75-67	13726-13731	prior	_
75-68	13732-13734	to	_
75-69	13735-13738	ICA	_
75-70	13739-13749	extraction	_
75-71	13749-13750	.	_

#Text=For analysis purposes, the source maps were scaled to ICA-estimated BPND (B̃PM) through the product of (yM × ÃM,i).
76-1	13751-13754	For	_
76-2	13755-13763	analysis	_
76-3	13764-13772	purposes	_
76-4	13772-13773	,	_
76-5	13774-13777	the	_
76-6	13778-13784	source	_
76-7	13785-13789	maps	_
76-8	13790-13794	were	_
76-9	13795-13801	scaled	_
76-10	13802-13804	to	_
76-11	13805-13818	ICA-estimated	_
76-12	13819-13823	BPND	_
76-13	13824-13825	(	_
76-14	13825-13829	B̃PM	_
76-15	13829-13830	)	_
76-16	13831-13838	through	_
76-17	13839-13842	the	_
76-18	13843-13850	product	_
76-19	13851-13853	of	_
76-20	13854-13855	(	_
76-21	13855-13857	yM	_
76-22	13858-13859	×	_
76-23	13860-13862	ÃM	_
76-24	13862-13863	,	_
76-25	13863-13864	i	_
76-26	13864-13865	)	_
76-27	13865-13866	.	_

#Text=For display and anatomical assignment purposes, the scaled source maps were thresholded at B̃PM≥0.5 (with no cluster-extent threshold) based on the relevant range of [11C]-(+)-PHNO BPND of 1.5–4.
77-1	13867-13870	For	_
77-2	13871-13878	display	_
77-3	13879-13882	and	_
77-4	13883-13893	anatomical	_
77-5	13894-13904	assignment	_
77-6	13905-13913	purposes	_
77-7	13913-13914	,	_
77-8	13915-13918	the	_
77-9	13919-13925	scaled	_
77-10	13926-13932	source	_
77-11	13933-13937	maps	_
77-12	13938-13942	were	_
77-13	13943-13954	thresholded	_
77-14	13955-13957	at	_
77-15	13958-13962	B̃PM	_
77-16	13962-13963	≥	_
77-17	13963-13966	0.5	_
77-18	13967-13968	(	_
77-19	13968-13972	with	_
77-20	13973-13975	no	_
77-21	13976-13990	cluster-extent	_
77-22	13991-14000	threshold	_
77-23	14000-14001	)	_
77-24	14002-14007	based	_
77-25	14008-14010	on	_
77-26	14011-14014	the	_
77-27	14015-14023	relevant	_
77-28	14024-14029	range	_
77-29	14030-14032	of	_
77-30	14033-14034	[	_
77-31	14034-14037	11C	_
77-32	14037-14038	]	_
77-33	14038-14039	-	_
77-34	14039-14040	(	_
77-35	14040-14041	+	_
77-36	14041-14042	)	_
77-37	14042-14043	-	_
77-38	14043-14047	PHNO	_
77-39	14048-14052	BPND	_
77-40	14053-14055	of	_
77-41	14056-14059	1.5	_
77-42	14059-14060	–	_
77-43	14060-14061	4	_
77-44	14061-14062	.	_

#Text=To examine source compositions relative to regional estimates of D2R/D3R availability, intensity-scaled source maps were generated for all subjects, and regional B̃PM values were extracted from the seven ROIs and compared the D2R-related and D3R-related proportions of BPND calculated using reported regional fractions of [11C]-(+)-PHNO BPND.
78-1	14063-14065	To	_
78-2	14066-14073	examine	_
78-3	14074-14080	source	_
78-4	14081-14093	compositions	_
78-5	14094-14102	relative	_
78-6	14103-14105	to	_
78-7	14106-14114	regional	_
78-8	14115-14124	estimates	_
78-9	14125-14127	of	_
78-10	14128-14131	D2R	_
78-11	14131-14132	/	_
78-12	14132-14135	D3R	_
78-13	14136-14148	availability	_
78-14	14148-14149	,	_
78-15	14150-14166	intensity-scaled	_
78-16	14167-14173	source	_
78-17	14174-14178	maps	_
78-18	14179-14183	were	_
78-19	14184-14193	generated	_
78-20	14194-14197	for	_
78-21	14198-14201	all	_
78-22	14202-14210	subjects	_
78-23	14210-14211	,	_
78-24	14212-14215	and	_
78-25	14216-14224	regional	_
78-26	14225-14229	B̃PM	_
78-27	14230-14236	values	_
78-28	14237-14241	were	_
78-29	14242-14251	extracted	_
78-30	14252-14256	from	_
78-31	14257-14260	the	_
78-32	14261-14266	seven	_
78-33	14267-14271	ROIs	_
78-34	14272-14275	and	_
78-35	14276-14284	compared	_
78-36	14285-14288	the	_
78-37	14289-14300	D2R-related	_
78-38	14301-14304	and	_
78-39	14305-14316	D3R-related	_
78-40	14317-14328	proportions	_
78-41	14329-14331	of	_
78-42	14332-14336	BPND	_
78-43	14337-14347	calculated	_
78-44	14348-14353	using	_
78-45	14354-14362	reported	_
78-46	14363-14371	regional	_
78-47	14372-14381	fractions	_
78-48	14382-14384	of	_
78-49	14385-14386	[	_
78-50	14386-14389	11C	_
78-51	14389-14390	]	_
78-52	14390-14391	-	_
78-53	14391-14392	(	_
78-54	14392-14393	+	_
78-55	14393-14394	)	_
78-56	14394-14395	-	_
78-57	14395-14399	PHNO	_
78-58	14400-14404	BPND	_
78-59	14404-14405	.	_

#Text=That is, regional BPND values obtained in the ROI-based analysis (see Section 2.4. and Figure 1) were multiplied by average D2R-and D3R-related fractions reported in (Supplementary Table 1) to obtain regional estimates of local D2R/D3R BPND (i.e., ).
79-1	14406-14410	That	_
79-2	14411-14413	is	_
79-3	14413-14414	,	_
79-4	14415-14423	regional	_
79-5	14424-14428	BPND	_
79-6	14429-14435	values	_
79-7	14436-14444	obtained	_
79-8	14445-14447	in	_
79-9	14448-14451	the	_
79-10	14452-14461	ROI-based	_
79-11	14462-14470	analysis	_
79-12	14471-14472	(	_
79-13	14472-14475	see	_
79-14	14476-14483	Section	_
79-15	14484-14487	2.4	_
79-16	14487-14488	.	_
79-17	14489-14492	and	_
79-18	14493-14499	Figure	_
79-19	14500-14501	1	_
79-20	14501-14502	)	_
79-21	14503-14507	were	_
79-22	14508-14518	multiplied	_
79-23	14519-14521	by	_
79-24	14522-14529	average	_
79-25	14530-14537	D2R-and	_
79-26	14538-14549	D3R-related	_
79-27	14550-14559	fractions	_
79-28	14560-14568	reported	_
79-29	14569-14571	in	_
79-30	14572-14573	(	_
79-31	14573-14586	Supplementary	_
79-32	14587-14592	Table	_
79-33	14593-14594	1	_
79-34	14594-14595	)	_
79-35	14596-14598	to	_
79-36	14599-14605	obtain	_
79-37	14606-14614	regional	_
79-38	14615-14624	estimates	_
79-39	14625-14627	of	_
79-40	14628-14633	local	_
79-41	14634-14637	D2R	_
79-42	14637-14638	/	_
79-43	14638-14641	D3R	_
79-44	14642-14646	BPND	_
79-45	14647-14648	(	_
79-46	14648-14651	i.e	_
79-47	14651-14652	.	_
79-48	14652-14653	,	_
79-49	14654-14655	)	_
79-50	14655-14656	.	_

#Text=Average regional B̃PM for each source were then examined in relation to the calculated estimates of  and  using Pearson correlations to assess potential association with D2R-related and D3R-related BPND proportions.
#Text=2.6.
80-1	14657-14664	Average	_
80-2	14665-14673	regional	_
80-3	14674-14678	B̃PM	_
80-4	14679-14682	for	_
80-5	14683-14687	each	_
80-6	14688-14694	source	_
80-7	14695-14699	were	_
80-8	14700-14704	then	_
80-9	14705-14713	examined	_
80-10	14714-14716	in	_
80-11	14717-14725	relation	_
80-12	14726-14728	to	_
80-13	14729-14732	the	_
80-14	14733-14743	calculated	_
80-15	14744-14753	estimates	_
80-16	14754-14756	of	_
80-17	14758-14761	and	_
80-18	14763-14768	using	_
80-19	14769-14776	Pearson	_
80-20	14777-14789	correlations	_
80-21	14790-14792	to	_
80-22	14793-14799	assess	_
80-23	14800-14809	potential	_
80-24	14810-14821	association	_
80-25	14822-14826	with	_
80-26	14827-14838	D2R-related	_
80-27	14839-14842	and	_
80-28	14843-14854	D3R-related	_
80-29	14855-14859	BPND	_
80-30	14860-14871	proportions	_
80-31	14871-14872	.	_
80-32	14873-14876	2.6	_
80-33	14876-14877	.	_

#Text=Statistical procedures
#Text=Group differences in ROI BPND values and ICA source intensities were assessed with two separate multivariate analyses of variance (i.e., group × ROI and group × source) and post-hoc univariate analyses.
81-1	14878-14889	Statistical	_
81-2	14890-14900	procedures	_
81-3	14901-14906	Group	_
81-4	14907-14918	differences	_
81-5	14919-14921	in	_
81-6	14922-14925	ROI	_
81-7	14926-14930	BPND	_
81-8	14931-14937	values	_
81-9	14938-14941	and	_
81-10	14942-14945	ICA	_
81-11	14946-14952	source	_
81-12	14953-14964	intensities	_
81-13	14965-14969	were	_
81-14	14970-14978	assessed	_
81-15	14979-14983	with	_
81-16	14984-14987	two	_
81-17	14988-14996	separate	_
81-18	14997-15009	multivariate	_
81-19	15010-15018	analyses	_
81-20	15019-15021	of	_
81-21	15022-15030	variance	_
81-22	15031-15032	(	_
81-23	15032-15035	i.e	_
81-24	15035-15036	.	_
81-25	15036-15037	,	_
81-26	15038-15043	group	_
81-27	15044-15045	×	_
81-28	15046-15049	ROI	_
81-29	15050-15053	and	_
81-30	15054-15059	group	_
81-31	15060-15061	×	_
81-32	15062-15068	source	_
81-33	15068-15069	)	_
81-34	15070-15073	and	_
81-35	15074-15082	post-hoc	_
81-36	15083-15093	univariate	_
81-37	15094-15102	analyses	_
81-38	15102-15103	.	_

#Text=Due to non-tracer conditions of [11C]-(+)-PHNO for D3Rs at the administered dose, multivariate analyses including the estimated free concentration of [11C]-(+)-PHNO (based on the average mass concentration in the cerebellum from 90–120 mins, multiplied by the specific activity) as a covariate were performed and revealed no significant mass dose effect on results (p’s>0.4).
82-1	15104-15107	Due	_
82-2	15108-15110	to	_
82-3	15111-15121	non-tracer	_
82-4	15122-15132	conditions	_
82-5	15133-15135	of	_
82-6	15136-15137	[	_
82-7	15137-15140	11C	_
82-8	15140-15141	]	_
82-9	15141-15142	-	_
82-10	15142-15143	(	_
82-11	15143-15144	+	_
82-12	15144-15145	)	_
82-13	15145-15146	-	_
82-14	15146-15150	PHNO	_
82-15	15151-15154	for	_
82-16	15155-15159	D3Rs	_
82-17	15160-15162	at	_
82-18	15163-15166	the	_
82-19	15167-15179	administered	_
82-20	15180-15184	dose	_
82-21	15184-15185	,	_
82-22	15186-15198	multivariate	_
82-23	15199-15207	analyses	_
82-24	15208-15217	including	_
82-25	15218-15221	the	_
82-26	15222-15231	estimated	_
82-27	15232-15236	free	_
82-28	15237-15250	concentration	_
82-29	15251-15253	of	_
82-30	15254-15255	[	_
82-31	15255-15258	11C	_
82-32	15258-15259	]	_
82-33	15259-15260	-	_
82-34	15260-15261	(	_
82-35	15261-15262	+	_
82-36	15262-15263	)	_
82-37	15263-15264	-	_
82-38	15264-15268	PHNO	_
82-39	15269-15270	(	_
82-40	15270-15275	based	_
82-41	15276-15278	on	_
82-42	15279-15282	the	_
82-43	15283-15290	average	_
82-44	15291-15295	mass	_
82-45	15296-15309	concentration	_
82-46	15310-15312	in	_
82-47	15313-15316	the	_
82-48	15317-15327	cerebellum	_
82-49	15328-15332	from	_
82-50	15333-15335	90	_
82-51	15335-15336	–	_
82-52	15336-15339	120	_
82-53	15340-15344	mins	_
82-54	15344-15345	,	_
82-55	15346-15356	multiplied	_
82-56	15357-15359	by	_
82-57	15360-15363	the	_
82-58	15364-15372	specific	_
82-59	15373-15381	activity	_
82-60	15381-15382	)	_
82-61	15383-15385	as	_
82-62	15386-15387	a	_
82-63	15388-15397	covariate	_
82-64	15398-15402	were	_
82-65	15403-15412	performed	_
82-66	15413-15416	and	_
82-67	15417-15425	revealed	_
82-68	15426-15428	no	_
82-69	15429-15440	significant	_
82-70	15441-15445	mass	_
82-71	15446-15450	dose	_
82-72	15451-15457	effect	_
82-73	15458-15460	on	_
82-74	15461-15468	results	_
82-75	15469-15470	(	_
82-76	15470-15471	p	_
82-77	15471-15472	’	_
82-78	15472-15473	s	_
82-79	15473-15474	>	_
82-80	15474-15477	0.4	_
82-81	15477-15478	)	_
82-82	15478-15479	.	_

#Text=Given reported associations between [11C]-(+)-PHNO BPND and age and body-mass, all between-group multivariate and univariate analyses were repeated adjusting for age and body-mass.
83-1	15480-15485	Given	_
83-2	15486-15494	reported	_
83-3	15495-15507	associations	_
83-4	15508-15515	between	_
83-5	15516-15517	[	_
83-6	15517-15520	11C	_
83-7	15520-15521	]	_
83-8	15521-15522	-	_
83-9	15522-15523	(	_
83-10	15523-15524	+	_
83-11	15524-15525	)	_
83-12	15525-15526	-	_
83-13	15526-15530	PHNO	_
83-14	15531-15535	BPND	_
83-15	15536-15539	and	_
83-16	15540-15543	age	_
83-17	15544-15547	and	_
83-18	15548-15557	body-mass	_
83-19	15557-15558	,	_
83-20	15559-15562	all	_
83-21	15563-15576	between-group	_
83-22	15577-15589	multivariate	_
83-23	15590-15593	and	_
83-24	15594-15604	univariate	_
83-25	15605-15613	analyses	_
83-26	15614-15618	were	_
83-27	15619-15627	repeated	_
83-28	15628-15637	adjusting	_
83-29	15638-15641	for	_
83-30	15642-15645	age	_
83-31	15646-15649	and	_
83-32	15650-15659	body-mass	_
83-33	15659-15660	.	_

#Text=Additional analyses were performed to examine potential influences of alcohol use across all participants and cigarette smoking within CUD participants.
84-1	15661-15671	Additional	_
84-2	15672-15680	analyses	_
84-3	15681-15685	were	_
84-4	15686-15695	performed	_
84-5	15696-15698	to	_
84-6	15699-15706	examine	_
84-7	15707-15716	potential	_
84-8	15717-15727	influences	_
84-9	15728-15730	of	_
84-10	15731-15738	alcohol	_
84-11	15739-15742	use	_
84-12	15743-15749	across	_
84-13	15750-15753	all	_
84-14	15754-15766	participants	_
84-15	15767-15770	and	_
84-16	15771-15780	cigarette	_
84-17	15781-15788	smoking	_
84-18	15789-15795	within	_
84-19	15796-15799	CUD	_
84-20	15800-15812	participants	_
84-21	15812-15813	.	_

#Text=Exploratory correlational analyses were performed to examine relationships between regional and source-based binding measures with years of cocaine use.
#Text=3.
85-1	15814-15825	Exploratory	_
85-2	15826-15839	correlational	_
85-3	15840-15848	analyses	_
85-4	15849-15853	were	_
85-5	15854-15863	performed	_
85-6	15864-15866	to	_
85-7	15867-15874	examine	_
85-8	15875-15888	relationships	_
85-9	15889-15896	between	_
85-10	15897-15905	regional	_
85-11	15906-15909	and	_
85-12	15910-15922	source-based	_
85-13	15923-15930	binding	_
85-14	15931-15939	measures	_
85-15	15940-15944	with	_
85-16	15945-15950	years	_
85-17	15951-15953	of	_
85-18	15954-15961	cocaine	_
85-19	15962-15965	use	_
85-20	15965-15966	.	_
85-21	15967-15968	3	_
85-22	15968-15969	.	_

#Text=Results
#Text=Participant characteristics and radioactivity information are provided in Table 1.
86-1	15970-15977	Results	_
86-2	15978-15989	Participant	_
86-3	15990-16005	characteristics	_
86-4	16006-16009	and	_
86-5	16010-16023	radioactivity	_
86-6	16024-16035	information	_
86-7	16036-16039	are	_
86-8	16040-16048	provided	_
86-9	16049-16051	in	_
86-10	16052-16057	Table	_
86-11	16058-16059	1	_
86-12	16059-16060	.	_

#Text=There were no group differences in body-mass or radiotracer injection parameters.
87-1	16061-16066	There	_
87-2	16067-16071	were	_
87-3	16072-16074	no	_
87-4	16075-16080	group	_
87-5	16081-16092	differences	_
87-6	16093-16095	in	_
87-7	16096-16105	body-mass	_
87-8	16106-16108	or	_
87-9	16109-16120	radiotracer	_
87-10	16121-16130	injection	_
87-11	16131-16141	parameters	_
87-12	16141-16142	.	_

#Text=CUD participants were more likely to be daily tobacco smokers (χ2=32.4, p<0.001) and did not differ from HCs in weekly alcohol consumption.
88-1	16143-16146	CUD	_
88-2	16147-16159	participants	_
88-3	16160-16164	were	_
88-4	16165-16169	more	_
88-5	16170-16176	likely	_
88-6	16177-16179	to	_
88-7	16180-16182	be	_
88-8	16183-16188	daily	_
88-9	16189-16196	tobacco	_
88-10	16197-16204	smokers	_
88-11	16205-16206	(	_
88-12	16206-16208	χ2	_
88-13	16208-16209	=	_
88-14	16209-16213	32.4	_
88-15	16213-16214	,	_
88-16	16215-16216	p	_
88-17	16216-16217	<	_
88-18	16217-16222	0.001	_
88-19	16222-16223	)	_
88-20	16224-16227	and	_
88-21	16228-16231	did	_
88-22	16232-16235	not	_
88-23	16236-16242	differ	_
88-24	16243-16247	from	_
88-25	16248-16251	HCs	_
88-26	16252-16254	in	_
88-27	16255-16261	weekly	_
88-28	16262-16269	alcohol	_
88-29	16270-16281	consumption	_
88-30	16281-16282	.	_

#Text=ROI volumes (in subject/native space) did not differ between groups (p’s>0.1).
#Text=3.1.
89-1	16283-16286	ROI	_
89-2	16287-16294	volumes	_
89-3	16295-16296	(	_
89-4	16296-16298	in	_
89-5	16299-16306	subject	_
89-6	16306-16307	/	_
89-7	16307-16313	native	_
89-8	16314-16319	space	_
89-9	16319-16320	)	_
89-10	16321-16324	did	_
89-11	16325-16328	not	_
89-12	16329-16335	differ	_
89-13	16336-16343	between	_
89-14	16344-16350	groups	_
89-15	16351-16352	(	_
89-16	16352-16353	p	_
89-17	16353-16354	’	_
89-18	16354-16355	s	_
89-19	16355-16356	>	_
89-20	16356-16359	0.1	_
89-21	16359-16360	)	_
89-22	16360-16361	.	_
89-23	16362-16365	3.1	_
89-24	16365-16366	.	_

#Text=Regional analyses of [11C]-(+)-PHNO BPND
#Text=Results of ROI and whole-brain analyses are displayed in Figure 1.
90-1	16367-16375	Regional	_
90-2	16376-16384	analyses	_
90-3	16385-16387	of	_
90-4	16388-16389	[	_
90-5	16389-16392	11C	_
90-6	16392-16393	]	_
90-7	16393-16394	-	_
90-8	16394-16395	(	_
90-9	16395-16396	+	_
90-10	16396-16397	)	_
90-11	16397-16398	-	_
90-12	16398-16402	PHNO	_
90-13	16403-16407	BPND	_
90-14	16408-16415	Results	_
90-15	16416-16418	of	_
90-16	16419-16422	ROI	_
90-17	16423-16426	and	_
90-18	16427-16438	whole-brain	_
90-19	16439-16447	analyses	_
90-20	16448-16451	are	_
90-21	16452-16461	displayed	_
90-22	16462-16464	in	_
90-23	16465-16471	Figure	_
90-24	16472-16473	1	_
90-25	16473-16474	.	_

#Text=There was a main effect of group across ROIs (F7,44=3.87, p=0.002), with CUD relative to HC displaying greater BPND in the SN (t50=2.91, p=0.005) and lower BPND in the DPU (t50=2.14, p=0.037), while a group difference in the DCA did not reach significance (t50=1.79, p=0.080) (Figure 1a).
91-1	16475-16480	There	_
91-2	16481-16484	was	_
91-3	16485-16486	a	_
91-4	16487-16491	main	_
91-5	16492-16498	effect	_
91-6	16499-16501	of	_
91-7	16502-16507	group	_
91-8	16508-16514	across	_
91-9	16515-16519	ROIs	_
91-10	16520-16521	(	_
91-11	16521-16526	F7,44	_
91-12	16526-16527	=	_
91-13	16527-16531	3.87	_
91-14	16531-16532	,	_
91-15	16533-16534	p	_
91-16	16534-16535	=	_
91-17	16535-16540	0.002	_
91-18	16540-16541	)	_
91-19	16541-16542	,	_
91-20	16543-16547	with	_
91-21	16548-16551	CUD	_
91-22	16552-16560	relative	_
91-23	16561-16563	to	_
91-24	16564-16566	HC	_
91-25	16567-16577	displaying	_
91-26	16578-16585	greater	_
91-27	16586-16590	BPND	_
91-28	16591-16593	in	_
91-29	16594-16597	the	_
91-30	16598-16600	SN	_
91-31	16601-16602	(	_
91-32	16602-16605	t50	_
91-33	16605-16606	=	_
91-34	16606-16610	2.91	_
91-35	16610-16611	,	_
91-36	16612-16613	p	_
91-37	16613-16614	=	_
91-38	16614-16619	0.005	_
91-39	16619-16620	)	_
91-40	16621-16624	and	_
91-41	16625-16630	lower	_
91-42	16631-16635	BPND	_
91-43	16636-16638	in	_
91-44	16639-16642	the	_
91-45	16643-16646	DPU	_
91-46	16647-16648	(	_
91-47	16648-16651	t50	_
91-48	16651-16652	=	_
91-49	16652-16656	2.14	_
91-50	16656-16657	,	_
91-51	16658-16659	p	_
91-52	16659-16660	=	_
91-53	16660-16665	0.037	_
91-54	16665-16666	)	_
91-55	16666-16667	,	_
91-56	16668-16673	while	_
91-57	16674-16675	a	_
91-58	16676-16681	group	_
91-59	16682-16692	difference	_
91-60	16693-16695	in	_
91-61	16696-16699	the	_
91-62	16700-16703	DCA	_
91-63	16704-16707	did	_
91-64	16708-16711	not	_
91-65	16712-16717	reach	_
91-66	16718-16730	significance	_
91-67	16731-16732	(	_
91-68	16732-16735	t50	_
91-69	16735-16736	=	_
91-70	16736-16740	1.79	_
91-71	16740-16741	,	_
91-72	16742-16743	p	_
91-73	16743-16744	=	_
91-74	16744-16749	0.080	_
91-75	16749-16750	)	_
91-76	16751-16752	(	_
91-77	16752-16758	Figure	_
91-78	16759-16761	1a	_
91-79	16761-16762	)	_
91-80	16762-16763	.	_

#Text=Whole-brain analysis confirmed CUD relative to HC participants exhibited greater BPND in the midbrain and lower BPND in the dorsal striatum (Figure 1b).
92-1	16764-16775	Whole-brain	_
92-2	16776-16784	analysis	_
92-3	16785-16794	confirmed	_
92-4	16795-16798	CUD	_
92-5	16799-16807	relative	_
92-6	16808-16810	to	_
92-7	16811-16813	HC	_
92-8	16814-16826	participants	_
92-9	16827-16836	exhibited	_
92-10	16837-16844	greater	_
92-11	16845-16849	BPND	_
92-12	16850-16852	in	_
92-13	16853-16856	the	_
92-14	16857-16865	midbrain	_
92-15	16866-16869	and	_
92-16	16870-16875	lower	_
92-17	16876-16880	BPND	_
92-18	16881-16883	in	_
92-19	16884-16887	the	_
92-20	16888-16894	dorsal	_
92-21	16895-16903	striatum	_
92-22	16904-16905	(	_
92-23	16905-16911	Figure	_
92-24	16912-16914	1b	_
92-25	16914-16915	)	_
92-26	16915-16916	.	_

#Text=Consistent with previous reports, there was a significant association between age and BPND (F7,42=3.25, p=0.008), and a marginal association between body-mass and BPND (F7,42=2.23, p=0.051).
93-1	16917-16927	Consistent	_
93-2	16928-16932	with	_
93-3	16933-16941	previous	_
93-4	16942-16949	reports	_
93-5	16949-16950	,	_
93-6	16951-16956	there	_
93-7	16957-16960	was	_
93-8	16961-16962	a	_
93-9	16963-16974	significant	_
93-10	16975-16986	association	_
93-11	16987-16994	between	_
93-12	16995-16998	age	_
93-13	16999-17002	and	_
93-14	17003-17007	BPND	_
93-15	17008-17009	(	_
93-16	17009-17014	F7,42	_
93-17	17014-17015	=	_
93-18	17015-17019	3.25	_
93-19	17019-17020	,	_
93-20	17021-17022	p	_
93-21	17022-17023	=	_
93-22	17023-17028	0.008	_
93-23	17028-17029	)	_
93-24	17029-17030	,	_
93-25	17031-17034	and	_
93-26	17035-17036	a	_
93-27	17037-17045	marginal	_
93-28	17046-17057	association	_
93-29	17058-17065	between	_
93-30	17066-17075	body-mass	_
93-31	17076-17079	and	_
93-32	17080-17084	BPND	_
93-33	17085-17086	(	_
93-34	17086-17091	F7,42	_
93-35	17091-17092	=	_
93-36	17092-17096	2.23	_
93-37	17096-17097	,	_
93-38	17098-17099	p	_
93-39	17099-17100	=	_
93-40	17100-17105	0.051	_
93-41	17105-17106	)	_
93-42	17106-17107	.	_

#Text=Adjusting for influences of age and body-mass, group differences in the SN remained significant (F1,48=11.29, p=0.002) while differences in the DPU did not reach significance (F1,48=3.72, p=0.060).
94-1	17108-17117	Adjusting	_
94-2	17118-17121	for	_
94-3	17122-17132	influences	_
94-4	17133-17135	of	_
94-5	17136-17139	age	_
94-6	17140-17143	and	_
94-7	17144-17153	body-mass	_
94-8	17153-17154	,	_
94-9	17155-17160	group	_
94-10	17161-17172	differences	_
94-11	17173-17175	in	_
94-12	17176-17179	the	_
94-13	17180-17182	SN	_
94-14	17183-17191	remained	_
94-15	17192-17203	significant	_
94-16	17204-17205	(	_
94-17	17205-17210	F1,48	_
94-18	17210-17211	=	_
94-19	17211-17216	11.29	_
94-20	17216-17217	,	_
94-21	17218-17219	p	_
94-22	17219-17220	=	_
94-23	17220-17225	0.002	_
94-24	17225-17226	)	_
94-25	17227-17232	while	_
94-26	17233-17244	differences	_
94-27	17245-17247	in	_
94-28	17248-17251	the	_
94-29	17252-17255	DPU	_
94-30	17256-17259	did	_
94-31	17260-17263	not	_
94-32	17264-17269	reach	_
94-33	17270-17282	significance	_
94-34	17283-17284	(	_
94-35	17284-17289	F1,48	_
94-36	17289-17290	=	_
94-37	17290-17294	3.72	_
94-38	17294-17295	,	_
94-39	17296-17297	p	_
94-40	17297-17298	=	_
94-41	17298-17303	0.060	_
94-42	17303-17304	)	_
94-43	17304-17305	.	_

#Text=There was no main effect of alcohol use on BPND (F7,44=0.87, p=0.54), and group differences survived adjusting for the number of cigarettes smoked daily (F7,43=3.89, p=0.002).
95-1	17306-17311	There	_
95-2	17312-17315	was	_
95-3	17316-17318	no	_
95-4	17319-17323	main	_
95-5	17324-17330	effect	_
95-6	17331-17333	of	_
95-7	17334-17341	alcohol	_
95-8	17342-17345	use	_
95-9	17346-17348	on	_
95-10	17349-17353	BPND	_
95-11	17354-17355	(	_
95-12	17355-17360	F7,44	_
95-13	17360-17361	=	_
95-14	17361-17365	0.87	_
95-15	17365-17366	,	_
95-16	17367-17368	p	_
95-17	17368-17369	=	_
95-18	17369-17373	0.54	_
95-19	17373-17374	)	_
95-20	17374-17375	,	_
95-21	17376-17379	and	_
95-22	17380-17385	group	_
95-23	17386-17397	differences	_
95-24	17398-17406	survived	_
95-25	17407-17416	adjusting	_
95-26	17417-17420	for	_
95-27	17421-17424	the	_
95-28	17425-17431	number	_
95-29	17432-17434	of	_
95-30	17435-17445	cigarettes	_
95-31	17446-17452	smoked	_
95-32	17453-17458	daily	_
95-33	17459-17460	(	_
95-34	17460-17465	F7,43	_
95-35	17465-17466	=	_
95-36	17466-17470	3.89	_
95-37	17470-17471	,	_
95-38	17472-17473	p	_
95-39	17473-17474	=	_
95-40	17474-17479	0.002	_
95-41	17479-17480	)	_
95-42	17480-17481	.	_

#Text=Within CUD participants, there was no association between BPND and daily cigarettes smoked (F7,18=0.55, p=0.79) or years of cocaine use (F7,18=1.07, p=0.42).
#Text=3.2.
96-1	17482-17488	Within	_
96-2	17489-17492	CUD	_
96-3	17493-17505	participants	_
96-4	17505-17506	,	_
96-5	17507-17512	there	_
96-6	17513-17516	was	_
96-7	17517-17519	no	_
96-8	17520-17531	association	_
96-9	17532-17539	between	_
96-10	17540-17544	BPND	_
96-11	17545-17548	and	_
96-12	17549-17554	daily	_
96-13	17555-17565	cigarettes	_
96-14	17566-17572	smoked	_
96-15	17573-17574	(	_
96-16	17574-17579	F7,18	_
96-17	17579-17580	=	_
96-18	17580-17584	0.55	_
96-19	17584-17585	,	_
96-20	17586-17587	p	_
96-21	17587-17588	=	_
96-22	17588-17592	0.79	_
96-23	17592-17593	)	_
96-24	17594-17596	or	_
96-25	17597-17602	years	_
96-26	17603-17605	of	_
96-27	17606-17613	cocaine	_
96-28	17614-17617	use	_
96-29	17618-17619	(	_
96-30	17619-17624	F7,18	_
96-31	17624-17625	=	_
96-32	17625-17629	1.07	_
96-33	17629-17630	,	_
96-34	17631-17632	p	_
96-35	17632-17633	=	_
96-36	17633-17637	0.42	_
96-37	17637-17638	)	_
96-38	17638-17639	.	_
96-39	17640-17643	3.2	_
96-40	17643-17644	.	_

#Text=ICA of [11C]-(+)-PHNO BPND
#Text=The exploratory ICA identified three sources of [11C]-(+)-PHNO binding that represent systems of brain regions displaying coherent variation in BPND through the sample (Figure 2; Table 2).
97-1	17645-17648	ICA	_
97-2	17649-17651	of	_
97-3	17652-17653	[	_
97-4	17653-17656	11C	_
97-5	17656-17657	]	_
97-6	17657-17658	-	_
97-7	17658-17659	(	_
97-8	17659-17660	+	_
97-9	17660-17661	)	_
97-10	17661-17662	-	_
97-11	17662-17666	PHNO	_
97-12	17667-17671	BPND	_
97-13	17672-17675	The	_
97-14	17676-17687	exploratory	_
97-15	17688-17691	ICA	_
97-16	17692-17702	identified	_
97-17	17703-17708	three	_
97-18	17709-17716	sources	_
97-19	17717-17719	of	_
97-20	17720-17721	[	_
97-21	17721-17724	11C	_
97-22	17724-17725	]	_
97-23	17725-17726	-	_
97-24	17726-17727	(	_
97-25	17727-17728	+	_
97-26	17728-17729	)	_
97-27	17729-17730	-	_
97-28	17730-17734	PHNO	_
97-29	17735-17742	binding	_
97-30	17743-17747	that	_
97-31	17748-17757	represent	_
97-32	17758-17765	systems	_
97-33	17766-17768	of	_
97-34	17769-17774	brain	_
97-35	17775-17782	regions	_
97-36	17783-17793	displaying	_
97-37	17794-17802	coherent	_
97-38	17803-17812	variation	_
97-39	17813-17815	in	_
97-40	17816-17820	BPND	_
97-41	17821-17828	through	_
97-42	17829-17832	the	_
97-43	17833-17839	sample	_
97-44	17840-17841	(	_
97-45	17841-17847	Figure	_
97-46	17848-17849	2	_
97-47	17849-17850	;	_
97-48	17851-17856	Table	_
97-49	17857-17858	2	_
97-50	17858-17859	)	_
97-51	17859-17860	.	_

#Text=Source 1 represented a ‘striatopallidal source’, with largest contributions in the DPU, DCA, GP, VP and VS.
98-1	17861-17867	Source	_
98-2	17868-17869	1	_
98-3	17870-17881	represented	_
98-4	17882-17883	a	_
98-5	17884-17885	‘	_
98-6	17885-17900	striatopallidal	_
98-7	17901-17907	source	_
98-8	17907-17908	’	_
98-9	17908-17909	,	_
98-10	17910-17914	with	_
98-11	17915-17922	largest	_
98-12	17923-17936	contributions	_
98-13	17937-17939	in	_
98-14	17940-17943	the	_
98-15	17944-17947	DPU	_
98-16	17947-17948	,	_
98-17	17949-17952	DCA	_
98-18	17952-17953	,	_
98-19	17954-17956	GP	_
98-20	17956-17957	,	_
98-21	17958-17960	VP	_
98-22	17961-17964	and	_
98-23	17965-17967	VS	_
98-24	17967-17968	.	_

#Text=Source 2 represented a ‘pallidonigral source’ comprised of the SN, GP, VP and HY.
99-1	17969-17975	Source	_
99-2	17976-17977	2	_
99-3	17978-17989	represented	_
99-4	17990-17991	a	_
99-5	17992-17993	‘	_
99-6	17993-18006	pallidonigral	_
99-7	18007-18013	source	_
99-8	18013-18014	’	_
99-9	18015-18024	comprised	_
99-10	18025-18027	of	_
99-11	18028-18031	the	_
99-12	18032-18034	SN	_
99-13	18034-18035	,	_
99-14	18036-18038	GP	_
99-15	18038-18039	,	_
99-16	18040-18042	VP	_
99-17	18043-18046	and	_
99-18	18047-18049	HY	_
99-19	18049-18050	.	_

#Text=Source 3 represented a ventral ‘mesoaccumbens source’ encompassing HY, VP, VS and anterior regions of the midbrain extending into the SN.
100-1	18051-18057	Source	_
100-2	18058-18059	3	_
100-3	18060-18071	represented	_
100-4	18072-18073	a	_
100-5	18074-18081	ventral	_
100-6	18082-18083	‘	_
100-7	18083-18096	mesoaccumbens	_
100-8	18097-18103	source	_
100-9	18103-18104	’	_
100-10	18105-18117	encompassing	_
100-11	18118-18120	HY	_
100-12	18120-18121	,	_
100-13	18122-18124	VP	_
100-14	18124-18125	,	_
100-15	18126-18128	VS	_
100-16	18129-18132	and	_
100-17	18133-18141	anterior	_
100-18	18142-18149	regions	_
100-19	18150-18152	of	_
100-20	18153-18156	the	_
100-21	18157-18165	midbrain	_
100-22	18166-18175	extending	_
100-23	18176-18180	into	_
100-24	18181-18184	the	_
100-25	18185-18187	SN	_
100-26	18187-18188	.	_

#Text=Although extracted solely from the data, the identified sources were spatially consistent with the distribution of D2R-related and D3R-related availability across regions of interest (Figure 3).
101-1	18189-18197	Although	_
101-2	18198-18207	extracted	_
101-3	18208-18214	solely	_
101-4	18215-18219	from	_
101-5	18220-18223	the	_
101-6	18224-18228	data	_
101-7	18228-18229	,	_
101-8	18230-18233	the	_
101-9	18234-18244	identified	_
101-10	18245-18252	sources	_
101-11	18253-18257	were	_
101-12	18258-18267	spatially	_
101-13	18268-18278	consistent	_
101-14	18279-18283	with	_
101-15	18284-18287	the	_
101-16	18288-18300	distribution	_
101-17	18301-18303	of	_
101-18	18304-18315	D2R-related	_
101-19	18316-18319	and	_
101-20	18320-18331	D3R-related	_
101-21	18332-18344	availability	_
101-22	18345-18351	across	_
101-23	18352-18359	regions	_
101-24	18360-18362	of	_
101-25	18363-18371	interest	_
101-26	18372-18373	(	_
101-27	18373-18379	Figure	_
101-28	18380-18381	3	_
101-29	18381-18382	)	_
101-30	18382-18383	.	_

#Text=Specifically, regional B̃PM values of the striatopallidal source were associated with estimated D2R-related BPND proportions (r=0.89, p=0.008), and regional B̃PM of the pallidonigral source were associated with estimated D3R-related BPND proportions (r=0.89, p=0.007).
102-1	18384-18396	Specifically	_
102-2	18396-18397	,	_
102-3	18398-18406	regional	_
102-4	18407-18411	B̃PM	_
102-5	18412-18418	values	_
102-6	18419-18421	of	_
102-7	18422-18425	the	_
102-8	18426-18441	striatopallidal	_
102-9	18442-18448	source	_
102-10	18449-18453	were	_
102-11	18454-18464	associated	_
102-12	18465-18469	with	_
102-13	18470-18479	estimated	_
102-14	18480-18491	D2R-related	_
102-15	18492-18496	BPND	_
102-16	18497-18508	proportions	_
102-17	18509-18510	(	_
102-18	18510-18511	r	_
102-19	18511-18512	=	_
102-20	18512-18516	0.89	_
102-21	18516-18517	,	_
102-22	18518-18519	p	_
102-23	18519-18520	=	_
102-24	18520-18525	0.008	_
102-25	18525-18526	)	_
102-26	18526-18527	,	_
102-27	18528-18531	and	_
102-28	18532-18540	regional	_
102-29	18541-18545	B̃PM	_
102-30	18546-18548	of	_
102-31	18549-18552	the	_
102-32	18553-18566	pallidonigral	_
102-33	18567-18573	source	_
102-34	18574-18578	were	_
102-35	18579-18589	associated	_
102-36	18590-18594	with	_
102-37	18595-18604	estimated	_
102-38	18605-18616	D3R-related	_
102-39	18617-18621	BPND	_
102-40	18622-18633	proportions	_
102-41	18634-18635	(	_
102-42	18635-18636	r	_
102-43	18636-18637	=	_
102-44	18637-18641	0.89	_
102-45	18641-18642	,	_
102-46	18643-18644	p	_
102-47	18644-18645	=	_
102-48	18645-18650	0.007	_
102-49	18650-18651	)	_
102-50	18651-18652	.	_

#Text=The mesoaccumbens source was not associated with either D2R-related or D3R-related binding proportions (p’s>0.1).
103-1	18653-18656	The	_
103-2	18657-18670	mesoaccumbens	_
103-3	18671-18677	source	_
103-4	18678-18681	was	_
103-5	18682-18685	not	_
103-6	18686-18696	associated	_
103-7	18697-18701	with	_
103-8	18702-18708	either	_
103-9	18709-18720	D2R-related	_
103-10	18721-18723	or	_
103-11	18724-18735	D3R-related	_
103-12	18736-18743	binding	_
103-13	18744-18755	proportions	_
103-14	18756-18757	(	_
103-15	18757-18758	p	_
103-16	18758-18759	’	_
103-17	18759-18760	s	_
103-18	18760-18761	>	_
103-19	18761-18764	0.1	_
103-20	18764-18765	)	_
103-21	18765-18766	.	_

#Text=ICA subject intensities for the three sources did not correlate with each other (p’s>0.2).
104-1	18767-18770	ICA	_
104-2	18771-18778	subject	_
104-3	18779-18790	intensities	_
104-4	18791-18794	for	_
104-5	18795-18798	the	_
104-6	18799-18804	three	_
104-7	18805-18812	sources	_
104-8	18813-18816	did	_
104-9	18817-18820	not	_
104-10	18821-18830	correlate	_
104-11	18831-18835	with	_
104-12	18836-18840	each	_
104-13	18841-18846	other	_
104-14	18847-18848	(	_
104-15	18848-18849	p	_
104-16	18849-18850	’	_
104-17	18850-18851	s	_
104-18	18851-18852	>	_
104-19	18852-18855	0.2	_
104-20	18855-18856	)	_
104-21	18856-18857	.	_

#Text=There were no associations between source intensities and age (F3,46=1.53, p=0.22) or body-mass F3,46=1.80, p=0.16).
105-1	18858-18863	There	_
105-2	18864-18868	were	_
105-3	18869-18871	no	_
105-4	18872-18884	associations	_
105-5	18885-18892	between	_
105-6	18893-18899	source	_
105-7	18900-18911	intensities	_
105-8	18912-18915	and	_
105-9	18916-18919	age	_
105-10	18920-18921	(	_
105-11	18921-18926	F3,46	_
105-12	18926-18927	=	_
105-13	18927-18931	1.53	_
105-14	18931-18932	,	_
105-15	18933-18934	p	_
105-16	18934-18935	=	_
105-17	18935-18939	0.22	_
105-18	18939-18940	)	_
105-19	18941-18943	or	_
105-20	18944-18953	body-mass	_
105-21	18954-18959	F3,46	_
105-22	18959-18960	=	_
105-23	18960-18964	1.80	_
105-24	18964-18965	,	_
105-25	18966-18967	p	_
105-26	18967-18968	=	_
105-27	18968-18972	0.16	_
105-28	18972-18973	)	_
105-29	18973-18974	.	_

#Text=There was no main effect of alcohol use on source intensities (F3,46=1.48, p=0.23).
#Text=3.3. [11C]-(+)-PHNO BPND sources and CUD
#Text=There was a main effect of group on ICA-intensity across the three identified sources (F3,48=4.28, p=0.009).
106-1	18975-18980	There	_
106-2	18981-18984	was	_
106-3	18985-18987	no	_
106-4	18988-18992	main	_
106-5	18993-18999	effect	_
106-6	19000-19002	of	_
106-7	19003-19010	alcohol	_
106-8	19011-19014	use	_
106-9	19015-19017	on	_
106-10	19018-19024	source	_
106-11	19025-19036	intensities	_
106-12	19037-19038	(	_
106-13	19038-19043	F3,46	_
106-14	19043-19044	=	_
106-15	19044-19048	1.48	_
106-16	19048-19049	,	_
106-17	19050-19051	p	_
106-18	19051-19052	=	_
106-19	19052-19056	0.23	_
106-20	19056-19057	)	_
106-21	19057-19058	.	_
106-22	19059-19062	3.3	_
106-23	19062-19063	.	_
106-24	19064-19065	[	_
106-25	19065-19068	11C	_
106-26	19068-19069	]	_
106-27	19069-19070	-	_
106-28	19070-19071	(	_
106-29	19071-19072	+	_
106-30	19072-19073	)	_
106-31	19073-19074	-	_
106-32	19074-19078	PHNO	_
106-33	19079-19083	BPND	_
106-34	19084-19091	sources	_
106-35	19092-19095	and	_
106-36	19096-19099	CUD	_
106-37	19100-19105	There	_
106-38	19106-19109	was	_
106-39	19110-19111	a	_
106-40	19112-19116	main	_
106-41	19117-19123	effect	_
106-42	19124-19126	of	_
106-43	19127-19132	group	_
106-44	19133-19135	on	_
106-45	19136-19149	ICA-intensity	_
106-46	19150-19156	across	_
106-47	19157-19160	the	_
106-48	19161-19166	three	_
106-49	19167-19177	identified	_
106-50	19178-19185	sources	_
106-51	19186-19187	(	_
106-52	19187-19192	F3,48	_
106-53	19192-19193	=	_
106-54	19193-19197	4.28	_
106-55	19197-19198	,	_
106-56	19199-19200	p	_
106-57	19200-19201	=	_
106-58	19201-19206	0.009	_
106-59	19206-19207	)	_
106-60	19207-19208	.	_

#Text=CUD relative to HC participants displayed lower intensities of the striatopallidal source (t50=2.58, p=0.013; Figure 3a) and greater intensity of the pallidonigral source (t50=2.03, p=0.047; Figure 3b).
107-1	19209-19212	CUD	_
107-2	19213-19221	relative	_
107-3	19222-19224	to	_
107-4	19225-19227	HC	_
107-5	19228-19240	participants	_
107-6	19241-19250	displayed	_
107-7	19251-19256	lower	_
107-8	19257-19268	intensities	_
107-9	19269-19271	of	_
107-10	19272-19275	the	_
107-11	19276-19291	striatopallidal	_
107-12	19292-19298	source	_
107-13	19299-19300	(	_
107-14	19300-19303	t50	_
107-15	19303-19304	=	_
107-16	19304-19308	2.58	_
107-17	19308-19309	,	_
107-18	19310-19311	p	_
107-19	19311-19312	=	_
107-20	19312-19317	0.013	_
107-21	19317-19318	;	_
107-22	19319-19325	Figure	_
107-23	19326-19328	3a	_
107-24	19328-19329	)	_
107-25	19330-19333	and	_
107-26	19334-19341	greater	_
107-27	19342-19351	intensity	_
107-28	19352-19354	of	_
107-29	19355-19358	the	_
107-30	19359-19372	pallidonigral	_
107-31	19373-19379	source	_
107-32	19380-19381	(	_
107-33	19381-19384	t50	_
107-34	19384-19385	=	_
107-35	19385-19389	2.03	_
107-36	19389-19390	,	_
107-37	19391-19392	p	_
107-38	19392-19393	=	_
107-39	19393-19398	0.047	_
107-40	19398-19399	;	_
107-41	19400-19406	Figure	_
107-42	19407-19409	3b	_
107-43	19409-19410	)	_
107-44	19410-19411	.	_

#Text=Group differences in the mesoaccumbens source did not reach significance (t50=1.63, p=0.109).
108-1	19412-19417	Group	_
108-2	19418-19429	differences	_
108-3	19430-19432	in	_
108-4	19433-19436	the	_
108-5	19437-19450	mesoaccumbens	_
108-6	19451-19457	source	_
108-7	19458-19461	did	_
108-8	19462-19465	not	_
108-9	19466-19471	reach	_
108-10	19472-19484	significance	_
108-11	19485-19486	(	_
108-12	19486-19489	t50	_
108-13	19489-19490	=	_
108-14	19490-19494	1.63	_
108-15	19494-19495	,	_
108-16	19496-19497	p	_
108-17	19497-19498	=	_
108-18	19498-19503	0.109	_
108-19	19503-19504	)	_
108-20	19504-19505	.	_

#Text=Different from the regional analysis above, the intensity of the striatopallidal source was negatively associated with years of cocaine use (r=0.39, p=0.048; Figure 3a) and pallidonigral source intensity was positively correlated with years of cocaine use (r=0.40, p=0.042; Figure 3b).
109-1	19506-19515	Different	_
109-2	19516-19520	from	_
109-3	19521-19524	the	_
109-4	19525-19533	regional	_
109-5	19534-19542	analysis	_
109-6	19543-19548	above	_
109-7	19548-19549	,	_
109-8	19550-19553	the	_
109-9	19554-19563	intensity	_
109-10	19564-19566	of	_
109-11	19567-19570	the	_
109-12	19571-19586	striatopallidal	_
109-13	19587-19593	source	_
109-14	19594-19597	was	_
109-15	19598-19608	negatively	_
109-16	19609-19619	associated	_
109-17	19620-19624	with	_
109-18	19625-19630	years	_
109-19	19631-19633	of	_
109-20	19634-19641	cocaine	_
109-21	19642-19645	use	_
109-22	19646-19647	(	_
109-23	19647-19648	r	_
109-24	19648-19649	=	_
109-25	19649-19653	0.39	_
109-26	19653-19654	,	_
109-27	19655-19656	p	_
109-28	19656-19657	=	_
109-29	19657-19662	0.048	_
109-30	19662-19663	;	_
109-31	19664-19670	Figure	_
109-32	19671-19673	3a	_
109-33	19673-19674	)	_
109-34	19675-19678	and	_
109-35	19679-19692	pallidonigral	_
109-36	19693-19699	source	_
109-37	19700-19709	intensity	_
109-38	19710-19713	was	_
109-39	19714-19724	positively	_
109-40	19725-19735	correlated	_
109-41	19736-19740	with	_
109-42	19741-19746	years	_
109-43	19747-19749	of	_
109-44	19750-19757	cocaine	_
109-45	19758-19761	use	_
109-46	19762-19763	(	_
109-47	19763-19764	r	_
109-48	19764-19765	=	_
109-49	19765-19769	0.40	_
109-50	19769-19770	,	_
109-51	19771-19772	p	_
109-52	19772-19773	=	_
109-53	19773-19778	0.042	_
109-54	19778-19779	;	_
109-55	19780-19786	Figure	_
109-56	19787-19789	3b	_
109-57	19789-19790	)	_
109-58	19790-19791	.	_

#Text=Group differences survived adjusting for the number of cigarettes smoked daily (F3,47=4.28, p=0.009), and within CUD participants there was no association between source intensities and the number of cigarettes smoked daily (F3,22=0.75, p=0.53).
#Text=4.
110-1	19792-19797	Group	_
110-2	19798-19809	differences	_
110-3	19810-19818	survived	_
110-4	19819-19828	adjusting	_
110-5	19829-19832	for	_
110-6	19833-19836	the	_
110-7	19837-19843	number	_
110-8	19844-19846	of	_
110-9	19847-19857	cigarettes	_
110-10	19858-19864	smoked	_
110-11	19865-19870	daily	_
110-12	19871-19872	(	_
110-13	19872-19877	F3,47	_
110-14	19877-19878	=	_
110-15	19878-19882	4.28	_
110-16	19882-19883	,	_
110-17	19884-19885	p	_
110-18	19885-19886	=	_
110-19	19886-19891	0.009	_
110-20	19891-19892	)	_
110-21	19892-19893	,	_
110-22	19894-19897	and	_
110-23	19898-19904	within	_
110-24	19905-19908	CUD	_
110-25	19909-19921	participants	_
110-26	19922-19927	there	_
110-27	19928-19931	was	_
110-28	19932-19934	no	_
110-29	19935-19946	association	_
110-30	19947-19954	between	_
110-31	19955-19961	source	_
110-32	19962-19973	intensities	_
110-33	19974-19977	and	_
110-34	19978-19981	the	_
110-35	19982-19988	number	_
110-36	19989-19991	of	_
110-37	19992-20002	cigarettes	_
110-38	20003-20009	smoked	_
110-39	20010-20015	daily	_
110-40	20016-20017	(	_
110-41	20017-20022	F3,22	_
110-42	20022-20023	=	_
110-43	20023-20027	0.75	_
110-44	20027-20028	,	_
110-45	20029-20030	p	_
110-46	20030-20031	=	_
110-47	20031-20035	0.53	_
110-48	20035-20036	)	_
110-49	20036-20037	.	_
110-50	20038-20039	4	_
110-51	20039-20040	.	_

#Text=Discussion
#Text=The current study extends prior research of D2R/D3R availability in CUD using [11C]-(+)-PHNO.
111-1	20041-20051	Discussion	_
111-2	20052-20055	The	_
111-3	20056-20063	current	_
111-4	20064-20069	study	_
111-5	20070-20077	extends	_
111-6	20078-20083	prior	_
111-7	20084-20092	research	_
111-8	20093-20095	of	_
111-9	20096-20099	D2R	_
111-10	20099-20100	/	_
111-11	20100-20103	D3R	_
111-12	20104-20116	availability	_
111-13	20117-20119	in	_
111-14	20120-20123	CUD	_
111-15	20124-20129	using	_
111-16	20130-20131	[	_
111-17	20131-20134	11C	_
111-18	20134-20135	]	_
111-19	20135-20136	-	_
111-20	20136-20137	(	_
111-21	20137-20138	+	_
111-22	20138-20139	)	_
111-23	20139-20140	-	_
111-24	20140-20144	PHNO	_
111-25	20144-20145	.	_

#Text=Regional analyses revealed CUD-related dorsal striatal reductions in D2R-related BPND, consistent with D2R/D3Rantagonist radioligand research but not previously detected with the D3R-preferring [11C]-(+)-PHNO, and confirmed greater availability in the SN in CUD.
112-1	20146-20154	Regional	_
112-2	20155-20163	analyses	_
112-3	20164-20172	revealed	_
112-4	20173-20184	CUD-related	_
112-5	20185-20191	dorsal	_
112-6	20192-20200	striatal	_
112-7	20201-20211	reductions	_
112-8	20212-20214	in	_
112-9	20215-20226	D2R-related	_
112-10	20227-20231	BPND	_
112-11	20231-20232	,	_
112-12	20233-20243	consistent	_
112-13	20244-20248	with	_
112-14	20249-20252	D2R	_
112-15	20252-20253	/	_
112-16	20253-20266	D3Rantagonist	_
112-17	20267-20278	radioligand	_
112-18	20279-20287	research	_
112-19	20288-20291	but	_
112-20	20292-20295	not	_
112-21	20296-20306	previously	_
112-22	20307-20315	detected	_
112-23	20316-20320	with	_
112-24	20321-20324	the	_
112-25	20325-20339	D3R-preferring	_
112-26	20340-20341	[	_
112-27	20341-20344	11C	_
112-28	20344-20345	]	_
112-29	20345-20346	-	_
112-30	20346-20347	(	_
112-31	20347-20348	+	_
112-32	20348-20349	)	_
112-33	20349-20350	-	_
112-34	20350-20354	PHNO	_
112-35	20354-20355	,	_
112-36	20356-20359	and	_
112-37	20360-20369	confirmed	_
112-38	20370-20377	greater	_
112-39	20378-20390	availability	_
112-40	20391-20393	in	_
112-41	20394-20397	the	_
112-42	20398-20400	SN	_
112-43	20401-20403	in	_
112-44	20404-20407	CUD	_
112-45	20407-20408	.	_

#Text=Exploratory ICA identified three sources of [11C]-(+)-PHNO BPND that were correlated with regional proportions of D2R-related and D3R-related BPND and spatially consistent with known subcortical dopamine circuitry.
113-1	20409-20420	Exploratory	_
113-2	20421-20424	ICA	_
113-3	20425-20435	identified	_
113-4	20436-20441	three	_
113-5	20442-20449	sources	_
113-6	20450-20452	of	_
113-7	20453-20454	[	_
113-8	20454-20457	11C	_
113-9	20457-20458	]	_
113-10	20458-20459	-	_
113-11	20459-20460	(	_
113-12	20460-20461	+	_
113-13	20461-20462	)	_
113-14	20462-20463	-	_
113-15	20463-20467	PHNO	_
113-16	20468-20472	BPND	_
113-17	20473-20477	that	_
113-18	20478-20482	were	_
113-19	20483-20493	correlated	_
113-20	20494-20498	with	_
113-21	20499-20507	regional	_
113-22	20508-20519	proportions	_
113-23	20520-20522	of	_
113-24	20523-20534	D2R-related	_
113-25	20535-20538	and	_
113-26	20539-20550	D3R-related	_
113-27	20551-20555	BPND	_
113-28	20556-20559	and	_
113-29	20560-20569	spatially	_
113-30	20570-20580	consistent	_
113-31	20581-20585	with	_
113-32	20586-20591	known	_
113-33	20592-20603	subcortical	_
113-34	20604-20612	dopamine	_
113-35	20613-20622	circuitry	_
113-36	20622-20623	.	_

#Text=Individuals with CUD relative to HC exhibited reduced intensity of a D2R-related striatopallidal source and greater intensity of a D3R-related pallidonigral source that were both associated with years of cocaine use, an association not found when analyzing regions individually.
114-1	20624-20635	Individuals	_
114-2	20636-20640	with	_
114-3	20641-20644	CUD	_
114-4	20645-20653	relative	_
114-5	20654-20656	to	_
114-6	20657-20659	HC	_
114-7	20660-20669	exhibited	_
114-8	20670-20677	reduced	_
114-9	20678-20687	intensity	_
114-10	20688-20690	of	_
114-11	20691-20692	a	_
114-12	20693-20704	D2R-related	_
114-13	20705-20720	striatopallidal	_
114-14	20721-20727	source	_
114-15	20728-20731	and	_
114-16	20732-20739	greater	_
114-17	20740-20749	intensity	_
114-18	20750-20752	of	_
114-19	20753-20754	a	_
114-20	20755-20766	D3R-related	_
114-21	20767-20780	pallidonigral	_
114-22	20781-20787	source	_
114-23	20788-20792	that	_
114-24	20793-20797	were	_
114-25	20798-20802	both	_
114-26	20803-20813	associated	_
114-27	20814-20818	with	_
114-28	20819-20824	years	_
114-29	20825-20827	of	_
114-30	20828-20835	cocaine	_
114-31	20836-20839	use	_
114-32	20839-20840	,	_
114-33	20841-20843	an	_
114-34	20844-20855	association	_
114-35	20856-20859	not	_
114-36	20860-20865	found	_
114-37	20866-20870	when	_
114-38	20871-20880	analyzing	_
114-39	20881-20888	regions	_
114-40	20889-20901	individually	_
114-41	20901-20902	.	_

#Text=Notably, the ICA-identified sources suggest CUD-related alterations may be present in regions of mixed D2R/D3R concentration (e.g., ventral striatum, globus pallidus) not previously observed using traditional analyses of D2R/D3R radioligands.
115-1	20903-20910	Notably	_
115-2	20910-20911	,	_
115-3	20912-20915	the	_
115-4	20916-20930	ICA-identified	_
115-5	20931-20938	sources	_
115-6	20939-20946	suggest	_
115-7	20947-20958	CUD-related	_
115-8	20959-20970	alterations	_
115-9	20971-20974	may	_
115-10	20975-20977	be	_
115-11	20978-20985	present	_
115-12	20986-20988	in	_
115-13	20989-20996	regions	_
115-14	20997-20999	of	_
115-15	21000-21005	mixed	_
115-16	21006-21009	D2R	_
115-17	21009-21010	/	_
115-18	21010-21013	D3R	_
115-19	21014-21027	concentration	_
115-20	21028-21029	(	_
115-21	21029-21032	e.g	_
115-22	21032-21033	.	_
115-23	21033-21034	,	_
115-24	21035-21042	ventral	_
115-25	21043-21051	striatum	_
115-26	21051-21052	,	_
115-27	21053-21059	globus	_
115-28	21060-21068	pallidus	_
115-29	21068-21069	)	_
115-30	21070-21073	not	_
115-31	21074-21084	previously	_
115-32	21085-21093	observed	_
115-33	21094-21099	using	_
115-34	21100-21111	traditional	_
115-35	21112-21120	analyses	_
115-36	21121-21123	of	_
115-37	21124-21127	D2R	_
115-38	21127-21128	/	_
115-39	21128-21131	D3R	_
115-40	21132-21144	radioligands	_
115-41	21144-21145	.	_

#Text=The current findings underscore the advantage of [11C]-(+)-PHNO in simultaneous investigation of both D2R and D3R alterations in addictions, especially when combined with ICA in exploring sources of dopamine receptor availability.
116-1	21146-21149	The	_
116-2	21150-21157	current	_
116-3	21158-21166	findings	_
116-4	21167-21177	underscore	_
116-5	21178-21181	the	_
116-6	21182-21191	advantage	_
116-7	21192-21194	of	_
116-8	21195-21196	[	_
116-9	21196-21199	11C	_
116-10	21199-21200	]	_
116-11	21200-21201	-	_
116-12	21201-21202	(	_
116-13	21202-21203	+	_
116-14	21203-21204	)	_
116-15	21204-21205	-	_
116-16	21205-21209	PHNO	_
116-17	21210-21212	in	_
116-18	21213-21225	simultaneous	_
116-19	21226-21239	investigation	_
116-20	21240-21242	of	_
116-21	21243-21247	both	_
116-22	21248-21251	D2R	_
116-23	21252-21255	and	_
116-24	21256-21259	D3R	_
116-25	21260-21271	alterations	_
116-26	21272-21274	in	_
116-27	21275-21285	addictions	_
116-28	21285-21286	,	_
116-29	21287-21297	especially	_
116-30	21298-21302	when	_
116-31	21303-21311	combined	_
116-32	21312-21316	with	_
116-33	21317-21320	ICA	_
116-34	21321-21323	in	_
116-35	21324-21333	exploring	_
116-36	21334-21341	sources	_
116-37	21342-21344	of	_
116-38	21345-21353	dopamine	_
116-39	21354-21362	receptor	_
116-40	21363-21375	availability	_
116-41	21375-21376	.	_

#Text=The patterns of concurrently increased and decreased receptor availability, particularly within structures (e.g., the ventral striatum), lend insight into the clinical challenges of dopaminergic pharmacotherapy for CUD.
#Text=4.1.
117-1	21377-21380	The	_
117-2	21381-21389	patterns	_
117-3	21390-21392	of	_
117-4	21393-21405	concurrently	_
117-5	21406-21415	increased	_
117-6	21416-21419	and	_
117-7	21420-21429	decreased	_
117-8	21430-21438	receptor	_
117-9	21439-21451	availability	_
117-10	21451-21452	,	_
117-11	21453-21465	particularly	_
117-12	21466-21472	within	_
117-13	21473-21483	structures	_
117-14	21484-21485	(	_
117-15	21485-21488	e.g	_
117-16	21488-21489	.	_
117-17	21489-21490	,	_
117-18	21491-21494	the	_
117-19	21495-21502	ventral	_
117-20	21503-21511	striatum	_
117-21	21511-21512	)	_
117-22	21512-21513	,	_
117-23	21514-21518	lend	_
117-24	21519-21526	insight	_
117-25	21527-21531	into	_
117-26	21532-21535	the	_
117-27	21536-21544	clinical	_
117-28	21545-21555	challenges	_
117-29	21556-21558	of	_
117-30	21559-21571	dopaminergic	_
117-31	21572-21587	pharmacotherapy	_
117-32	21588-21591	for	_
117-33	21592-21595	CUD	_
117-34	21595-21596	.	_
117-35	21597-21600	4.1	_
117-36	21600-21601	.	_

#Text=Regional [11C]-(+)-PHNO BPND in CUD
#Text=Alterations in D2-like receptor systems in CUD have been reported using multiple radioligands, and the current ROI and whole-brain observations of greater midbrain and reduced dorsal striatal BPND are consistent with previous research.
118-1	21602-21610	Regional	_
118-2	21611-21612	[	_
118-3	21612-21615	11C	_
118-4	21615-21616	]	_
118-5	21616-21617	-	_
118-6	21617-21618	(	_
118-7	21618-21619	+	_
118-8	21619-21620	)	_
118-9	21620-21621	-	_
118-10	21621-21625	PHNO	_
118-11	21626-21630	BPND	_
118-12	21631-21633	in	_
118-13	21634-21637	CUD	_
118-14	21638-21649	Alterations	_
118-15	21650-21652	in	_
118-16	21653-21655	D2	_
118-17	21655-21656	-	_
118-18	21656-21660	like	_
118-19	21661-21669	receptor	_
118-20	21670-21677	systems	_
118-21	21678-21680	in	_
118-22	21681-21684	CUD	_
118-23	21685-21689	have	_
118-24	21690-21694	been	_
118-25	21695-21703	reported	_
118-26	21704-21709	using	_
118-27	21710-21718	multiple	_
118-28	21719-21731	radioligands	_
118-29	21731-21732	,	_
118-30	21733-21736	and	_
118-31	21737-21740	the	_
118-32	21741-21748	current	_
118-33	21749-21752	ROI	_
118-34	21753-21756	and	_
118-35	21757-21768	whole-brain	_
118-36	21769-21781	observations	_
118-37	21782-21784	of	_
118-38	21785-21792	greater	_
118-39	21793-21801	midbrain	_
118-40	21802-21805	and	_
118-41	21806-21813	reduced	_
118-42	21814-21820	dorsal	_
118-43	21821-21829	striatal	_
118-44	21830-21834	BPND	_
118-45	21835-21838	are	_
118-46	21839-21849	consistent	_
118-47	21850-21854	with	_
118-48	21855-21863	previous	_
118-49	21864-21872	research	_
118-50	21872-21873	.	_

#Text=Reduced D2R-related BPND in the striatum and greater D3R-related BPND in the SN and have been linked to increased impulsivity in cocaine/stimulant addictions.
119-1	21874-21881	Reduced	_
119-2	21882-21893	D2R-related	_
119-3	21894-21898	BPND	_
119-4	21899-21901	in	_
119-5	21902-21905	the	_
119-6	21906-21914	striatum	_
119-7	21915-21918	and	_
119-8	21919-21926	greater	_
119-9	21927-21938	D3R-related	_
119-10	21939-21943	BPND	_
119-11	21944-21946	in	_
119-12	21947-21950	the	_
119-13	21951-21953	SN	_
119-14	21954-21957	and	_
119-15	21958-21962	have	_
119-16	21963-21967	been	_
119-17	21968-21974	linked	_
119-18	21975-21977	to	_
119-19	21978-21987	increased	_
119-20	21988-21999	impulsivity	_
119-21	22000-22002	in	_
119-22	22003-22010	cocaine	_
119-23	22010-22011	/	_
119-24	22011-22020	stimulant	_
119-25	22021-22031	addictions	_
119-26	22031-22032	.	_

#Text=Lower striatal D2R BPND has been associated with poor behavioral therapy outcomes in CUD.
120-1	22033-22038	Lower	_
120-2	22039-22047	striatal	_
120-3	22048-22051	D2R	_
120-4	22052-22056	BPND	_
120-5	22057-22060	has	_
120-6	22061-22065	been	_
120-7	22066-22076	associated	_
120-8	22077-22081	with	_
120-9	22082-22086	poor	_
120-10	22087-22097	behavioral	_
120-11	22098-22105	therapy	_
120-12	22106-22114	outcomes	_
120-13	22115-22117	in	_
120-14	22118-22121	CUD	_
120-15	22121-22122	.	_

#Text=The relationship between reduced striatal BPND and years of cocaine use in the current study is consistent with preclinical evidence of the effects of cocaine exposure on D2R availability.
121-1	22123-22126	The	_
121-2	22127-22139	relationship	_
121-3	22140-22147	between	_
121-4	22148-22155	reduced	_
121-5	22156-22164	striatal	_
121-6	22165-22169	BPND	_
121-7	22170-22173	and	_
121-8	22174-22179	years	_
121-9	22180-22182	of	_
121-10	22183-22190	cocaine	_
121-11	22191-22194	use	_
121-12	22195-22197	in	_
121-13	22198-22201	the	_
121-14	22202-22209	current	_
121-15	22210-22215	study	_
121-16	22216-22218	is	_
121-17	22219-22229	consistent	_
121-18	22230-22234	with	_
121-19	22235-22246	preclinical	_
121-20	22247-22255	evidence	_
121-21	22256-22258	of	_
121-22	22259-22262	the	_
121-23	22263-22270	effects	_
121-24	22271-22273	of	_
121-25	22274-22281	cocaine	_
121-26	22282-22290	exposure	_
121-27	22291-22293	on	_
121-28	22294-22297	D2R	_
121-29	22298-22310	availability	_
121-30	22310-22311	.	_

#Text=Similarly, increases in D3R systems follow cocaine exposure in animal models, though the previous finding of a relationship between D3R-related SN BPND and years of cocaine use was not replicated in the current regional analysis.
122-1	22312-22321	Similarly	_
122-2	22321-22322	,	_
122-3	22323-22332	increases	_
122-4	22333-22335	in	_
122-5	22336-22339	D3R	_
122-6	22340-22347	systems	_
122-7	22348-22354	follow	_
122-8	22355-22362	cocaine	_
122-9	22363-22371	exposure	_
122-10	22372-22374	in	_
122-11	22375-22381	animal	_
122-12	22382-22388	models	_
122-13	22388-22389	,	_
122-14	22390-22396	though	_
122-15	22397-22400	the	_
122-16	22401-22409	previous	_
122-17	22410-22417	finding	_
122-18	22418-22420	of	_
122-19	22421-22422	a	_
122-20	22423-22435	relationship	_
122-21	22436-22443	between	_
122-22	22444-22455	D3R-related	_
122-23	22456-22458	SN	_
122-24	22459-22463	BPND	_
122-25	22464-22467	and	_
122-26	22468-22473	years	_
122-27	22474-22476	of	_
122-28	22477-22484	cocaine	_
122-29	22485-22488	use	_
122-30	22489-22492	was	_
122-31	22493-22496	not	_
122-32	22497-22507	replicated	_
122-33	22508-22510	in	_
122-34	22511-22514	the	_
122-35	22515-22522	current	_
122-36	22523-22531	regional	_
122-37	22532-22540	analysis	_
122-38	22540-22541	.	_

#Text=Dissociating potential dopaminergic vulnerabilities to addictive disorders and dopaminergic consequences of substance use remains an important area of addictions research.
#Text=4.2.
123-1	22542-22554	Dissociating	_
123-2	22555-22564	potential	_
123-3	22565-22577	dopaminergic	_
123-4	22578-22593	vulnerabilities	_
123-5	22594-22596	to	_
123-6	22597-22606	addictive	_
123-7	22607-22616	disorders	_
123-8	22617-22620	and	_
123-9	22621-22633	dopaminergic	_
123-10	22634-22646	consequences	_
123-11	22647-22649	of	_
123-12	22650-22659	substance	_
123-13	22660-22663	use	_
123-14	22664-22671	remains	_
123-15	22672-22674	an	_
123-16	22675-22684	important	_
123-17	22685-22689	area	_
123-18	22690-22692	of	_
123-19	22693-22703	addictions	_
123-20	22704-22712	research	_
123-21	22712-22713	.	_
123-22	22714-22717	4.2	_
123-23	22717-22718	.	_

#Text=Sources of [11C]-(+)-PHNO BPND
#Text=ICA identified three sources of [11C]-(+)-PHNO BPND that were correlated with estimated regional proportions of D2R-related and D3R-related BPND and spatially consistent with dopamine circuitry.
124-1	22719-22726	Sources	_
124-2	22727-22729	of	_
124-3	22730-22731	[	_
124-4	22731-22734	11C	_
124-5	22734-22735	]	_
124-6	22735-22736	-	_
124-7	22736-22737	(	_
124-8	22737-22738	+	_
124-9	22738-22739	)	_
124-10	22739-22740	-	_
124-11	22740-22744	PHNO	_
124-12	22745-22749	BPND	_
124-13	22750-22753	ICA	_
124-14	22754-22764	identified	_
124-15	22765-22770	three	_
124-16	22771-22778	sources	_
124-17	22779-22781	of	_
124-18	22782-22783	[	_
124-19	22783-22786	11C	_
124-20	22786-22787	]	_
124-21	22787-22788	-	_
124-22	22788-22789	(	_
124-23	22789-22790	+	_
124-24	22790-22791	)	_
124-25	22791-22792	-	_
124-26	22792-22796	PHNO	_
124-27	22797-22801	BPND	_
124-28	22802-22806	that	_
124-29	22807-22811	were	_
124-30	22812-22822	correlated	_
124-31	22823-22827	with	_
124-32	22828-22837	estimated	_
124-33	22838-22846	regional	_
124-34	22847-22858	proportions	_
124-35	22859-22861	of	_
124-36	22862-22873	D2R-related	_
124-37	22874-22877	and	_
124-38	22878-22889	D3R-related	_
124-39	22890-22894	BPND	_
124-40	22895-22898	and	_
124-41	22899-22908	spatially	_
124-42	22909-22919	consistent	_
124-43	22920-22924	with	_
124-44	22925-22933	dopamine	_
124-45	22934-22943	circuitry	_
124-46	22943-22944	.	_

#Text=The striatopallidal source was identified in nodes of the ‘indirect’ dopamine pathway linking the striatum (DPU, DCA and VS) to the SN through connections with the pallidum (GP and VP).
125-1	22945-22948	The	_
125-2	22949-22964	striatopallidal	_
125-3	22965-22971	source	_
125-4	22972-22975	was	_
125-5	22976-22986	identified	_
125-6	22987-22989	in	_
125-7	22990-22995	nodes	_
125-8	22996-22998	of	_
125-9	22999-23002	the	_
125-10	23003-23004	‘	_
125-11	23004-23012	indirect	_
125-12	23012-23013	’	_
125-13	23014-23022	dopamine	_
125-14	23023-23030	pathway	_
125-15	23031-23038	linking	_
125-16	23039-23042	the	_
125-17	23043-23051	striatum	_
125-18	23052-23053	(	_
125-19	23053-23056	DPU	_
125-20	23056-23057	,	_
125-21	23058-23061	DCA	_
125-22	23062-23065	and	_
125-23	23066-23068	VS	_
125-24	23068-23069	)	_
125-25	23070-23072	to	_
125-26	23073-23076	the	_
125-27	23077-23079	SN	_
125-28	23080-23087	through	_
125-29	23088-23099	connections	_
125-30	23100-23104	with	_
125-31	23105-23108	the	_
125-32	23109-23117	pallidum	_
125-33	23118-23119	(	_
125-34	23119-23121	GP	_
125-35	23122-23125	and	_
125-36	23126-23128	VP	_
125-37	23128-23129	)	_
125-38	23129-23130	.	_

#Text=The indirect pathway is comprised of D2R-expressing GABAergic medium spiny neurons interconnecting the striatum and pallidum.
126-1	23131-23134	The	_
126-2	23135-23143	indirect	_
126-3	23144-23151	pathway	_
126-4	23152-23154	is	_
126-5	23155-23164	comprised	_
126-6	23165-23167	of	_
126-7	23168-23182	D2R-expressing	_
126-8	23183-23192	GABAergic	_
126-9	23193-23199	medium	_
126-10	23200-23205	spiny	_
126-11	23206-23213	neurons	_
126-12	23214-23229	interconnecting	_
126-13	23230-23233	the	_
126-14	23234-23242	striatum	_
126-15	23243-23246	and	_
126-16	23247-23255	pallidum	_
126-17	23255-23256	.	_

#Text=Consistent with this indirect pathway anatomy, the intensity of the identified striatopallidal source was strongly associated with estimated regional D2R components of [11C]-(+)-PHNO BPND.
127-1	23257-23267	Consistent	_
127-2	23268-23272	with	_
127-3	23273-23277	this	_
127-4	23278-23286	indirect	_
127-5	23287-23294	pathway	_
127-6	23295-23302	anatomy	_
127-7	23302-23303	,	_
127-8	23304-23307	the	_
127-9	23308-23317	intensity	_
127-10	23318-23320	of	_
127-11	23321-23324	the	_
127-12	23325-23335	identified	_
127-13	23336-23351	striatopallidal	_
127-14	23352-23358	source	_
127-15	23359-23362	was	_
127-16	23363-23371	strongly	_
127-17	23372-23382	associated	_
127-18	23383-23387	with	_
127-19	23388-23397	estimated	_
127-20	23398-23406	regional	_
127-21	23407-23410	D2R	_
127-22	23411-23421	components	_
127-23	23422-23424	of	_
127-24	23425-23426	[	_
127-25	23426-23429	11C	_
127-26	23429-23430	]	_
127-27	23430-23431	-	_
127-28	23431-23432	(	_
127-29	23432-23433	+	_
127-30	23433-23434	)	_
127-31	23434-23435	-	_
127-32	23435-23439	PHNO	_
127-33	23440-23444	BPND	_
127-34	23444-23445	.	_

#Text=Preclinical models indicate striatopallidal D2R mechanisms may counterbalance reward-related responsivity, with impaired functioning associated with a greater sensitivity to drug-related rewards.
128-1	23446-23457	Preclinical	_
128-2	23458-23464	models	_
128-3	23465-23473	indicate	_
128-4	23474-23489	striatopallidal	_
128-5	23490-23493	D2R	_
128-6	23494-23504	mechanisms	_
128-7	23505-23508	may	_
128-8	23509-23523	counterbalance	_
128-9	23524-23538	reward-related	_
128-10	23539-23551	responsivity	_
128-11	23551-23552	,	_
128-12	23553-23557	with	_
128-13	23558-23566	impaired	_
128-14	23567-23578	functioning	_
128-15	23579-23589	associated	_
128-16	23590-23594	with	_
128-17	23595-23596	a	_
128-18	23597-23604	greater	_
128-19	23605-23616	sensitivity	_
128-20	23617-23619	to	_
128-21	23620-23632	drug-related	_
128-22	23633-23640	rewards	_
128-23	23640-23641	.	_

#Text=Evidence also suggests a role of indirect-pathway striatal D2R with behavioral inflexibility relative to aversive conditions and compulsive cocaine-seeking.
129-1	23642-23650	Evidence	_
129-2	23651-23655	also	_
129-3	23656-23664	suggests	_
129-4	23665-23666	a	_
129-5	23667-23671	role	_
129-6	23672-23674	of	_
129-7	23675-23691	indirect-pathway	_
129-8	23692-23700	striatal	_
129-9	23701-23704	D2R	_
129-10	23705-23709	with	_
129-11	23710-23720	behavioral	_
129-12	23721-23734	inflexibility	_
129-13	23735-23743	relative	_
129-14	23744-23746	to	_
129-15	23747-23755	aversive	_
129-16	23756-23766	conditions	_
129-17	23767-23770	and	_
129-18	23771-23781	compulsive	_
129-19	23782-23797	cocaine-seeking	_
129-20	23797-23798	.	_

#Text=The pallidonigral source identified by ICA was composed of regions highly correlated with estimates of regional proportions of D3R [11C]-(+)-PHNO BPND.
130-1	23799-23802	The	_
130-2	23803-23816	pallidonigral	_
130-3	23817-23823	source	_
130-4	23824-23834	identified	_
130-5	23835-23837	by	_
130-6	23838-23841	ICA	_
130-7	23842-23845	was	_
130-8	23846-23854	composed	_
130-9	23855-23857	of	_
130-10	23858-23865	regions	_
130-11	23866-23872	highly	_
130-12	23873-23883	correlated	_
130-13	23884-23888	with	_
130-14	23889-23898	estimates	_
130-15	23899-23901	of	_
130-16	23902-23910	regional	_
130-17	23911-23922	proportions	_
130-18	23923-23925	of	_
130-19	23926-23929	D3R	_
130-20	23930-23931	[	_
130-21	23931-23934	11C	_
130-22	23934-23935	]	_
130-23	23935-23936	-	_
130-24	23936-23937	(	_
130-25	23937-23938	+	_
130-26	23938-23939	)	_
130-27	23939-23940	-	_
130-28	23940-23944	PHNO	_
130-29	23945-23949	BPND	_
130-30	23949-23950	.	_

#Text=The pallidonigral source is spatially consistent with dopamine circuitry between the pallidal structures and the midbrain.
131-1	23951-23954	The	_
131-2	23955-23968	pallidonigral	_
131-3	23969-23975	source	_
131-4	23976-23978	is	_
131-5	23979-23988	spatially	_
131-6	23989-23999	consistent	_
131-7	24000-24004	with	_
131-8	24005-24013	dopamine	_
131-9	24014-24023	circuitry	_
131-10	24024-24031	between	_
131-11	24032-24035	the	_
131-12	24036-24044	pallidal	_
131-13	24045-24055	structures	_
131-14	24056-24059	and	_
131-15	24060-24063	the	_
131-16	24064-24072	midbrain	_
131-17	24072-24073	.	_

#Text=While less is understood regarding specific functionality of D3R systems, integration of GP, VP and SN regions suggest a role of this system in drug-related reinforcement processing and motivational/appetitive states.
132-1	24074-24079	While	_
132-2	24080-24084	less	_
132-3	24085-24087	is	_
132-4	24088-24098	understood	_
132-5	24099-24108	regarding	_
132-6	24109-24117	specific	_
132-7	24118-24131	functionality	_
132-8	24132-24134	of	_
132-9	24135-24138	D3R	_
132-10	24139-24146	systems	_
132-11	24146-24147	,	_
132-12	24148-24159	integration	_
132-13	24160-24162	of	_
132-14	24163-24165	GP	_
132-15	24165-24166	,	_
132-16	24167-24169	VP	_
132-17	24170-24173	and	_
132-18	24174-24176	SN	_
132-19	24177-24184	regions	_
132-20	24185-24192	suggest	_
132-21	24193-24194	a	_
132-22	24195-24199	role	_
132-23	24200-24202	of	_
132-24	24203-24207	this	_
132-25	24208-24214	system	_
132-26	24215-24217	in	_
132-27	24218-24230	drug-related	_
132-28	24231-24244	reinforcement	_
132-29	24245-24255	processing	_
132-30	24256-24259	and	_
132-31	24260-24272	motivational	_
132-32	24272-24273	/	_
132-33	24273-24283	appetitive	_
132-34	24284-24290	states	_
132-35	24290-24291	.	_

#Text=Incentive salience models of addiction identify ‘wanting’ as a motivation state, dissociable from the hedonic state of ‘liking’, as a process that becomes sensitized over the course of an addiction, and is associated with greater D3R availability in the SN in polysubstance and methamphetamine users.
133-1	24292-24301	Incentive	_
133-2	24302-24310	salience	_
133-3	24311-24317	models	_
133-4	24318-24320	of	_
133-5	24321-24330	addiction	_
133-6	24331-24339	identify	_
133-7	24340-24341	‘	_
133-8	24341-24348	wanting	_
133-9	24348-24349	’	_
133-10	24350-24352	as	_
133-11	24353-24354	a	_
133-12	24355-24365	motivation	_
133-13	24366-24371	state	_
133-14	24371-24372	,	_
133-15	24373-24384	dissociable	_
133-16	24385-24389	from	_
133-17	24390-24393	the	_
133-18	24394-24401	hedonic	_
133-19	24402-24407	state	_
133-20	24408-24410	of	_
133-21	24411-24412	‘	_
133-22	24412-24418	liking	_
133-23	24418-24419	’	_
133-24	24419-24420	,	_
133-25	24421-24423	as	_
133-26	24424-24425	a	_
133-27	24426-24433	process	_
133-28	24434-24438	that	_
133-29	24439-24446	becomes	_
133-30	24447-24457	sensitized	_
133-31	24458-24462	over	_
133-32	24463-24466	the	_
133-33	24467-24473	course	_
133-34	24474-24476	of	_
133-35	24477-24479	an	_
133-36	24480-24489	addiction	_
133-37	24489-24490	,	_
133-38	24491-24494	and	_
133-39	24495-24497	is	_
133-40	24498-24508	associated	_
133-41	24509-24513	with	_
133-42	24514-24521	greater	_
133-43	24522-24525	D3R	_
133-44	24526-24538	availability	_
133-45	24539-24541	in	_
133-46	24542-24545	the	_
133-47	24546-24548	SN	_
133-48	24549-24551	in	_
133-49	24552-24565	polysubstance	_
133-50	24566-24569	and	_
133-51	24570-24585	methamphetamine	_
133-52	24586-24591	users	_
133-53	24591-24592	.	_

#Text=The mesoaccumbens source was identified in SN, VS and VP regions.
134-1	24593-24596	The	_
134-2	24597-24610	mesoaccumbens	_
134-3	24611-24617	source	_
134-4	24618-24621	was	_
134-5	24622-24632	identified	_
134-6	24633-24635	in	_
134-7	24636-24638	SN	_
134-8	24638-24639	,	_
134-9	24640-24642	VS	_
134-10	24643-24646	and	_
134-11	24647-24649	VP	_
134-12	24650-24657	regions	_
134-13	24657-24658	.	_

#Text=While the SN and VP are D3R-rich regions, there was no relationship between regional source intensities and estimated D3R-related (or D3R-related) proportions of [11C]-(+)-PHNO BPND across ROIs.
135-1	24659-24664	While	_
135-2	24665-24668	the	_
135-3	24669-24671	SN	_
135-4	24672-24675	and	_
135-5	24676-24678	VP	_
135-6	24679-24682	are	_
135-7	24683-24691	D3R-rich	_
135-8	24692-24699	regions	_
135-9	24699-24700	,	_
135-10	24701-24706	there	_
135-11	24707-24710	was	_
135-12	24711-24713	no	_
135-13	24714-24726	relationship	_
135-14	24727-24734	between	_
135-15	24735-24743	regional	_
135-16	24744-24750	source	_
135-17	24751-24762	intensities	_
135-18	24763-24766	and	_
135-19	24767-24776	estimated	_
135-20	24777-24788	D3R-related	_
135-21	24789-24790	(	_
135-22	24790-24792	or	_
135-23	24793-24804	D3R-related	_
135-24	24804-24805	)	_
135-25	24806-24817	proportions	_
135-26	24818-24820	of	_
135-27	24821-24822	[	_
135-28	24822-24825	11C	_
135-29	24825-24826	]	_
135-30	24826-24827	-	_
135-31	24827-24828	(	_
135-32	24828-24829	+	_
135-33	24829-24830	)	_
135-34	24830-24831	-	_
135-35	24831-24835	PHNO	_
135-36	24836-24840	BPND	_
135-37	24841-24847	across	_
135-38	24848-24852	ROIs	_
135-39	24852-24853	.	_

#Text=Decreased D2R/D3R availability in the SN and VS is associated with increased sensitivity to reinforcing effects of stimulants mediated through increased striatal dopamine release.
136-1	24854-24863	Decreased	_
136-2	24864-24867	D2R	_
136-3	24867-24868	/	_
136-4	24868-24871	D3R	_
136-5	24872-24884	availability	_
136-6	24885-24887	in	_
136-7	24888-24891	the	_
136-8	24892-24894	SN	_
136-9	24895-24898	and	_
136-10	24899-24901	VS	_
136-11	24902-24904	is	_
136-12	24905-24915	associated	_
136-13	24916-24920	with	_
136-14	24921-24930	increased	_
136-15	24931-24942	sensitivity	_
136-16	24943-24945	to	_
136-17	24946-24957	reinforcing	_
136-18	24958-24965	effects	_
136-19	24966-24968	of	_
136-20	24969-24979	stimulants	_
136-21	24980-24988	mediated	_
136-22	24989-24996	through	_
136-23	24997-25006	increased	_
136-24	25007-25015	striatal	_
136-25	25016-25024	dopamine	_
136-26	25025-25032	release	_
136-27	25032-25033	.	_

#Text=Neuroadaptive increases in SN and VS D3R associated with cocaine exposure may act to downregulate the stimulant-induced release of dopamine in the striatum in individuals with CUD.
137-1	25034-25047	Neuroadaptive	_
137-2	25048-25057	increases	_
137-3	25058-25060	in	_
137-4	25061-25063	SN	_
137-5	25064-25067	and	_
137-6	25068-25070	VS	_
137-7	25071-25074	D3R	_
137-8	25075-25085	associated	_
137-9	25086-25090	with	_
137-10	25091-25098	cocaine	_
137-11	25099-25107	exposure	_
137-12	25108-25111	may	_
137-13	25112-25115	act	_
137-14	25116-25118	to	_
137-15	25119-25131	downregulate	_
137-16	25132-25135	the	_
137-17	25136-25153	stimulant-induced	_
137-18	25154-25161	release	_
137-19	25162-25164	of	_
137-20	25165-25173	dopamine	_
137-21	25174-25176	in	_
137-22	25177-25180	the	_
137-23	25181-25189	striatum	_
137-24	25190-25192	in	_
137-25	25193-25204	individuals	_
137-26	25205-25209	with	_
137-27	25210-25213	CUD	_
137-28	25213-25214	.	_

#Text=While a functional role of D2R/D3R in VS and midbrain circuitry appears critical in balancing dopamine transmission in CUD, mesoaccumbens source intensities were not altered in CUD (or associated with years of cocaine use), and additional research and/or validation of the reliability of this source is warranted.
#Text=4.3.
138-1	25215-25220	While	_
138-2	25221-25222	a	_
138-3	25223-25233	functional	_
138-4	25234-25238	role	_
138-5	25239-25241	of	_
138-6	25242-25245	D2R	_
138-7	25245-25246	/	_
138-8	25246-25249	D3R	_
138-9	25250-25252	in	_
138-10	25253-25255	VS	_
138-11	25256-25259	and	_
138-12	25260-25268	midbrain	_
138-13	25269-25278	circuitry	_
138-14	25279-25286	appears	_
138-15	25287-25295	critical	_
138-16	25296-25298	in	_
138-17	25299-25308	balancing	_
138-18	25309-25317	dopamine	_
138-19	25318-25330	transmission	_
138-20	25331-25333	in	_
138-21	25334-25337	CUD	_
138-22	25337-25338	,	_
138-23	25339-25352	mesoaccumbens	_
138-24	25353-25359	source	_
138-25	25360-25371	intensities	_
138-26	25372-25376	were	_
138-27	25377-25380	not	_
138-28	25381-25388	altered	_
138-29	25389-25391	in	_
138-30	25392-25395	CUD	_
138-31	25396-25397	(	_
138-32	25397-25399	or	_
138-33	25400-25410	associated	_
138-34	25411-25415	with	_
138-35	25416-25421	years	_
138-36	25422-25424	of	_
138-37	25425-25432	cocaine	_
138-38	25433-25436	use	_
138-39	25436-25437	)	_
138-40	25437-25438	,	_
138-41	25439-25442	and	_
138-42	25443-25453	additional	_
138-43	25454-25462	research	_
138-44	25463-25466	and	_
138-45	25466-25467	/	_
138-46	25467-25469	or	_
138-47	25470-25480	validation	_
138-48	25481-25483	of	_
138-49	25484-25487	the	_
138-50	25488-25499	reliability	_
138-51	25500-25502	of	_
138-52	25503-25507	this	_
138-53	25508-25514	source	_
138-54	25515-25517	is	_
138-55	25518-25527	warranted	_
138-56	25527-25528	.	_
138-57	25529-25532	4.3	_
138-58	25532-25533	.	_

#Text=Clinical implications of D2-like receptor sources in addictive disorders
#Text=CUD-related differences in source intensities were consistent with regional analyses, broadly identifying lower D2R-related and greater D3R-related source intensities.
139-1	25534-25542	Clinical	_
139-2	25543-25555	implications	_
139-3	25556-25558	of	_
139-4	25559-25561	D2	_
139-5	25561-25562	-	_
139-6	25562-25566	like	_
139-7	25567-25575	receptor	_
139-8	25576-25583	sources	_
139-9	25584-25586	in	_
139-10	25587-25596	addictive	_
139-11	25597-25606	disorders	_
139-12	25607-25618	CUD-related	_
139-13	25619-25630	differences	_
139-14	25631-25633	in	_
139-15	25634-25640	source	_
139-16	25641-25652	intensities	_
139-17	25653-25657	were	_
139-18	25658-25668	consistent	_
139-19	25669-25673	with	_
139-20	25674-25682	regional	_
139-21	25683-25691	analyses	_
139-22	25691-25692	,	_
139-23	25693-25700	broadly	_
139-24	25701-25712	identifying	_
139-25	25713-25718	lower	_
139-26	25719-25730	D2R-related	_
139-27	25731-25734	and	_
139-28	25735-25742	greater	_
139-29	25743-25754	D3R-related	_
139-30	25755-25761	source	_
139-31	25762-25773	intensities	_
139-32	25773-25774	.	_

#Text=ICA-identified sources extend individual regional observations, detecting CUD-related differences in regions characterized by mixed-D2R/D3R concentrations.
140-1	25775-25789	ICA-identified	_
140-2	25790-25797	sources	_
140-3	25798-25804	extend	_
140-4	25805-25815	individual	_
140-5	25816-25824	regional	_
140-6	25825-25837	observations	_
140-7	25837-25838	,	_
140-8	25839-25848	detecting	_
140-9	25849-25860	CUD-related	_
140-10	25861-25872	differences	_
140-11	25873-25875	in	_
140-12	25876-25883	regions	_
140-13	25884-25897	characterized	_
140-14	25898-25900	by	_
140-15	25901-25910	mixed-D2R	_
140-16	25910-25911	/	_
140-17	25911-25914	D3R	_
140-18	25915-25929	concentrations	_
140-19	25929-25930	.	_

#Text=Patterns of source-intensity difference suggest concurrent upregulation and downregulation of receptor availability in the VS and pallidal regions.
141-1	25931-25939	Patterns	_
141-2	25940-25942	of	_
141-3	25943-25959	source-intensity	_
141-4	25960-25970	difference	_
141-5	25971-25978	suggest	_
141-6	25979-25989	concurrent	_
141-7	25990-26002	upregulation	_
141-8	26003-26006	and	_
141-9	26007-26021	downregulation	_
141-10	26022-26024	of	_
141-11	26025-26033	receptor	_
141-12	26034-26046	availability	_
141-13	26047-26049	in	_
141-14	26050-26053	the	_
141-15	26054-26056	VS	_
141-16	26057-26060	and	_
141-17	26061-26069	pallidal	_
141-18	26070-26077	regions	_
141-19	26077-26078	.	_

#Text=In the current study, alterations in striatopallidal and pallidonigral sources, proposed to reflect complementary mechanisms of the indirect dopamine pathway, were associated with years of cocaine use.
142-1	26079-26081	In	_
142-2	26082-26085	the	_
142-3	26086-26093	current	_
142-4	26094-26099	study	_
142-5	26099-26100	,	_
142-6	26101-26112	alterations	_
142-7	26113-26115	in	_
142-8	26116-26131	striatopallidal	_
142-9	26132-26135	and	_
142-10	26136-26149	pallidonigral	_
142-11	26150-26157	sources	_
142-12	26157-26158	,	_
142-13	26159-26167	proposed	_
142-14	26168-26170	to	_
142-15	26171-26178	reflect	_
142-16	26179-26192	complementary	_
142-17	26193-26203	mechanisms	_
142-18	26204-26206	of	_
142-19	26207-26210	the	_
142-20	26211-26219	indirect	_
142-21	26220-26228	dopamine	_
142-22	26229-26236	pathway	_
142-23	26236-26237	,	_
142-24	26238-26242	were	_
142-25	26243-26253	associated	_
142-26	26254-26258	with	_
142-27	26259-26264	years	_
142-28	26265-26267	of	_
142-29	26268-26275	cocaine	_
142-30	26276-26279	use	_
142-31	26279-26280	.	_

#Text=The intensities of these two sources were significantly related to CUD chronicity, suggesting receptor alterations may represent reciprocal compensatory adaptations through the course of addiction.
143-1	26281-26284	The	_
143-2	26285-26296	intensities	_
143-3	26297-26299	of	_
143-4	26300-26305	these	_
143-5	26306-26309	two	_
143-6	26310-26317	sources	_
143-7	26318-26322	were	_
143-8	26323-26336	significantly	_
143-9	26337-26344	related	_
143-10	26345-26347	to	_
143-11	26348-26351	CUD	_
143-12	26352-26362	chronicity	_
143-13	26362-26363	,	_
143-14	26364-26374	suggesting	_
143-15	26375-26383	receptor	_
143-16	26384-26395	alterations	_
143-17	26396-26399	may	_
143-18	26400-26409	represent	_
143-19	26410-26420	reciprocal	_
143-20	26421-26433	compensatory	_
143-21	26434-26445	adaptations	_
143-22	26446-26453	through	_
143-23	26454-26457	the	_
143-24	26458-26464	course	_
143-25	26465-26467	of	_
143-26	26468-26477	addiction	_
143-27	26477-26478	.	_

#Text=Despite extensive efforts to identify effective pharmacotherapies for CUD, there is currently no FDA-approved medication with an indication for CUD.
144-1	26479-26486	Despite	_
144-2	26487-26496	extensive	_
144-3	26497-26504	efforts	_
144-4	26505-26507	to	_
144-5	26508-26516	identify	_
144-6	26517-26526	effective	_
144-7	26527-26544	pharmacotherapies	_
144-8	26545-26548	for	_
144-9	26549-26552	CUD	_
144-10	26552-26553	,	_
144-11	26554-26559	there	_
144-12	26560-26562	is	_
144-13	26563-26572	currently	_
144-14	26573-26575	no	_
144-15	26576-26588	FDA-approved	_
144-16	26589-26599	medication	_
144-17	26600-26604	with	_
144-18	26605-26607	an	_
144-19	26608-26618	indication	_
144-20	26619-26622	for	_
144-21	26623-26626	CUD	_
144-22	26626-26627	.	_

#Text=Although it has been proposed that dopamine-agonist therapies may aid in the maintenance of cocaine abstinence, preclinical evidence of the influences of D2R and D3R agonists and antagonists on cocaine-related behaviors is mixed.
145-1	26628-26636	Although	_
145-2	26637-26639	it	_
145-3	26640-26643	has	_
145-4	26644-26648	been	_
145-5	26649-26657	proposed	_
145-6	26658-26662	that	_
145-7	26663-26679	dopamine-agonist	_
145-8	26680-26689	therapies	_
145-9	26690-26693	may	_
145-10	26694-26697	aid	_
145-11	26698-26700	in	_
145-12	26701-26704	the	_
145-13	26705-26716	maintenance	_
145-14	26717-26719	of	_
145-15	26720-26727	cocaine	_
145-16	26728-26738	abstinence	_
145-17	26738-26739	,	_
145-18	26740-26751	preclinical	_
145-19	26752-26760	evidence	_
145-20	26761-26763	of	_
145-21	26764-26767	the	_
145-22	26768-26778	influences	_
145-23	26779-26781	of	_
145-24	26782-26785	D2R	_
145-25	26786-26789	and	_
145-26	26790-26793	D3R	_
145-27	26794-26802	agonists	_
145-28	26803-26806	and	_
145-29	26807-26818	antagonists	_
145-30	26819-26821	on	_
145-31	26822-26837	cocaine-related	_
145-32	26838-26847	behaviors	_
145-33	26848-26850	is	_
145-34	26851-26856	mixed	_
145-35	26856-26857	.	_

#Text=The current findings illustrate the underlying complexity of targeting receptor subtypes that may integrate into multiple functional systems and influence drug-related behavior differently depending on the region of action.
146-1	26858-26861	The	_
146-2	26862-26869	current	_
146-3	26870-26878	findings	_
146-4	26879-26889	illustrate	_
146-5	26890-26893	the	_
146-6	26894-26904	underlying	_
146-7	26905-26915	complexity	_
146-8	26916-26918	of	_
146-9	26919-26928	targeting	_
146-10	26929-26937	receptor	_
146-11	26938-26946	subtypes	_
146-12	26947-26951	that	_
146-13	26952-26955	may	_
146-14	26956-26965	integrate	_
146-15	26966-26970	into	_
146-16	26971-26979	multiple	_
146-17	26980-26990	functional	_
146-18	26991-26998	systems	_
146-19	26999-27002	and	_
146-20	27003-27012	influence	_
146-21	27013-27025	drug-related	_
146-22	27026-27034	behavior	_
146-23	27035-27046	differently	_
146-24	27047-27056	depending	_
146-25	27057-27059	on	_
146-26	27060-27063	the	_
146-27	27064-27070	region	_
146-28	27071-27073	of	_
146-29	27074-27080	action	_
146-30	27080-27081	.	_

#Text=Adding to the challenge of dopaminergic pharmacotherapies are the neuroplastic adaptations associated with cocaine exposure and chronic use, suggesting dopaminergic interventions may be aimed at ‘moving targets’, resulting in heterogeneous response profiles across individuals at different stages of addiction.
#Text=4.4.
147-1	27082-27088	Adding	_
147-2	27089-27091	to	_
147-3	27092-27095	the	_
147-4	27096-27105	challenge	_
147-5	27106-27108	of	_
147-6	27109-27121	dopaminergic	_
147-7	27122-27139	pharmacotherapies	_
147-8	27140-27143	are	_
147-9	27144-27147	the	_
147-10	27148-27160	neuroplastic	_
147-11	27161-27172	adaptations	_
147-12	27173-27183	associated	_
147-13	27184-27188	with	_
147-14	27189-27196	cocaine	_
147-15	27197-27205	exposure	_
147-16	27206-27209	and	_
147-17	27210-27217	chronic	_
147-18	27218-27221	use	_
147-19	27221-27222	,	_
147-20	27223-27233	suggesting	_
147-21	27234-27246	dopaminergic	_
147-22	27247-27260	interventions	_
147-23	27261-27264	may	_
147-24	27265-27267	be	_
147-25	27268-27273	aimed	_
147-26	27274-27276	at	_
147-27	27277-27278	‘	_
147-28	27278-27284	moving	_
147-29	27285-27292	targets	_
147-30	27292-27293	’	_
147-31	27293-27294	,	_
147-32	27295-27304	resulting	_
147-33	27305-27307	in	_
147-34	27308-27321	heterogeneous	_
147-35	27322-27330	response	_
147-36	27331-27339	profiles	_
147-37	27340-27346	across	_
147-38	27347-27358	individuals	_
147-39	27359-27361	at	_
147-40	27362-27371	different	_
147-41	27372-27378	stages	_
147-42	27379-27381	of	_
147-43	27382-27391	addiction	_
147-44	27391-27392	.	_
147-45	27393-27396	4.4	_
147-46	27396-27397	.	_

#Text=Strengths and limitations
#Text=The current study investigated the largest sample of CUD participants completing [11C]-(+)-PHNO PET to date (N=26 relative to previous samples that included 10 to 16 individuals), and demonstrates [11C]-(+)-PHNO sensitivity to reductions in dorsal striatal D2R availability frequently reported in CUD using equal-affinity D2R/D3R antagonist radioligands.
148-1	27398-27407	Strengths	_
148-2	27408-27411	and	_
148-3	27412-27423	limitations	_
148-4	27424-27427	The	_
148-5	27428-27435	current	_
148-6	27436-27441	study	_
148-7	27442-27454	investigated	_
148-8	27455-27458	the	_
148-9	27459-27466	largest	_
148-10	27467-27473	sample	_
148-11	27474-27476	of	_
148-12	27477-27480	CUD	_
148-13	27481-27493	participants	_
148-14	27494-27504	completing	_
148-15	27505-27506	[	_
148-16	27506-27509	11C	_
148-17	27509-27510	]	_
148-18	27510-27511	-	_
148-19	27511-27512	(	_
148-20	27512-27513	+	_
148-21	27513-27514	)	_
148-22	27514-27515	-	_
148-23	27515-27519	PHNO	_
148-24	27520-27523	PET	_
148-25	27524-27526	to	_
148-26	27527-27531	date	_
148-27	27532-27533	(	_
148-28	27533-27534	N	_
148-29	27534-27535	=	_
148-30	27535-27537	26	_
148-31	27538-27546	relative	_
148-32	27547-27549	to	_
148-33	27550-27558	previous	_
148-34	27559-27566	samples	_
148-35	27567-27571	that	_
148-36	27572-27580	included	_
148-37	27581-27583	10	_
148-38	27584-27586	to	_
148-39	27587-27589	16	_
148-40	27590-27601	individuals	_
148-41	27601-27602	)	_
148-42	27602-27603	,	_
148-43	27604-27607	and	_
148-44	27608-27620	demonstrates	_
148-45	27621-27622	[	_
148-46	27622-27625	11C	_
148-47	27625-27626	]	_
148-48	27626-27627	-	_
148-49	27627-27628	(	_
148-50	27628-27629	+	_
148-51	27629-27630	)	_
148-52	27630-27631	-	_
148-53	27631-27635	PHNO	_
148-54	27636-27647	sensitivity	_
148-55	27648-27650	to	_
148-56	27651-27661	reductions	_
148-57	27662-27664	in	_
148-58	27665-27671	dorsal	_
148-59	27672-27680	striatal	_
148-60	27681-27684	D2R	_
148-61	27685-27697	availability	_
148-62	27698-27708	frequently	_
148-63	27709-27717	reported	_
148-64	27718-27720	in	_
148-65	27721-27724	CUD	_
148-66	27725-27730	using	_
148-67	27731-27745	equal-affinity	_
148-68	27746-27749	D2R	_
148-69	27749-27750	/	_
148-70	27750-27753	D3R	_
148-71	27754-27764	antagonist	_
148-72	27765-27777	radioligands	_
148-73	27777-27778	.	_

#Text=The current sample was largely comprised of previously reported subjects.
149-1	27779-27782	The	_
149-2	27783-27790	current	_
149-3	27791-27797	sample	_
149-4	27798-27801	was	_
149-5	27802-27809	largely	_
149-6	27810-27819	comprised	_
149-7	27820-27822	of	_
149-8	27823-27833	previously	_
149-9	27834-27842	reported	_
149-10	27843-27851	subjects	_
149-11	27851-27852	.	_

#Text=ROI results of CUD-related BPND alterations in the DPU survived post-hoc analysis co-varying for cohort (p=0.03), suggesting greater statistical power (rather than potential differences in individual variability across independent cohorts) contributed to the significant detection of D2R-related differences in individuals with CUD.
150-1	27853-27856	ROI	_
150-2	27857-27864	results	_
150-3	27865-27867	of	_
150-4	27868-27879	CUD-related	_
150-5	27880-27884	BPND	_
150-6	27885-27896	alterations	_
150-7	27897-27899	in	_
150-8	27900-27903	the	_
150-9	27904-27907	DPU	_
150-10	27908-27916	survived	_
150-11	27917-27925	post-hoc	_
150-12	27926-27934	analysis	_
150-13	27935-27945	co-varying	_
150-14	27946-27949	for	_
150-15	27950-27956	cohort	_
150-16	27957-27958	(	_
150-17	27958-27959	p	_
150-18	27959-27960	=	_
150-19	27960-27964	0.03	_
150-20	27964-27965	)	_
150-21	27965-27966	,	_
150-22	27967-27977	suggesting	_
150-23	27978-27985	greater	_
150-24	27986-27997	statistical	_
150-25	27998-28003	power	_
150-26	28004-28005	(	_
150-27	28005-28011	rather	_
150-28	28012-28016	than	_
150-29	28017-28026	potential	_
150-30	28027-28038	differences	_
150-31	28039-28041	in	_
150-32	28042-28052	individual	_
150-33	28053-28064	variability	_
150-34	28065-28071	across	_
150-35	28072-28083	independent	_
150-36	28084-28091	cohorts	_
150-37	28091-28092	)	_
150-38	28093-28104	contributed	_
150-39	28105-28107	to	_
150-40	28108-28111	the	_
150-41	28112-28123	significant	_
150-42	28124-28133	detection	_
150-43	28134-28136	of	_
150-44	28137-28148	D2R-related	_
150-45	28149-28160	differences	_
150-46	28161-28163	in	_
150-47	28164-28175	individuals	_
150-48	28176-28180	with	_
150-49	28181-28184	CUD	_
150-50	28184-28185	.	_

#Text=This study also represents the first application of ICA to explore sources of covarying D2R/D3R availability and examine alterations associated with CUD.
151-1	28186-28190	This	_
151-2	28191-28196	study	_
151-3	28197-28201	also	_
151-4	28202-28212	represents	_
151-5	28213-28216	the	_
151-6	28217-28222	first	_
151-7	28223-28234	application	_
151-8	28235-28237	of	_
151-9	28238-28241	ICA	_
151-10	28242-28244	to	_
151-11	28245-28252	explore	_
151-12	28253-28260	sources	_
151-13	28261-28263	of	_
151-14	28264-28273	covarying	_
151-15	28274-28277	D2R	_
151-16	28277-28278	/	_
151-17	28278-28281	D3R	_
151-18	28282-28294	availability	_
151-19	28295-28298	and	_
151-20	28299-28306	examine	_
151-21	28307-28318	alterations	_
151-22	28319-28329	associated	_
151-23	28330-28334	with	_
151-24	28335-28338	CUD	_
151-25	28338-28339	.	_

#Text=The data-driven ICA extraction was blind to the spatial distributions of D2R/D3R concentrations and blind to subject group assignments.
152-1	28340-28343	The	_
152-2	28344-28355	data-driven	_
152-3	28356-28359	ICA	_
152-4	28360-28370	extraction	_
152-5	28371-28374	was	_
152-6	28375-28380	blind	_
152-7	28381-28383	to	_
152-8	28384-28387	the	_
152-9	28388-28395	spatial	_
152-10	28396-28409	distributions	_
152-11	28410-28412	of	_
152-12	28413-28416	D2R	_
152-13	28416-28417	/	_
152-14	28417-28420	D3R	_
152-15	28421-28435	concentrations	_
152-16	28436-28439	and	_
152-17	28440-28445	blind	_
152-18	28446-28448	to	_
152-19	28449-28456	subject	_
152-20	28457-28462	group	_
152-21	28463-28474	assignments	_
152-22	28474-28475	.	_

#Text=The current mixed-sample design, while allowing direct comparison of source intensities in CUD relative to HC, identified three sources of [11C]-(+)-PHNO BPND and alternative strategies of component extraction (e.g., higher-dimension ICA) may identify alternative sources.
153-1	28476-28479	The	_
153-2	28480-28487	current	_
153-3	28488-28500	mixed-sample	_
153-4	28501-28507	design	_
153-5	28507-28508	,	_
153-6	28509-28514	while	_
153-7	28515-28523	allowing	_
153-8	28524-28530	direct	_
153-9	28531-28541	comparison	_
153-10	28542-28544	of	_
153-11	28545-28551	source	_
153-12	28552-28563	intensities	_
153-13	28564-28566	in	_
153-14	28567-28570	CUD	_
153-15	28571-28579	relative	_
153-16	28580-28582	to	_
153-17	28583-28585	HC	_
153-18	28585-28586	,	_
153-19	28587-28597	identified	_
153-20	28598-28603	three	_
153-21	28604-28611	sources	_
153-22	28612-28614	of	_
153-23	28615-28616	[	_
153-24	28616-28619	11C	_
153-25	28619-28620	]	_
153-26	28620-28621	-	_
153-27	28621-28622	(	_
153-28	28622-28623	+	_
153-29	28623-28624	)	_
153-30	28624-28625	-	_
153-31	28625-28629	PHNO	_
153-32	28630-28634	BPND	_
153-33	28635-28638	and	_
153-34	28639-28650	alternative	_
153-35	28651-28661	strategies	_
153-36	28662-28664	of	_
153-37	28665-28674	component	_
153-38	28675-28685	extraction	_
153-39	28686-28687	(	_
153-40	28687-28690	e.g	_
153-41	28690-28691	.	_
153-42	28691-28692	,	_
153-43	28693-28709	higher-dimension	_
153-44	28710-28713	ICA	_
153-45	28713-28714	)	_
153-46	28715-28718	may	_
153-47	28719-28727	identify	_
153-48	28728-28739	alternative	_
153-49	28740-28747	sources	_
153-50	28747-28748	.	_

#Text=Alternative computational strategies (e.g., principal component analysis; PCA) have also been used to investigate PET data using ROI-based and voxel-wise approaches, and may identify different factor structures in [11C]-(+)-PHNO data.
154-1	28749-28760	Alternative	_
154-2	28761-28774	computational	_
154-3	28775-28785	strategies	_
154-4	28786-28787	(	_
154-5	28787-28790	e.g	_
154-6	28790-28791	.	_
154-7	28791-28792	,	_
154-8	28793-28802	principal	_
154-9	28803-28812	component	_
154-10	28813-28821	analysis	_
154-11	28821-28822	;	_
154-12	28823-28826	PCA	_
154-13	28826-28827	)	_
154-14	28828-28832	have	_
154-15	28833-28837	also	_
154-16	28838-28842	been	_
154-17	28843-28847	used	_
154-18	28848-28850	to	_
154-19	28851-28862	investigate	_
154-20	28863-28866	PET	_
154-21	28867-28871	data	_
154-22	28872-28877	using	_
154-23	28878-28887	ROI-based	_
154-24	28888-28891	and	_
154-25	28892-28902	voxel-wise	_
154-26	28903-28913	approaches	_
154-27	28913-28914	,	_
154-28	28915-28918	and	_
154-29	28919-28922	may	_
154-30	28923-28931	identify	_
154-31	28932-28941	different	_
154-32	28942-28948	factor	_
154-33	28949-28959	structures	_
154-34	28960-28962	in	_
154-35	28963-28964	[	_
154-36	28964-28967	11C	_
154-37	28967-28968	]	_
154-38	28968-28969	-	_
154-39	28969-28970	(	_
154-40	28970-28971	+	_
154-41	28971-28972	)	_
154-42	28972-28973	-	_
154-43	28973-28977	PHNO	_
154-44	28978-28982	data	_
154-45	28982-28983	.	_

#Text=Proposed associations with D2R-related and D3R-related availability in identified sources were based on calculated estimates using fractions of D3R-related [11C]-(+)-PHNO BPND derived in healthy controls using antagonists that are not 100% selective for D3R receptors.
155-1	28984-28992	Proposed	_
155-2	28993-29005	associations	_
155-3	29006-29010	with	_
155-4	29011-29022	D2R-related	_
155-5	29023-29026	and	_
155-6	29027-29038	D3R-related	_
155-7	29039-29051	availability	_
155-8	29052-29054	in	_
155-9	29055-29065	identified	_
155-10	29066-29073	sources	_
155-11	29074-29078	were	_
155-12	29079-29084	based	_
155-13	29085-29087	on	_
155-14	29088-29098	calculated	_
155-15	29099-29108	estimates	_
155-16	29109-29114	using	_
155-17	29115-29124	fractions	_
155-18	29125-29127	of	_
155-19	29128-29139	D3R-related	_
155-20	29140-29141	[	_
155-21	29141-29144	11C	_
155-22	29144-29145	]	_
155-23	29145-29146	-	_
155-24	29146-29147	(	_
155-25	29147-29148	+	_
155-26	29148-29149	)	_
155-27	29149-29150	-	_
155-28	29150-29154	PHNO	_
155-29	29155-29159	BPND	_
155-30	29160-29167	derived	_
155-31	29168-29170	in	_
155-32	29171-29178	healthy	_
155-33	29179-29187	controls	_
155-34	29188-29193	using	_
155-35	29194-29205	antagonists	_
155-36	29206-29210	that	_
155-37	29211-29214	are	_
155-38	29215-29218	not	_
155-39	29219-29223	100%	_
155-40	29224-29233	selective	_
155-41	29234-29237	for	_
155-42	29238-29241	D3R	_
155-43	29242-29251	receptors	_
155-44	29251-29252	.	_

#Text=Thus, imprecise estimates, and potentially altered regional D2R/D3R-related fractions in individuals with CUD, limit conclusive determination of source signals relative to receptor subtypes.
156-1	29253-29257	Thus	_
156-2	29257-29258	,	_
156-3	29259-29268	imprecise	_
156-4	29269-29278	estimates	_
156-5	29278-29279	,	_
156-6	29280-29283	and	_
156-7	29284-29295	potentially	_
156-8	29296-29303	altered	_
156-9	29304-29312	regional	_
156-10	29313-29316	D2R	_
156-11	29316-29317	/	_
156-12	29317-29328	D3R-related	_
156-13	29329-29338	fractions	_
156-14	29339-29341	in	_
156-15	29342-29353	individuals	_
156-16	29354-29358	with	_
156-17	29359-29362	CUD	_
156-18	29362-29363	,	_
156-19	29364-29369	limit	_
156-20	29370-29380	conclusive	_
156-21	29381-29394	determination	_
156-22	29395-29397	of	_
156-23	29398-29404	source	_
156-24	29405-29412	signals	_
156-25	29413-29421	relative	_
156-26	29422-29424	to	_
156-27	29425-29433	receptor	_
156-28	29434-29442	subtypes	_
156-29	29442-29443	.	_

#Text=Research using ICA in conjunction with specific D2R and D3R blocking agents would be needed to validate these exploratory source compositions.
157-1	29444-29452	Research	_
157-2	29453-29458	using	_
157-3	29459-29462	ICA	_
157-4	29463-29465	in	_
157-5	29466-29477	conjunction	_
157-6	29478-29482	with	_
157-7	29483-29491	specific	_
157-8	29492-29495	D2R	_
157-9	29496-29499	and	_
157-10	29500-29503	D3R	_
157-11	29504-29512	blocking	_
157-12	29513-29519	agents	_
157-13	29520-29525	would	_
157-14	29526-29528	be	_
157-15	29529-29535	needed	_
157-16	29536-29538	to	_
157-17	29539-29547	validate	_
157-18	29548-29553	these	_
157-19	29554-29565	exploratory	_
157-20	29566-29572	source	_
157-21	29573-29585	compositions	_
157-22	29585-29586	.	_

#Text=Similarly, interpretations of potential functional involvement of identified sources was based on spatial patterns of regional integration relative to the extant and evolving literature, and direct examination of source relationships with measures of impulsivity, compulsivity, and substance use-related domains (e.g., self-administration, craving and cue-reactivity) may reveal alternative associations.
158-1	29587-29596	Similarly	_
158-2	29596-29597	,	_
158-3	29598-29613	interpretations	_
158-4	29614-29616	of	_
158-5	29617-29626	potential	_
158-6	29627-29637	functional	_
158-7	29638-29649	involvement	_
158-8	29650-29652	of	_
158-9	29653-29663	identified	_
158-10	29664-29671	sources	_
158-11	29672-29675	was	_
158-12	29676-29681	based	_
158-13	29682-29684	on	_
158-14	29685-29692	spatial	_
158-15	29693-29701	patterns	_
158-16	29702-29704	of	_
158-17	29705-29713	regional	_
158-18	29714-29725	integration	_
158-19	29726-29734	relative	_
158-20	29735-29737	to	_
158-21	29738-29741	the	_
158-22	29742-29748	extant	_
158-23	29749-29752	and	_
158-24	29753-29761	evolving	_
158-25	29762-29772	literature	_
158-26	29772-29773	,	_
158-27	29774-29777	and	_
158-28	29778-29784	direct	_
158-29	29785-29796	examination	_
158-30	29797-29799	of	_
158-31	29800-29806	source	_
158-32	29807-29820	relationships	_
158-33	29821-29825	with	_
158-34	29826-29834	measures	_
158-35	29835-29837	of	_
158-36	29838-29849	impulsivity	_
158-37	29849-29850	,	_
158-38	29851-29863	compulsivity	_
158-39	29863-29864	,	_
158-40	29865-29868	and	_
158-41	29869-29878	substance	_
158-42	29879-29890	use-related	_
158-43	29891-29898	domains	_
158-44	29899-29900	(	_
158-45	29900-29903	e.g	_
158-46	29903-29904	.	_
158-47	29904-29905	,	_
158-48	29906-29925	self-administration	_
158-49	29925-29926	,	_
158-50	29927-29934	craving	_
158-51	29935-29938	and	_
158-52	29939-29953	cue-reactivity	_
158-53	29953-29954	)	_
158-54	29955-29958	may	_
158-55	29959-29965	reveal	_
158-56	29966-29977	alternative	_
158-57	29978-29990	associations	_
158-58	29990-29991	.	_

#Text=Potential influences of co-occurring nicotine dependence in CUD participants on D2R/D3R availability warrants consideration given group differences in regular tobacco smoking.
159-1	29992-30001	Potential	_
159-2	30002-30012	influences	_
159-3	30013-30015	of	_
159-4	30016-30028	co-occurring	_
159-5	30029-30037	nicotine	_
159-6	30038-30048	dependence	_
159-7	30049-30051	in	_
159-8	30052-30055	CUD	_
159-9	30056-30068	participants	_
159-10	30069-30071	on	_
159-11	30072-30075	D2R	_
159-12	30075-30076	/	_
159-13	30076-30079	D3R	_
159-14	30080-30092	availability	_
159-15	30093-30101	warrants	_
159-16	30102-30115	consideration	_
159-17	30116-30121	given	_
159-18	30122-30127	group	_
159-19	30128-30139	differences	_
159-20	30140-30142	in	_
159-21	30143-30150	regular	_
159-22	30151-30158	tobacco	_
159-23	30159-30166	smoking	_
159-24	30166-30167	.	_

#Text=Though daily smoking amounts were not associated with PET results within CUD participants, future studies including a nicotine-dependent comparison sample would allow examination of cocaine-specific alterations in D2R/D3R receptor systems.
160-1	30168-30174	Though	_
160-2	30175-30180	daily	_
160-3	30181-30188	smoking	_
160-4	30189-30196	amounts	_
160-5	30197-30201	were	_
160-6	30202-30205	not	_
160-7	30206-30216	associated	_
160-8	30217-30221	with	_
160-9	30222-30225	PET	_
160-10	30226-30233	results	_
160-11	30234-30240	within	_
160-12	30241-30244	CUD	_
160-13	30245-30257	participants	_
160-14	30257-30258	,	_
160-15	30259-30265	future	_
160-16	30266-30273	studies	_
160-17	30274-30283	including	_
160-18	30284-30285	a	_
160-19	30286-30304	nicotine-dependent	_
160-20	30305-30315	comparison	_
160-21	30316-30322	sample	_
160-22	30323-30328	would	_
160-23	30329-30334	allow	_
160-24	30335-30346	examination	_
160-25	30347-30349	of	_
160-26	30350-30366	cocaine-specific	_
160-27	30367-30378	alterations	_
160-28	30379-30381	in	_
160-29	30382-30385	D2R	_
160-30	30385-30386	/	_
160-31	30386-30389	D3R	_
160-32	30390-30398	receptor	_
160-33	30399-30406	systems	_
160-34	30406-30407	.	_

#Text=Additional research is needed to replicate current observations and explore these dopamine systems in other addictive disorders.
#Text=4.5.
161-1	30408-30418	Additional	_
161-2	30419-30427	research	_
161-3	30428-30430	is	_
161-4	30431-30437	needed	_
161-5	30438-30440	to	_
161-6	30441-30450	replicate	_
161-7	30451-30458	current	_
161-8	30459-30471	observations	_
161-9	30472-30475	and	_
161-10	30476-30483	explore	_
161-11	30484-30489	these	_
161-12	30490-30498	dopamine	_
161-13	30499-30506	systems	_
161-14	30507-30509	in	_
161-15	30510-30515	other	_
161-16	30516-30525	addictive	_
161-17	30526-30535	disorders	_
161-18	30535-30536	.	_
161-19	30537-30540	4.5	_
161-20	30540-30541	.	_

#Text=Conclusions
#Text=The current study extends previous research of regional D2R/D3R availability in CUD measured with [11C]-(+)-PHNO, detecting lower BPND the dorsal striatum and replicating greater BPND in the midbrain.
162-1	30542-30553	Conclusions	_
162-2	30554-30557	The	_
162-3	30558-30565	current	_
162-4	30566-30571	study	_
162-5	30572-30579	extends	_
162-6	30580-30588	previous	_
162-7	30589-30597	research	_
162-8	30598-30600	of	_
162-9	30601-30609	regional	_
162-10	30610-30613	D2R	_
162-11	30613-30614	/	_
162-12	30614-30617	D3R	_
162-13	30618-30630	availability	_
162-14	30631-30633	in	_
162-15	30634-30637	CUD	_
162-16	30638-30646	measured	_
162-17	30647-30651	with	_
162-18	30652-30653	[	_
162-19	30653-30656	11C	_
162-20	30656-30657	]	_
162-21	30657-30658	-	_
162-22	30658-30659	(	_
162-23	30659-30660	+	_
162-24	30660-30661	)	_
162-25	30661-30662	-	_
162-26	30662-30666	PHNO	_
162-27	30666-30667	,	_
162-28	30668-30677	detecting	_
162-29	30678-30683	lower	_
162-30	30684-30688	BPND	_
162-31	30689-30692	the	_
162-32	30693-30699	dorsal	_
162-33	30700-30708	striatum	_
162-34	30709-30712	and	_
162-35	30713-30724	replicating	_
162-36	30725-30732	greater	_
162-37	30733-30737	BPND	_
162-38	30738-30740	in	_
162-39	30741-30744	the	_
162-40	30745-30753	midbrain	_
162-41	30753-30754	.	_

#Text=Source-based analysis using ICA identified three distinct sources of BPND, indicating lower intensity of a striatopallidal source and greater intensity of a pallidonigral source in CUD.
163-1	30755-30767	Source-based	_
163-2	30768-30776	analysis	_
163-3	30777-30782	using	_
163-4	30783-30786	ICA	_
163-5	30787-30797	identified	_
163-6	30798-30803	three	_
163-7	30804-30812	distinct	_
163-8	30813-30820	sources	_
163-9	30821-30823	of	_
163-10	30824-30828	BPND	_
163-11	30828-30829	,	_
163-12	30830-30840	indicating	_
163-13	30841-30846	lower	_
163-14	30847-30856	intensity	_
163-15	30857-30859	of	_
163-16	30860-30861	a	_
163-17	30862-30877	striatopallidal	_
163-18	30878-30884	source	_
163-19	30885-30888	and	_
163-20	30889-30896	greater	_
163-21	30897-30906	intensity	_
163-22	30907-30909	of	_
163-23	30910-30911	a	_
163-24	30912-30925	pallidonigral	_
163-25	30926-30932	source	_
163-26	30933-30935	in	_
163-27	30936-30939	CUD	_
163-28	30939-30940	.	_

#Text=These source-based patterns of BPND suggest cocaine-related alterations in D2R and D3R may not be limited to the dorsal striatum and midbrain respectively, but may extend into the pallidum and ventral striatum.
164-1	30941-30946	These	_
164-2	30947-30959	source-based	_
164-3	30960-30968	patterns	_
164-4	30969-30971	of	_
164-5	30972-30976	BPND	_
164-6	30977-30984	suggest	_
164-7	30985-31000	cocaine-related	_
164-8	31001-31012	alterations	_
164-9	31013-31015	in	_
164-10	31016-31019	D2R	_
164-11	31020-31023	and	_
164-12	31024-31027	D3R	_
164-13	31028-31031	may	_
164-14	31032-31035	not	_
164-15	31036-31038	be	_
164-16	31039-31046	limited	_
164-17	31047-31049	to	_
164-18	31050-31053	the	_
164-19	31054-31060	dorsal	_
164-20	31061-31069	striatum	_
164-21	31070-31073	and	_
164-22	31074-31082	midbrain	_
164-23	31083-31095	respectively	_
164-24	31095-31096	,	_
164-25	31097-31100	but	_
164-26	31101-31104	may	_
164-27	31105-31111	extend	_
164-28	31112-31116	into	_
164-29	31117-31120	the	_
164-30	31121-31129	pallidum	_
164-31	31130-31133	and	_
164-32	31134-31141	ventral	_
164-33	31142-31150	striatum	_
164-34	31150-31151	.	_

#Text=Furthermore, the alterations in striatopallidal and pallidonigral sources were associated with duration of cocaine use, and may indicate reciprocal and compensatory mechanisms of dopaminergic function in addiction.
165-1	31152-31163	Furthermore	_
165-2	31163-31164	,	_
165-3	31165-31168	the	_
165-4	31169-31180	alterations	_
165-5	31181-31183	in	_
165-6	31184-31199	striatopallidal	_
165-7	31200-31203	and	_
165-8	31204-31217	pallidonigral	_
165-9	31218-31225	sources	_
165-10	31226-31230	were	_
165-11	31231-31241	associated	_
165-12	31242-31246	with	_
165-13	31247-31255	duration	_
165-14	31256-31258	of	_
165-15	31259-31266	cocaine	_
165-16	31267-31270	use	_
165-17	31270-31271	,	_
165-18	31272-31275	and	_
165-19	31276-31279	may	_
165-20	31280-31288	indicate	_
165-21	31289-31299	reciprocal	_
165-22	31300-31303	and	_
165-23	31304-31316	compensatory	_
165-24	31317-31327	mechanisms	_
165-25	31328-31330	of	_
165-26	31331-31343	dopaminergic	_
165-27	31344-31352	function	_
165-28	31353-31355	in	_
165-29	31356-31365	addiction	_
165-30	31365-31366	.	_

#Text=Additional investigation into concurrent alterations in D2-like dopamine receptor systems (e.g., prior to drug exposure, during initial use and withdrawal, and following extended abstinence) should provide important insight into treatment development efforts for CUD.
166-1	31367-31377	Additional	_
166-2	31378-31391	investigation	_
166-3	31392-31396	into	_
166-4	31397-31407	concurrent	_
166-5	31408-31419	alterations	_
166-6	31420-31422	in	_
166-7	31423-31425	D2	_
166-8	31425-31426	-	_
166-9	31426-31430	like	_
166-10	31431-31439	dopamine	_
166-11	31440-31448	receptor	_
166-12	31449-31456	systems	_
166-13	31457-31458	(	_
166-14	31458-31461	e.g	_
166-15	31461-31462	.	_
166-16	31462-31463	,	_
166-17	31464-31469	prior	_
166-18	31470-31472	to	_
166-19	31473-31477	drug	_
166-20	31478-31486	exposure	_
166-21	31486-31487	,	_
166-22	31488-31494	during	_
166-23	31495-31502	initial	_
166-24	31503-31506	use	_
166-25	31507-31510	and	_
166-26	31511-31521	withdrawal	_
166-27	31521-31522	,	_
166-28	31523-31526	and	_
166-29	31527-31536	following	_
166-30	31537-31545	extended	_
166-31	31546-31556	abstinence	_
166-32	31556-31557	)	_
166-33	31558-31564	should	_
166-34	31565-31572	provide	_
166-35	31573-31582	important	_
166-36	31583-31590	insight	_
166-37	31591-31595	into	_
166-38	31596-31605	treatment	_
166-39	31606-31617	development	_
166-40	31618-31625	efforts	_
166-41	31626-31629	for	_
166-42	31630-31633	CUD	_
166-43	31633-31634	.	_

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
167-1	31635-31648	Supplementary	_
167-2	31649-31657	Material	_
167-3	31658-31662	This	_
167-4	31663-31665	is	_
167-5	31666-31667	a	_
167-6	31668-31671	PDF	_
167-7	31672-31676	file	_
167-8	31677-31679	of	_
167-9	31680-31682	an	_
167-10	31683-31691	unedited	_
167-11	31692-31702	manuscript	_
167-12	31703-31707	that	_
167-13	31708-31711	has	_
167-14	31712-31716	been	_
167-15	31717-31725	accepted	_
167-16	31726-31729	for	_
167-17	31730-31741	publication	_
167-18	31741-31742	.	_

#Text=As a service to our customers we are providing this early version of the manuscript.
168-1	31743-31745	As	_
168-2	31746-31747	a	_
168-3	31748-31755	service	_
168-4	31756-31758	to	_
168-5	31759-31762	our	_
168-6	31763-31772	customers	_
168-7	31773-31775	we	_
168-8	31776-31779	are	_
168-9	31780-31789	providing	_
168-10	31790-31794	this	_
168-11	31795-31800	early	_
168-12	31801-31808	version	_
168-13	31809-31811	of	_
168-14	31812-31815	the	_
168-15	31816-31826	manuscript	_
168-16	31826-31827	.	_

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
169-1	31828-31831	The	_
169-2	31832-31842	manuscript	_
169-3	31843-31847	will	_
169-4	31848-31855	undergo	_
169-5	31856-31867	copyediting	_
169-6	31867-31868	,	_
169-7	31869-31880	typesetting	_
169-8	31880-31881	,	_
169-9	31882-31885	and	_
169-10	31886-31892	review	_
169-11	31893-31895	of	_
169-12	31896-31899	the	_
169-13	31900-31909	resulting	_
169-14	31910-31915	proof	_
169-15	31916-31922	before	_
169-16	31923-31925	it	_
169-17	31926-31928	is	_
169-18	31929-31938	published	_
169-19	31939-31941	in	_
169-20	31942-31945	its	_
169-21	31946-31951	final	_
169-22	31952-31959	citable	_
169-23	31960-31964	form	_
169-24	31964-31965	.	_

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
170-1	31966-31972	Please	_
170-2	31973-31977	note	_
170-3	31978-31982	that	_
170-4	31983-31989	during	_
170-5	31990-31993	the	_
170-6	31994-32004	production	_
170-7	32005-32012	process	_
170-8	32013-32019	errors	_
170-9	32020-32023	may	_
170-10	32024-32026	be	_
170-11	32027-32037	discovered	_
170-12	32038-32043	which	_
170-13	32044-32049	could	_
170-14	32050-32056	affect	_
170-15	32057-32060	the	_
170-16	32061-32068	content	_
170-17	32068-32069	,	_
170-18	32070-32073	and	_
170-19	32074-32077	all	_
170-20	32078-32083	legal	_
170-21	32084-32095	disclaimers	_
170-22	32096-32100	that	_
170-23	32101-32106	apply	_
170-24	32107-32109	to	_
170-25	32110-32113	the	_
170-26	32114-32121	journal	_
170-27	32122-32129	pertain	_
170-28	32129-32130	.	_

#Text=Declaration of interest
#Text=The authors report that they have no financial conflicts of interest with respect to the content of this manuscript.
171-1	32142-32153	Declaration	_
171-2	32154-32156	of	_
171-3	32157-32165	interest	_
171-4	32175-32178	The	_
171-5	32179-32186	authors	_
171-6	32187-32193	report	_
171-7	32194-32198	that	_
171-8	32199-32203	they	_
171-9	32204-32208	have	_
171-10	32209-32211	no	_
171-11	32212-32221	financial	_
171-12	32222-32231	conflicts	_
171-13	32232-32234	of	_
171-14	32235-32243	interest	_
171-15	32244-32248	with	_
171-16	32249-32256	respect	_
171-17	32257-32259	to	_
171-18	32260-32263	the	_
171-19	32264-32271	content	_
171-20	32272-32274	of	_
171-21	32275-32279	this	_
171-22	32280-32290	manuscript	_
171-23	32290-32291	.	_

#Text=References
#Text=Effects of chronic cocaine abuse on postsynaptic dopamine receptors
#Text=Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
#Text=Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior
#Text=Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine
#Text=Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers
#Text=Cocaine uptake is decreased in the brain of detoxified cocaine abusers
#Text=In vivo evidence for reduced striatal vesicular monoamine transporter (VMAT2) availability in cocaine abusers
#Text=Dopamine D3 receptor alterations in cocaine-dependent humans imaged with [11C](+)PHNO
#Text=Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO
#Text=Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials
#Text=Dopamine agonists for the treatment of cocaine dependence
#Text=In vivo imaging of cerebral dopamine D3 receptors in alcoholism
#Text=Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum
#Text=Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse
#Text=Deficits in dopamine D2 receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction
#Text=Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex
#Text=Heightened dopaminergic response to amphetamine at the D3 dopamine receptor in methamphetamine users
#Text=Dopamine receptor subtypes in reward and relapse
#Text=Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice
#Text=Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats
#Text=Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex
#Text=Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study
#Text=Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons
#Text=Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy
#Text=Mathematical modelling of [11C]-(+)-PHNO human competition studies
#Text=Imaging of dopamine D2/3 agonist binding in cocaine dependence: a [11C] NPA positron emission tomography study
#Text=Expression and pharmacological characterization of the human D3 dopamine receptor
#Text=Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo
#Text=In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice
#Text=Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist
#Text=Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925
#Text=A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [11C](+)PHNO
#Text=
#Text=The validity of Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic interview for DSM-IV and ICD-10
#Text=Parametric imaging and test–retest variability of 11C-(+)-PHNO binding to D2/D3 dopamine receptors in humans on the high-resolution research tomograph PET Scanner
#Text=Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3, 4, 4a, 5, 6, 10b-hexahydro-2 H-naphtho [1, 2-b][1, 4] oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography
#Text=Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT
#Text=Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging
#Text=[11C] PHNO parametric imaging and test-retest study in humans using the HRRT scanner
#Text=A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM)
#Text=Unified segmentation
#Text=Imaging human mesolimbic dopamine transmission with positron emission tomography&colon; I.
172-1	32292-32302	References	_
172-2	32303-32310	Effects	_
172-3	32311-32313	of	_
172-4	32314-32321	chronic	_
172-5	32322-32329	cocaine	_
172-6	32330-32335	abuse	_
172-7	32336-32338	on	_
172-8	32339-32351	postsynaptic	_
172-9	32352-32360	dopamine	_
172-10	32361-32370	receptors	_
172-11	32371-32380	Decreased	_
172-12	32381-32389	striatal	_
172-13	32390-32402	dopaminergic	_
172-14	32403-32417	responsiveness	_
172-15	32418-32420	in	_
172-16	32421-32431	detoxified	_
172-17	32432-32449	cocaine-dependent	_
172-18	32450-32458	subjects	_
172-19	32459-32466	Cocaine	_
172-20	32467-32477	dependence	_
172-21	32478-32481	and	_
172-22	32482-32484	d2	_
172-23	32485-32493	receptor	_
172-24	32494-32506	availability	_
172-25	32507-32509	in	_
172-26	32510-32513	the	_
172-27	32514-32524	functional	_
172-28	32525-32537	subdivisions	_
172-29	32538-32540	of	_
172-30	32541-32544	the	_
172-31	32545-32553	striatum	_
172-32	32553-32554	:	_
172-33	32555-32567	relationship	_
172-34	32568-32572	with	_
172-35	32573-32588	cocaine-seeking	_
172-36	32589-32597	behavior	_
172-37	32598-32617	Amphetamine-induced	_
172-38	32618-32626	dopamine	_
172-39	32627-32634	release	_
172-40	32634-32635	:	_
172-41	32636-32644	markedly	_
172-42	32645-32652	blunted	_
172-43	32653-32655	in	_
172-44	32656-32663	cocaine	_
172-45	32664-32674	dependence	_
172-46	32675-32678	and	_
172-47	32679-32689	predictive	_
172-48	32690-32692	of	_
172-49	32693-32696	the	_
172-50	32697-32703	choice	_
172-51	32704-32706	to	_
172-52	32707-32722	self-administer	_
172-53	32723-32730	cocaine	_
172-54	32731-32748	Stimulant-induced	_
172-55	32749-32757	dopamine	_
172-56	32758-32767	increases	_
172-57	32768-32771	are	_
172-58	32772-32780	markedly	_
172-59	32781-32788	blunted	_
172-60	32789-32791	in	_
172-61	32792-32798	active	_
172-62	32799-32806	cocaine	_
172-63	32807-32814	abusers	_
172-64	32815-32822	Cocaine	_
172-65	32823-32829	uptake	_
172-66	32830-32832	is	_
172-67	32833-32842	decreased	_
172-68	32843-32845	in	_
172-69	32846-32849	the	_
172-70	32850-32855	brain	_
172-71	32856-32858	of	_
172-72	32859-32869	detoxified	_
172-73	32870-32877	cocaine	_
172-74	32878-32885	abusers	_
172-75	32886-32888	In	_
172-76	32889-32893	vivo	_
172-77	32894-32902	evidence	_
172-78	32903-32906	for	_
172-79	32907-32914	reduced	_
172-80	32915-32923	striatal	_
172-81	32924-32933	vesicular	_
172-82	32934-32943	monoamine	_
172-83	32944-32955	transporter	_
172-84	32956-32957	(	_
172-85	32957-32962	VMAT2	_
172-86	32962-32963	)	_
172-87	32964-32976	availability	_
172-88	32977-32979	in	_
172-89	32980-32987	cocaine	_
172-90	32988-32995	abusers	_
172-91	32996-33004	Dopamine	_
172-92	33005-33007	D3	_
172-93	33008-33016	receptor	_
172-94	33017-33028	alterations	_
172-95	33029-33031	in	_
172-96	33032-33049	cocaine-dependent	_
172-97	33050-33056	humans	_
172-98	33057-33063	imaged	_
172-99	33064-33068	with	_
172-100	33069-33070	[	_
172-101	33070-33073	11C	_
172-102	33073-33074	]	_
172-103	33074-33075	(	_
172-104	33075-33076	+	_
172-105	33076-33077	)	_
172-106	33077-33081	PHNO	_
172-107	33082-33092	Heightened	_
172-108	33093-33095	D3	_
172-109	33096-33104	dopamine	_
172-110	33105-33113	receptor	_
172-111	33114-33120	levels	_
172-112	33121-33123	in	_
172-113	33124-33131	cocaine	_
172-114	33132-33142	dependence	_
172-115	33143-33146	and	_
172-116	33147-33160	contributions	_
172-117	33161-33163	to	_
172-118	33164-33167	the	_
172-119	33168-33177	addiction	_
172-120	33178-33188	behavioral	_
172-121	33189-33198	phenotype	_
172-122	33198-33199	:	_
172-123	33200-33201	a	_
172-124	33202-33210	positron	_
172-125	33211-33219	emission	_
172-126	33220-33230	tomography	_
172-127	33231-33236	study	_
172-128	33237-33241	with	_
172-129	33242-33243	[	_
172-130	33243-33246	11C	_
172-131	33246-33247	]	_
172-132	33247-33248	-	_
172-133	33248-33249	+	_
172-134	33249-33250	-	_
172-135	33250-33254	PHNO	_
172-136	33255-33263	Efficacy	_
172-137	33264-33266	of	_
172-138	33267-33275	indirect	_
172-139	33276-33284	dopamine	_
172-140	33285-33293	agonists	_
172-141	33294-33297	for	_
172-142	33298-33313	psychostimulant	_
172-143	33314-33324	dependence	_
172-144	33324-33325	:	_
172-145	33326-33327	a	_
172-146	33328-33338	systematic	_
172-147	33339-33345	review	_
172-148	33346-33349	and	_
172-149	33350-33363	meta-analysis	_
172-150	33364-33366	of	_
172-151	33367-33377	randomized	_
172-152	33378-33388	controlled	_
172-153	33389-33395	trials	_
172-154	33396-33404	Dopamine	_
172-155	33405-33413	agonists	_
172-156	33414-33417	for	_
172-157	33418-33421	the	_
172-158	33422-33431	treatment	_
172-159	33432-33434	of	_
172-160	33435-33442	cocaine	_
172-161	33443-33453	dependence	_
172-162	33454-33456	In	_
172-163	33457-33461	vivo	_
172-164	33462-33469	imaging	_
172-165	33470-33472	of	_
172-166	33473-33481	cerebral	_
172-167	33482-33490	dopamine	_
172-168	33491-33493	D3	_
172-169	33494-33503	receptors	_
172-170	33504-33506	in	_
172-171	33507-33517	alcoholism	_
172-172	33518-33525	Alcohol	_
172-173	33526-33536	dependence	_
172-174	33537-33539	is	_
172-175	33540-33550	associated	_
172-176	33551-33555	with	_
172-177	33556-33563	blunted	_
172-178	33564-33572	dopamine	_
172-179	33573-33585	transmission	_
172-180	33586-33588	in	_
172-181	33589-33592	the	_
172-182	33593-33600	ventral	_
172-183	33601-33609	striatum	_
172-184	33610-33621	Association	_
172-185	33622-33624	of	_
172-186	33625-33628	low	_
172-187	33629-33637	striatal	_
172-188	33638-33646	dopamine	_
172-189	33647-33649	D2	_
172-190	33650-33658	receptor	_
172-191	33659-33671	availability	_
172-192	33672-33676	with	_
172-193	33677-33685	nicotine	_
172-194	33686-33696	dependence	_
172-195	33697-33704	similar	_
172-196	33705-33707	to	_
172-197	33708-33712	that	_
172-198	33713-33717	seen	_
172-199	33718-33722	with	_
172-200	33723-33728	other	_
172-201	33729-33734	drugs	_
172-202	33735-33737	of	_
172-203	33738-33743	abuse	_
172-204	33744-33752	Deficits	_
172-205	33753-33755	in	_
172-206	33756-33764	dopamine	_
172-207	33765-33767	D2	_
172-208	33768-33777	receptors	_
172-209	33778-33781	and	_
172-210	33782-33793	presynaptic	_
172-211	33794-33802	dopamine	_
172-212	33803-33805	in	_
172-213	33806-33812	heroin	_
172-214	33813-33823	dependence	_
172-215	33823-33824	:	_
172-216	33825-33838	commonalities	_
172-217	33839-33842	and	_
172-218	33843-33854	differences	_
172-219	33855-33859	with	_
172-220	33860-33865	other	_
172-221	33866-33871	types	_
172-222	33872-33874	of	_
172-223	33875-33884	addiction	_
172-224	33885-33888	Low	_
172-225	33889-33894	level	_
172-226	33895-33897	of	_
172-227	33898-33903	brain	_
172-228	33904-33912	dopamine	_
172-229	33913-33915	D2	_
172-230	33916-33925	receptors	_
172-231	33926-33928	in	_
172-232	33929-33944	methamphetamine	_
172-233	33945-33952	abusers	_
172-234	33952-33953	:	_
172-235	33954-33965	association	_
172-236	33966-33970	with	_
172-237	33971-33981	metabolism	_
172-238	33982-33984	in	_
172-239	33985-33988	the	_
172-240	33989-34002	orbitofrontal	_
172-241	34003-34009	cortex	_
172-242	34010-34020	Heightened	_
172-243	34021-34033	dopaminergic	_
172-244	34034-34042	response	_
172-245	34043-34045	to	_
172-246	34046-34057	amphetamine	_
172-247	34058-34060	at	_
172-248	34061-34064	the	_
172-249	34065-34067	D3	_
172-250	34068-34076	dopamine	_
172-251	34077-34085	receptor	_
172-252	34086-34088	in	_
172-253	34089-34104	methamphetamine	_
172-254	34105-34110	users	_
172-255	34111-34119	Dopamine	_
172-256	34120-34128	receptor	_
172-257	34129-34137	subtypes	_
172-258	34138-34140	in	_
172-259	34141-34147	reward	_
172-260	34148-34151	and	_
172-261	34152-34159	relapse	_
172-262	34160-34173	Contributions	_
172-263	34174-34176	of	_
172-264	34177-34185	dopamine	_
172-265	34186-34188	D1	_
172-266	34188-34189	,	_
172-267	34190-34192	D2	_
172-268	34192-34193	,	_
172-269	34194-34197	and	_
172-270	34198-34200	D3	_
172-271	34201-34209	receptor	_
172-272	34210-34218	subtypes	_
172-273	34219-34221	to	_
172-274	34222-34225	the	_
172-275	34226-34236	disruptive	_
172-276	34237-34244	effects	_
172-277	34245-34247	of	_
172-278	34248-34255	cocaine	_
172-279	34256-34258	on	_
172-280	34259-34267	prepulse	_
172-281	34268-34278	inhibition	_
172-282	34279-34281	in	_
172-283	34282-34286	mice	_
172-284	34287-34293	Double	_
172-285	34294-34306	dissociation	_
172-286	34307-34309	of	_
172-287	34310-34313	the	_
172-288	34314-34321	effects	_
172-289	34322-34324	of	_
172-290	34325-34336	haloperidol	_
172-291	34337-34340	and	_
172-292	34341-34344	the	_
172-293	34345-34353	dopamine	_
172-294	34354-34356	D3	_
172-295	34357-34365	receptor	_
172-296	34366-34376	antagonist	_
172-297	34377-34380	ABT	_
172-298	34380-34381	-	_
172-299	34381-34384	127	_
172-300	34385-34387	on	_
172-301	34388-34399	acquisition	_
172-302	34400-34402	vs	_
172-303	34402-34403	.	_
172-304	34404-34414	expression	_
172-305	34415-34417	of	_
172-306	34418-34437	cocaine-conditioned	_
172-307	34438-34446	activity	_
172-308	34447-34449	in	_
172-309	34450-34454	rats	_
172-310	34455-34464	Selective	_
172-311	34465-34473	blockade	_
172-312	34474-34476	of	_
172-313	34477-34485	dopamine	_
172-314	34486-34488	D3	_
172-315	34489-34498	receptors	_
172-316	34499-34507	enhances	_
172-317	34508-34513	while	_
172-318	34514-34516	D2	_
172-319	34517-34525	receptor	_
172-320	34526-34536	antagonism	_
172-321	34537-34544	impairs	_
172-322	34545-34551	social	_
172-323	34552-34559	novelty	_
172-324	34560-34574	discrimination	_
172-325	34575-34578	and	_
172-326	34579-34584	novel	_
172-327	34585-34591	object	_
172-328	34592-34603	recognition	_
172-329	34604-34606	in	_
172-330	34607-34611	rats	_
172-331	34611-34612	:	_
172-332	34613-34614	a	_
172-333	34615-34618	key	_
172-334	34619-34623	role	_
172-335	34624-34627	for	_
172-336	34628-34631	the	_
172-337	34632-34642	prefrontal	_
172-338	34643-34649	cortex	_
172-339	34650-34656	Higher	_
172-340	34657-34664	binding	_
172-341	34665-34667	of	_
172-342	34668-34671	the	_
172-343	34672-34680	dopamine	_
172-344	34681-34683	D3	_
172-345	34684-34703	receptor-preferring	_
172-346	34704-34710	ligand	_
172-347	34711-34712	[	_
172-348	34712-34715	11C	_
172-349	34715-34716	]	_
172-350	34716-34717	-	_
172-351	34717-34718	(	_
172-352	34718-34719	+	_
172-353	34719-34720	)	_
172-354	34720-34721	-	_
172-355	34721-34752	propyl-hexahydro-naphtho-oxazin	_
172-356	34753-34755	in	_
172-357	34756-34771	methamphetamine	_
172-358	34772-34780	polydrug	_
172-359	34781-34786	users	_
172-360	34786-34787	:	_
172-361	34788-34789	a	_
172-362	34790-34798	positron	_
172-363	34799-34807	emission	_
172-364	34808-34818	tomography	_
172-365	34819-34824	study	_
172-366	34825-34837	Distribution	_
172-367	34838-34840	of	_
172-368	34841-34849	dopamine	_
172-369	34850-34852	D3	_
172-370	34853-34861	receptor	_
172-371	34862-34872	expressing	_
172-372	34873-34880	neurons	_
172-373	34881-34883	in	_
172-374	34884-34887	the	_
172-375	34888-34893	human	_
172-376	34894-34903	forebrain	_
172-377	34903-34904	:	_
172-378	34905-34915	comparison	_
172-379	34916-34920	with	_
172-380	34921-34923	D2	_
172-381	34924-34932	receptor	_
172-382	34933-34943	expressing	_
172-383	34944-34951	neurons	_
172-384	34952-34959	Imaging	_
172-385	34960-34968	dopamine	_
172-386	34969-34978	receptors	_
172-387	34979-34981	in	_
172-388	34982-34988	humans	_
172-389	34989-34993	with	_
172-390	34994-34995	[	_
172-391	34995-34998	11C	_
172-392	34998-34999	]	_
172-393	34999-35000	-	_
172-394	35000-35001	(	_
172-395	35001-35002	+	_
172-396	35002-35003	)	_
172-397	35003-35004	-	_
172-398	35004-35008	PHNO	_
172-399	35008-35009	:	_
172-400	35010-35020	dissection	_
172-401	35021-35023	of	_
172-402	35024-35026	D3	_
172-403	35027-35033	signal	_
172-404	35034-35037	and	_
172-405	35038-35045	anatomy	_
172-406	35046-35058	Mathematical	_
172-407	35059-35068	modelling	_
172-408	35069-35071	of	_
172-409	35072-35073	[	_
172-410	35073-35076	11C	_
172-411	35076-35077	]	_
172-412	35077-35078	-	_
172-413	35078-35079	(	_
172-414	35079-35080	+	_
172-415	35080-35081	)	_
172-416	35081-35082	-	_
172-417	35082-35086	PHNO	_
172-418	35087-35092	human	_
172-419	35093-35104	competition	_
172-420	35105-35112	studies	_
172-421	35113-35120	Imaging	_
172-422	35121-35123	of	_
172-423	35124-35132	dopamine	_
172-424	35133-35135	D2	_
172-425	35135-35136	/	_
172-426	35136-35137	3	_
172-427	35138-35145	agonist	_
172-428	35146-35153	binding	_
172-429	35154-35156	in	_
172-430	35157-35164	cocaine	_
172-431	35165-35175	dependence	_
172-432	35175-35176	:	_
172-433	35177-35178	a	_
172-434	35179-35180	[	_
172-435	35180-35183	11C	_
172-436	35183-35184	]	_
172-437	35185-35188	NPA	_
172-438	35189-35197	positron	_
172-439	35198-35206	emission	_
172-440	35207-35217	tomography	_
172-441	35218-35223	study	_
172-442	35224-35234	Expression	_
172-443	35235-35238	and	_
172-444	35239-35254	pharmacological	_
172-445	35255-35271	characterization	_
172-446	35272-35274	of	_
172-447	35275-35278	the	_
172-448	35279-35284	human	_
172-449	35285-35287	D3	_
172-450	35288-35296	dopamine	_
172-451	35297-35305	receptor	_
172-452	35306-35314	Affinity	_
172-453	35315-35318	and	_
172-454	35319-35330	selectivity	_
172-455	35331-35333	of	_
172-456	35334-35335	[	_
172-457	35335-35338	11C	_
172-458	35338-35339	]	_
172-459	35339-35340	-	_
172-460	35340-35341	(	_
172-461	35341-35342	+	_
172-462	35342-35343	)	_
172-463	35343-35344	-	_
172-464	35344-35348	PHNO	_
172-465	35349-35352	for	_
172-466	35353-35356	the	_
172-467	35357-35359	D3	_
172-468	35360-35363	and	_
172-469	35364-35366	D2	_
172-470	35367-35376	receptors	_
172-471	35377-35379	in	_
172-472	35380-35383	the	_
172-473	35384-35390	rhesus	_
172-474	35391-35397	monkey	_
172-475	35398-35403	brain	_
172-476	35404-35406	in	_
172-477	35407-35411	vivo	_
172-478	35412-35414	In	_
172-479	35415-35419	vivo	_
172-480	35420-35434	quantification	_
172-481	35435-35437	of	_
172-482	35438-35446	regional	_
172-483	35447-35458	dopamine-D3	_
172-484	35459-35467	receptor	_
172-485	35468-35475	binding	_
172-486	35476-35485	potential	_
172-487	35486-35488	of	_
172-488	35489-35490	(	_
172-489	35490-35491	+	_
172-490	35491-35492	)	_
172-491	35492-35493	-	_
172-492	35493-35497	PHNO	_
172-493	35497-35498	:	_
172-494	35499-35506	Studies	_
172-495	35507-35509	in	_
172-496	35510-35519	non-human	_
172-497	35520-35528	primates	_
172-498	35529-35532	and	_
172-499	35533-35543	transgenic	_
172-500	35544-35548	mice	_
172-501	35549-35556	Imaging	_
172-502	35557-35565	dopamine	_
172-503	35566-35568	D3	_
172-504	35569-35578	receptors	_
172-505	35579-35581	in	_
172-506	35582-35585	the	_
172-507	35586-35591	human	_
172-508	35592-35597	brain	_
172-509	35598-35602	with	_
172-510	35603-35611	positron	_
172-511	35612-35620	emission	_
172-512	35621-35631	tomography	_
172-513	35631-35632	,	_
172-514	35633-35634	[	_
172-515	35634-35637	11C	_
172-516	35637-35638	]	_
172-517	35638-35642	PHNO	_
172-518	35642-35643	,	_
172-519	35644-35647	and	_
172-520	35648-35649	a	_
172-521	35650-35659	selective	_
172-522	35660-35662	D3	_
172-523	35663-35671	receptor	_
172-524	35672-35682	antagonist	_
172-525	35683-35691	Blockade	_
172-526	35692-35694	of	_
172-527	35695-35696	[	_
172-528	35696-35699	11C	_
172-529	35699-35700	]	_
172-530	35700-35701	(	_
172-531	35701-35702	+	_
172-532	35702-35703	)	_
172-533	35703-35704	-	_
172-534	35704-35708	PHNO	_
172-535	35709-35716	binding	_
172-536	35717-35719	in	_
172-537	35720-35725	human	_
172-538	35726-35734	subjects	_
172-539	35735-35737	by	_
172-540	35738-35741	the	_
172-541	35742-35750	dopamine	_
172-542	35751-35753	D3	_
172-543	35754-35762	receptor	_
172-544	35763-35773	antagonist	_
172-545	35774-35777	ABT	_
172-546	35777-35778	-	_
172-547	35778-35781	925	_
172-548	35782-35783	A	_
172-549	35784-35795	preliminary	_
172-550	35796-35801	study	_
172-551	35802-35804	of	_
172-552	35805-35813	dopamine	_
172-553	35814-35816	D2	_
172-554	35816-35817	/	_
172-555	35817-35818	3	_
172-556	35819-35827	receptor	_
172-557	35828-35840	availability	_
172-558	35841-35844	and	_
172-559	35845-35851	social	_
172-560	35852-35858	status	_
172-561	35859-35861	in	_
172-562	35862-35869	healthy	_
172-563	35870-35873	and	_
172-564	35874-35881	cocaine	_
172-565	35882-35891	dependent	_
172-566	35892-35898	humans	_
172-567	35899-35905	imaged	_
172-568	35906-35910	with	_
172-569	35911-35912	[	_
172-570	35912-35915	11C	_
172-571	35915-35916	]	_
172-572	35916-35917	(	_
172-573	35917-35918	+	_
172-574	35918-35919	)	_
172-575	35919-35923	PHNO	_
172-576	35925-35928	The	_
172-577	35929-35937	validity	_
172-578	35938-35940	of	_
172-579	35941-35945	Mini	_
172-580	35946-35959	International	_
172-581	35960-35976	Neuropsychiatric	_
172-582	35977-35986	Interview	_
172-583	35987-35988	(	_
172-584	35988-35992	MINI	_
172-585	35992-35993	)	_
172-586	35993-35994	:	_
172-587	35995-35998	The	_
172-588	35999-36010	development	_
172-589	36011-36014	and	_
172-590	36015-36025	validation	_
172-591	36026-36028	of	_
172-592	36029-36030	a	_
172-593	36031-36041	structured	_
172-594	36042-36052	diagnostic	_
172-595	36053-36062	interview	_
172-596	36063-36066	for	_
172-597	36067-36073	DSM-IV	_
172-598	36074-36077	and	_
172-599	36078-36081	ICD	_
172-600	36081-36082	-	_
172-601	36082-36084	10	_
172-602	36085-36095	Parametric	_
172-603	36096-36103	imaging	_
172-604	36104-36107	and	_
172-605	36108-36119	test–retest	_
172-606	36120-36131	variability	_
172-607	36132-36134	of	_
172-608	36135-36138	11C	_
172-609	36138-36139	-	_
172-610	36139-36140	(	_
172-611	36140-36141	+	_
172-612	36141-36142	)	_
172-613	36142-36143	-	_
172-614	36143-36147	PHNO	_
172-615	36148-36155	binding	_
172-616	36156-36158	to	_
172-617	36159-36161	D2	_
172-618	36161-36162	/	_
172-619	36162-36164	D3	_
172-620	36165-36173	dopamine	_
172-621	36174-36183	receptors	_
172-622	36184-36186	in	_
172-623	36187-36193	humans	_
172-624	36194-36196	on	_
172-625	36197-36200	the	_
172-626	36201-36216	high-resolution	_
172-627	36217-36225	research	_
172-628	36226-36235	tomograph	_
172-629	36236-36239	PET	_
172-630	36240-36247	Scanner	_
172-631	36248-36262	Radiosynthesis	_
172-632	36263-36266	and	_
172-633	36267-36277	Evaluation	_
172-634	36278-36280	of	_
172-635	36281-36282	[	_
172-636	36282-36285	11C	_
172-637	36285-36286	]	_
172-638	36286-36287	-	_
172-639	36287-36288	(	_
172-640	36288-36289	+	_
172-641	36289-36290	)	_
172-642	36290-36291	-	_
172-643	36291-36292	4	_
172-644	36292-36293	-	_
172-645	36293-36299	Propyl	_
172-646	36299-36300	-	_
172-647	36300-36301	3	_
172-648	36301-36302	,	_
172-649	36303-36304	4	_
172-650	36304-36305	,	_
172-651	36306-36308	4a	_
172-652	36308-36309	,	_
172-653	36310-36311	5	_
172-654	36311-36312	,	_
172-655	36313-36314	6	_
172-656	36314-36315	,	_
172-657	36316-36329	10b-hexahydro	_
172-658	36329-36330	-	_
172-659	36330-36331	2	_
172-660	36332-36341	H-naphtho	_
172-661	36342-36343	[	_
172-662	36343-36344	1	_
172-663	36344-36345	,	_
172-664	36346-36347	2	_
172-665	36347-36348	-	_
172-666	36348-36349	b	_
172-667	36349-36350	]	_
172-668	36350-36351	[	_
172-669	36351-36352	1	_
172-670	36352-36353	,	_
172-671	36354-36355	4	_
172-672	36355-36356	]	_
172-673	36357-36363	oxazin	_
172-674	36363-36364	-	_
172-675	36364-36365	9	_
172-676	36365-36366	-	_
172-677	36366-36368	ol	_
172-678	36369-36371	as	_
172-679	36372-36373	a	_
172-680	36374-36383	Potential	_
172-681	36384-36395	Radiotracer	_
172-682	36396-36399	for	_
172-683	36400-36402	in	_
172-684	36403-36407	Vivo	_
172-685	36408-36415	Imaging	_
172-686	36416-36418	of	_
172-687	36419-36422	the	_
172-688	36423-36431	Dopamine	_
172-689	36432-36434	D2	_
172-690	36435-36448	High-Affinity	_
172-691	36449-36454	State	_
172-692	36455-36459	with	_
172-693	36460-36468	Positron	_
172-694	36469-36477	Emission	_
172-695	36478-36488	Tomography	_
172-696	36489-36495	Design	_
172-697	36496-36498	of	_
172-698	36499-36500	a	_
172-699	36501-36520	motion-compensation	_
172-700	36521-36525	OSEM	_
172-701	36526-36535	list-mode	_
172-702	36536-36545	algorithm	_
172-703	36546-36549	for	_
172-704	36550-36569	resolution-recovery	_
172-705	36570-36584	reconstruction	_
172-706	36585-36588	for	_
172-707	36589-36592	the	_
172-708	36593-36597	HRRT	_
172-709	36598-36603	Noise	_
172-710	36604-36613	reduction	_
172-711	36614-36616	in	_
172-712	36617-36620	the	_
172-713	36621-36631	simplified	_
172-714	36632-36641	reference	_
172-715	36642-36648	tissue	_
172-716	36649-36654	model	_
172-717	36655-36658	for	_
172-718	36659-36672	neuroreceptor	_
172-719	36673-36683	functional	_
172-720	36684-36691	imaging	_
172-721	36692-36693	[	_
172-722	36693-36696	11C	_
172-723	36696-36697	]	_
172-724	36698-36702	PHNO	_
172-725	36703-36713	parametric	_
172-726	36714-36721	imaging	_
172-727	36722-36725	and	_
172-728	36726-36737	test-retest	_
172-729	36738-36743	study	_
172-730	36744-36746	in	_
172-731	36747-36753	humans	_
172-732	36754-36759	using	_
172-733	36760-36763	the	_
172-734	36764-36768	HRRT	_
172-735	36769-36776	scanner	_
172-736	36777-36778	A	_
172-737	36779-36792	probabilistic	_
172-738	36793-36798	atlas	_
172-739	36799-36802	and	_
172-740	36803-36812	reference	_
172-741	36813-36819	system	_
172-742	36820-36823	for	_
172-743	36824-36827	the	_
172-744	36828-36833	human	_
172-745	36834-36839	brain	_
172-746	36839-36840	:	_
172-747	36841-36854	International	_
172-748	36855-36865	Consortium	_
172-749	36866-36869	for	_
172-750	36870-36875	Brain	_
172-751	36876-36883	Mapping	_
172-752	36884-36885	(	_
172-753	36885-36889	ICBM	_
172-754	36889-36890	)	_
172-755	36891-36898	Unified	_
172-756	36899-36911	segmentation	_
172-757	36912-36919	Imaging	_
172-758	36920-36925	human	_
172-759	36926-36936	mesolimbic	_
172-760	36937-36945	dopamine	_
172-761	36946-36958	transmission	_
172-762	36959-36963	with	_
172-763	36964-36972	positron	_
172-764	36973-36981	emission	_
172-765	36982-36992	tomography	_
172-766	36992-36993	&	_
172-767	36993-36998	colon	_
172-768	36998-36999	;	_
172-769	37000-37001	I	_
172-770	37001-37002	.	_

#Text=Accuracy and precision of D2 receptor parameter measurements in ventral striatum
#Text=Source-based morphometry: The use of independent component analysis to identify gray matter differences with application to schizophrenia
#Text=Estimating the number of independent components for functional magnetic resonance imaging data
#Text=An information-maximization approach to blind separation and blind deconvolution
#Text=Ventral striatum binding of a dopamine D 2/3 receptor agonist but not antagonist predicts normal body mass index
#Text=Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers
#Text=Lack of age-dependent decrease in dopamine D3 receptor availability: A [11C]-(+)-PHNO and [11C]-raclopride positron emission tomography study
#Text=Body mass index relationships with dopamine D3 receptor availability as measured by [11C](+)PHNO
#Text=Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity
#Text=Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment
#Text=PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys
#Text=Dopamine receptor expression and distribution dynamically change in the rat nucleus accumbens after withdrawal from cocaine self-administration
#Text=Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior
#Text=Biomarkers in substance use disorders
#Text=Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization
#Text=Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptors
#Text=Distinct roles for direct and indirect pathway striatal neurons in reinforcement
#Text=Strengthening the accumbal indirect pathway promotes resilience to compulsive cocaine use
#Text=The neural basis of addiction: a pathology of motivation and choice
#Text=Roles of “wanting” and “liking” in motivating behavior: gambling, food, and drug addictions
#Text=Dopaminergic network differences in human impulsivity
#Text=Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities
#Text=Agonist medications for the treatment of cocaine use disorder
#Text=Cocaine self-administration in dopamine D3 receptor knockout mice
#Text=Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55
#Text=Effects of chronic buspirone treatment on cocaine self-administration
#Text=Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists
#Text=Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens
#Text=The effect of model order selection in group PICA
#Text=The interrelationship of dopamine D2-like receptor availability in striatal and extrastriatal brain regions in healthy humans: a principal component analysis of [18 F] fallypride binding
#Text=Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging
#Text=Regional analyses of [11C]-(+)-PHNO BPND.
173-1	37003-37011	Accuracy	_
173-2	37012-37015	and	_
173-3	37016-37025	precision	_
173-4	37026-37028	of	_
173-5	37029-37031	D2	_
173-6	37032-37040	receptor	_
173-7	37041-37050	parameter	_
173-8	37051-37063	measurements	_
173-9	37064-37066	in	_
173-10	37067-37074	ventral	_
173-11	37075-37083	striatum	_
173-12	37084-37096	Source-based	_
173-13	37097-37108	morphometry	_
173-14	37108-37109	:	_
173-15	37110-37113	The	_
173-16	37114-37117	use	_
173-17	37118-37120	of	_
173-18	37121-37132	independent	_
173-19	37133-37142	component	_
173-20	37143-37151	analysis	_
173-21	37152-37154	to	_
173-22	37155-37163	identify	_
173-23	37164-37168	gray	_
173-24	37169-37175	matter	_
173-25	37176-37187	differences	_
173-26	37188-37192	with	_
173-27	37193-37204	application	_
173-28	37205-37207	to	_
173-29	37208-37221	schizophrenia	_
173-30	37222-37232	Estimating	_
173-31	37233-37236	the	_
173-32	37237-37243	number	_
173-33	37244-37246	of	_
173-34	37247-37258	independent	_
173-35	37259-37269	components	_
173-36	37270-37273	for	_
173-37	37274-37284	functional	_
173-38	37285-37293	magnetic	_
173-39	37294-37303	resonance	_
173-40	37304-37311	imaging	_
173-41	37312-37316	data	_
173-42	37317-37319	An	_
173-43	37320-37344	information-maximization	_
173-44	37345-37353	approach	_
173-45	37354-37356	to	_
173-46	37357-37362	blind	_
173-47	37363-37373	separation	_
173-48	37374-37377	and	_
173-49	37378-37383	blind	_
173-50	37384-37397	deconvolution	_
173-51	37398-37405	Ventral	_
173-52	37406-37414	striatum	_
173-53	37415-37422	binding	_
173-54	37423-37425	of	_
173-55	37426-37427	a	_
173-56	37428-37436	dopamine	_
173-57	37437-37438	D	_
173-58	37439-37440	2	_
173-59	37440-37441	/	_
173-60	37441-37442	3	_
173-61	37443-37451	receptor	_
173-62	37452-37459	agonist	_
173-63	37460-37463	but	_
173-64	37464-37467	not	_
173-65	37468-37478	antagonist	_
173-66	37479-37487	predicts	_
173-67	37488-37494	normal	_
173-68	37495-37499	body	_
173-69	37500-37504	mass	_
173-70	37505-37510	index	_
173-71	37511-37522	Age-related	_
173-72	37523-37530	changes	_
173-73	37531-37533	in	_
173-74	37534-37541	binding	_
173-75	37542-37544	of	_
173-76	37545-37548	the	_
173-77	37549-37551	D2	_
173-78	37551-37552	/	_
173-79	37552-37553	3	_
173-80	37554-37562	receptor	_
173-81	37563-37574	radioligand	_
173-82	37575-37576	[	_
173-83	37576-37579	11C	_
173-84	37579-37580	]	_
173-85	37580-37581	(	_
173-86	37581-37582	+	_
173-87	37582-37583	)	_
173-88	37583-37587	PHNO	_
173-89	37588-37590	in	_
173-90	37591-37598	healthy	_
173-91	37599-37609	volunteers	_
173-92	37610-37614	Lack	_
173-93	37615-37617	of	_
173-94	37618-37631	age-dependent	_
173-95	37632-37640	decrease	_
173-96	37641-37643	in	_
173-97	37644-37652	dopamine	_
173-98	37653-37655	D3	_
173-99	37656-37664	receptor	_
173-100	37665-37677	availability	_
173-101	37677-37678	:	_
173-102	37679-37680	A	_
173-103	37681-37682	[	_
173-104	37682-37685	11C	_
173-105	37685-37686	]	_
173-106	37686-37687	-	_
173-107	37687-37688	(	_
173-108	37688-37689	+	_
173-109	37689-37690	)	_
173-110	37690-37691	-	_
173-111	37691-37695	PHNO	_
173-112	37696-37699	and	_
173-113	37700-37701	[	_
173-114	37701-37704	11C	_
173-115	37704-37705	]	_
173-116	37705-37706	-	_
173-117	37706-37716	raclopride	_
173-118	37717-37725	positron	_
173-119	37726-37734	emission	_
173-120	37735-37745	tomography	_
173-121	37746-37751	study	_
173-122	37752-37756	Body	_
173-123	37757-37761	mass	_
173-124	37762-37767	index	_
173-125	37768-37781	relationships	_
173-126	37782-37786	with	_
173-127	37787-37795	dopamine	_
173-128	37796-37798	D3	_
173-129	37799-37807	receptor	_
173-130	37808-37820	availability	_
173-131	37821-37823	as	_
173-132	37824-37832	measured	_
173-133	37833-37835	by	_
173-134	37836-37837	[	_
173-135	37837-37840	11C	_
173-136	37840-37841	]	_
173-137	37841-37842	(	_
173-138	37842-37843	+	_
173-139	37843-37844	)	_
173-140	37844-37848	PHNO	_
173-141	37849-37857	Striatal	_
173-142	37858-37866	dopamine	_
173-143	37867-37869	d2	_
173-144	37869-37870	/	_
173-145	37870-37872	d3	_
173-146	37873-37881	receptor	_
173-147	37882-37894	availability	_
173-148	37895-37897	is	_
173-149	37898-37905	reduced	_
173-150	37906-37908	in	_
173-151	37909-37924	methamphetamine	_
173-152	37925-37935	dependence	_
173-153	37936-37939	and	_
173-154	37940-37942	is	_
173-155	37943-37949	linked	_
173-156	37950-37952	to	_
173-157	37953-37964	impulsivity	_
173-158	37965-37972	Imaging	_
173-159	37973-37981	dopamine	_
173-160	37982-37994	transmission	_
173-161	37995-37997	in	_
173-162	37998-38005	cocaine	_
173-163	38006-38016	dependence	_
173-164	38016-38017	:	_
173-165	38018-38022	link	_
173-166	38023-38030	between	_
173-167	38031-38045	neurochemistry	_
173-168	38046-38049	and	_
173-169	38050-38058	response	_
173-170	38059-38061	to	_
173-171	38062-38071	treatment	_
173-172	38072-38075	PET	_
173-173	38076-38083	imaging	_
173-174	38084-38086	of	_
173-175	38087-38095	dopamine	_
173-176	38096-38098	D2	_
173-177	38099-38108	receptors	_
173-178	38109-38115	during	_
173-179	38116-38123	chronic	_
173-180	38124-38131	cocaine	_
173-181	38132-38151	self-administration	_
173-182	38152-38154	in	_
173-183	38155-38162	monkeys	_
173-184	38163-38171	Dopamine	_
173-185	38172-38180	receptor	_
173-186	38181-38191	expression	_
173-187	38192-38195	and	_
173-188	38196-38208	distribution	_
173-189	38209-38220	dynamically	_
173-190	38221-38227	change	_
173-191	38228-38230	in	_
173-192	38231-38234	the	_
173-193	38235-38238	rat	_
173-194	38239-38246	nucleus	_
173-195	38247-38256	accumbens	_
173-196	38257-38262	after	_
173-197	38263-38273	withdrawal	_
173-198	38274-38278	from	_
173-199	38279-38286	cocaine	_
173-200	38287-38306	self-administration	_
173-201	38307-38316	Increases	_
173-202	38317-38319	in	_
173-203	38320-38328	dopamine	_
173-204	38329-38331	D3	_
173-205	38332-38340	receptor	_
173-206	38341-38348	binding	_
173-207	38349-38351	in	_
173-208	38352-38356	rats	_
173-209	38357-38366	receiving	_
173-210	38367-38368	a	_
173-211	38369-38376	cocaine	_
173-212	38377-38386	challenge	_
173-213	38387-38389	at	_
173-214	38390-38397	various	_
173-215	38398-38402	time	_
173-216	38403-38409	points	_
173-217	38410-38415	after	_
173-218	38416-38423	cocaine	_
173-219	38424-38443	self-administration	_
173-220	38443-38444	:	_
173-221	38445-38457	implications	_
173-222	38458-38461	for	_
173-223	38462-38477	cocaine-seeking	_
173-224	38478-38486	behavior	_
173-225	38487-38497	Biomarkers	_
173-226	38498-38500	in	_
173-227	38501-38510	substance	_
173-228	38511-38514	use	_
173-229	38515-38524	disorders	_
173-230	38525-38534	Transient	_
173-231	38535-38543	neuronal	_
173-232	38544-38554	inhibition	_
173-233	38555-38562	reveals	_
173-234	38563-38571	opposing	_
173-235	38572-38577	roles	_
173-236	38578-38580	of	_
173-237	38581-38589	indirect	_
173-238	38590-38593	and	_
173-239	38594-38600	direct	_
173-240	38601-38609	pathways	_
173-241	38610-38612	in	_
173-242	38613-38626	sensitization	_
173-243	38627-38643	Pathway-specific	_
173-244	38644-38654	modulation	_
173-245	38655-38657	of	_
173-246	38658-38665	nucleus	_
173-247	38666-38675	accumbens	_
173-248	38676-38678	in	_
173-249	38679-38685	reward	_
173-250	38686-38689	and	_
173-251	38690-38698	aversive	_
173-252	38699-38707	behavior	_
173-253	38708-38711	via	_
173-254	38712-38721	selective	_
173-255	38722-38733	transmitter	_
173-256	38734-38743	receptors	_
173-257	38744-38752	Distinct	_
173-258	38753-38758	roles	_
173-259	38759-38762	for	_
173-260	38763-38769	direct	_
173-261	38770-38773	and	_
173-262	38774-38782	indirect	_
173-263	38783-38790	pathway	_
173-264	38791-38799	striatal	_
173-265	38800-38807	neurons	_
173-266	38808-38810	in	_
173-267	38811-38824	reinforcement	_
173-268	38825-38838	Strengthening	_
173-269	38839-38842	the	_
173-270	38843-38851	accumbal	_
173-271	38852-38860	indirect	_
173-272	38861-38868	pathway	_
173-273	38869-38877	promotes	_
173-274	38878-38888	resilience	_
173-275	38889-38891	to	_
173-276	38892-38902	compulsive	_
173-277	38903-38910	cocaine	_
173-278	38911-38914	use	_
173-279	38915-38918	The	_
173-280	38919-38925	neural	_
173-281	38926-38931	basis	_
173-282	38932-38934	of	_
173-283	38935-38944	addiction	_
173-284	38944-38945	:	_
173-285	38946-38947	a	_
173-286	38948-38957	pathology	_
173-287	38958-38960	of	_
173-288	38961-38971	motivation	_
173-289	38972-38975	and	_
173-290	38976-38982	choice	_
173-291	38983-38988	Roles	_
173-292	38989-38991	of	_
173-293	38992-38993	“	_
173-294	38993-39000	wanting	_
173-295	39000-39001	”	_
173-296	39002-39005	and	_
173-297	39006-39007	“	_
173-298	39007-39013	liking	_
173-299	39013-39014	”	_
173-300	39015-39017	in	_
173-301	39018-39028	motivating	_
173-302	39029-39037	behavior	_
173-303	39037-39038	:	_
173-304	39039-39047	gambling	_
173-305	39047-39048	,	_
173-306	39049-39053	food	_
173-307	39053-39054	,	_
173-308	39055-39058	and	_
173-309	39059-39063	drug	_
173-310	39064-39074	addictions	_
173-311	39075-39087	Dopaminergic	_
173-312	39088-39095	network	_
173-313	39096-39107	differences	_
173-314	39108-39110	in	_
173-315	39111-39116	human	_
173-316	39117-39128	impulsivity	_
173-317	39129-39137	Adaptive	_
173-318	39138-39146	increase	_
173-319	39147-39149	in	_
173-320	39150-39152	D3	_
173-321	39153-39161	dopamine	_
173-322	39162-39171	receptors	_
173-323	39172-39174	in	_
173-324	39175-39178	the	_
173-325	39179-39184	brain	_
173-326	39185-39191	reward	_
173-327	39192-39200	circuits	_
173-328	39201-39203	of	_
173-329	39204-39209	human	_
173-330	39210-39217	cocaine	_
173-331	39218-39228	fatalities	_
173-332	39229-39236	Agonist	_
173-333	39237-39248	medications	_
173-334	39249-39252	for	_
173-335	39253-39256	the	_
173-336	39257-39266	treatment	_
173-337	39267-39269	of	_
173-338	39270-39277	cocaine	_
173-339	39278-39281	use	_
173-340	39282-39290	disorder	_
173-341	39291-39298	Cocaine	_
173-342	39299-39318	self-administration	_
173-343	39319-39321	in	_
173-344	39322-39330	dopamine	_
173-345	39331-39333	D3	_
173-346	39334-39342	receptor	_
173-347	39343-39351	knockout	_
173-348	39352-39356	mice	_
173-349	39357-39366	Reduction	_
173-350	39367-39369	of	_
173-351	39370-39377	cocaine	_
173-352	39378-39397	self-administration	_
173-353	39398-39401	and	_
173-354	39402-39404	D3	_
173-355	39405-39422	receptor-mediated	_
173-356	39423-39431	behavior	_
173-357	39432-39434	by	_
173-358	39435-39438	two	_
173-359	39439-39444	novel	_
173-360	39445-39453	dopamine	_
173-361	39454-39456	D3	_
173-362	39457-39475	receptor-selective	_
173-363	39476-39483	partial	_
173-364	39484-39492	agonists	_
173-365	39492-39493	,	_
173-366	39494-39496	OS	_
173-367	39496-39497	-	_
173-368	39497-39498	3	_
173-369	39498-39499	-	_
173-370	39499-39502	106	_
173-371	39503-39506	and	_
173-372	39507-39513	WW-III	_
173-373	39513-39514	-	_
173-374	39514-39516	55	_
173-375	39517-39524	Effects	_
173-376	39525-39527	of	_
173-377	39528-39535	chronic	_
173-378	39536-39545	buspirone	_
173-379	39546-39555	treatment	_
173-380	39556-39558	on	_
173-381	39559-39566	cocaine	_
173-382	39567-39586	self-administration	_
173-383	39587-39591	Role	_
173-384	39592-39594	of	_
173-385	39595-39603	dopamine	_
173-386	39604-39606	D2	_
173-387	39606-39607	-	_
173-388	39607-39611	like	_
173-389	39612-39621	receptors	_
173-390	39622-39624	in	_
173-391	39625-39632	cocaine	_
173-392	39633-39652	self-administration	_
173-393	39652-39653	:	_
173-394	39654-39661	studies	_
173-395	39662-39666	with	_
173-396	39667-39669	D2	_
173-397	39670-39678	receptor	_
173-398	39679-39685	mutant	_
173-399	39686-39690	mice	_
173-400	39691-39694	and	_
173-401	39695-39700	novel	_
173-402	39701-39703	D2	_
173-403	39704-39712	receptor	_
173-404	39713-39724	antagonists	_
173-405	39725-39737	Differential	_
173-406	39738-39745	effects	_
173-407	39746-39748	of	_
173-408	39749-39752	the	_
173-409	39753-39761	dopamine	_
173-410	39762-39764	D2	_
173-411	39764-39765	/	_
173-412	39765-39767	D3	_
173-413	39768-39776	receptor	_
173-414	39777-39787	antagonist	_
173-415	39788-39797	sulpiride	_
173-416	39798-39800	on	_
173-417	39801-39820	self-administration	_
173-418	39821-39823	of	_
173-419	39824-39832	morphine	_
173-420	39833-39837	into	_
173-421	39838-39841	the	_
173-422	39842-39849	ventral	_
173-423	39850-39859	tegmental	_
173-424	39860-39864	area	_
173-425	39865-39867	or	_
173-426	39868-39871	the	_
173-427	39872-39879	nucleus	_
173-428	39880-39889	accumbens	_
173-429	39890-39893	The	_
173-430	39894-39900	effect	_
173-431	39901-39903	of	_
173-432	39904-39909	model	_
173-433	39910-39915	order	_
173-434	39916-39925	selection	_
173-435	39926-39928	in	_
173-436	39929-39934	group	_
173-437	39935-39939	PICA	_
173-438	39940-39943	The	_
173-439	39944-39961	interrelationship	_
173-440	39962-39964	of	_
173-441	39965-39973	dopamine	_
173-442	39974-39976	D2	_
173-443	39976-39977	-	_
173-444	39977-39981	like	_
173-445	39982-39990	receptor	_
173-446	39991-40003	availability	_
173-447	40004-40006	in	_
173-448	40007-40015	striatal	_
173-449	40016-40019	and	_
173-450	40020-40033	extrastriatal	_
173-451	40034-40039	brain	_
173-452	40040-40047	regions	_
173-453	40048-40050	in	_
173-454	40051-40058	healthy	_
173-455	40059-40065	humans	_
173-456	40065-40066	:	_
173-457	40067-40068	a	_
173-458	40069-40078	principal	_
173-459	40079-40088	component	_
173-460	40089-40097	analysis	_
173-461	40098-40100	of	_
173-462	40101-40102	[	_
173-463	40102-40104	18	_
173-464	40105-40106	F	_
173-465	40106-40107	]	_
173-466	40108-40118	fallypride	_
173-467	40119-40126	binding	_
173-468	40127-40136	Efficient	_
173-469	40137-40146	principal	_
173-470	40147-40156	component	_
173-471	40157-40165	analysis	_
173-472	40166-40169	for	_
173-473	40170-40182	multivariate	_
173-474	40183-40185	3D	_
173-475	40186-40197	voxel-based	_
173-476	40198-40205	mapping	_
173-477	40206-40208	of	_
173-478	40209-40214	brain	_
173-479	40215-40225	functional	_
173-480	40226-40233	imaging	_
173-481	40234-40238	data	_
173-482	40239-40243	sets	_
173-483	40244-40246	as	_
173-484	40247-40254	applied	_
173-485	40255-40257	to	_
173-486	40258-40265	FDG-PET	_
173-487	40266-40269	and	_
173-488	40270-40276	normal	_
173-489	40277-40282	aging	_
173-490	40283-40291	Regional	_
173-491	40292-40300	analyses	_
173-492	40301-40303	of	_
173-493	40304-40305	[	_
173-494	40305-40308	11C	_
173-495	40308-40309	]	_
173-496	40309-40310	-	_
173-497	40310-40311	(	_
173-498	40311-40312	+	_
173-499	40312-40313	)	_
173-500	40313-40314	-	_
173-501	40314-40318	PHNO	_
173-502	40319-40323	BPND	_
173-503	40323-40324	.	_

#Text=(a) Region of interest (ROI) analysis performed on smoothed parametric images.
174-1	40325-40326	(	_
174-2	40326-40327	a	_
174-3	40327-40328	)	_
174-4	40329-40335	Region	_
174-5	40336-40338	of	_
174-6	40339-40347	interest	_
174-7	40348-40349	(	_
174-8	40349-40352	ROI	_
174-9	40352-40353	)	_
174-10	40354-40362	analysis	_
174-11	40363-40372	performed	_
174-12	40373-40375	on	_
174-13	40376-40384	smoothed	_
174-14	40385-40395	parametric	_
174-15	40396-40402	images	_
174-16	40402-40403	.	_

#Text=CUD relative to HC participants displayed reduced BPND in the dorsal putamen (DPU; *p<0.05) and greater BPND in the substantia nigra (SN, **p<0.01).
175-1	40404-40407	CUD	_
175-2	40408-40416	relative	_
175-3	40417-40419	to	_
175-4	40420-40422	HC	_
175-5	40423-40435	participants	_
175-6	40436-40445	displayed	_
175-7	40446-40453	reduced	_
175-8	40454-40458	BPND	_
175-9	40459-40461	in	_
175-10	40462-40465	the	_
175-11	40466-40472	dorsal	_
175-12	40473-40480	putamen	_
175-13	40481-40482	(	_
175-14	40482-40485	DPU	_
175-15	40485-40486	;	_
175-16	40487-40488	*	_
175-17	40488-40489	p	_
175-18	40489-40490	<	_
175-19	40490-40494	0.05	_
175-20	40494-40495	)	_
175-21	40496-40499	and	_
175-22	40500-40507	greater	_
175-23	40508-40512	BPND	_
175-24	40513-40515	in	_
175-25	40516-40519	the	_
175-26	40520-40530	substantia	_
175-27	40531-40536	nigra	_
175-28	40537-40538	(	_
175-29	40538-40540	SN	_
175-30	40540-40541	,	_
175-31	40542-40543	*	_
175-32	40543-40544	*	_
175-33	40544-40545	p	_
175-34	40545-40546	<	_
175-35	40546-40550	0.01	_
175-36	40550-40551	)	_
175-37	40551-40552	.	_

#Text=Error bars indicate SD.
176-1	40553-40558	Error	_
176-2	40559-40563	bars	_
176-3	40564-40572	indicate	_
176-4	40573-40575	SD	_
176-5	40575-40576	.	_

#Text=(b) Whole-brain mean BPND across all participants with relative threshold mask borders used in GLM and ICA analyses indicated by the white outline (left) and GLM-identified regions of group differences in [11C]-(+)-PHNO BPND (right).
177-1	40577-40578	(	_
177-2	40578-40579	b	_
177-3	40579-40580	)	_
177-4	40581-40592	Whole-brain	_
177-5	40593-40597	mean	_
177-6	40598-40602	BPND	_
177-7	40603-40609	across	_
177-8	40610-40613	all	_
177-9	40614-40626	participants	_
177-10	40627-40631	with	_
177-11	40632-40640	relative	_
177-12	40641-40650	threshold	_
177-13	40651-40655	mask	_
177-14	40656-40663	borders	_
177-15	40664-40668	used	_
177-16	40669-40671	in	_
177-17	40672-40675	GLM	_
177-18	40676-40679	and	_
177-19	40680-40683	ICA	_
177-20	40684-40692	analyses	_
177-21	40693-40702	indicated	_
177-22	40703-40705	by	_
177-23	40706-40709	the	_
177-24	40710-40715	white	_
177-25	40716-40723	outline	_
177-26	40724-40725	(	_
177-27	40725-40729	left	_
177-28	40729-40730	)	_
177-29	40731-40734	and	_
177-30	40735-40749	GLM-identified	_
177-31	40750-40757	regions	_
177-32	40758-40760	of	_
177-33	40761-40766	group	_
177-34	40767-40778	differences	_
177-35	40779-40781	in	_
177-36	40782-40783	[	_
177-37	40783-40786	11C	_
177-38	40786-40787	]	_
177-39	40787-40788	-	_
177-40	40788-40789	(	_
177-41	40789-40790	+	_
177-42	40790-40791	)	_
177-43	40791-40792	-	_
177-44	40792-40796	PHNO	_
177-45	40797-40801	BPND	_
177-46	40802-40803	(	_
177-47	40803-40808	right	_
177-48	40808-40809	)	_
177-49	40809-40810	.	_

#Text=CUD relative to HC exhibited greater BPND in midbrain regions (red/yellow) and reduced BPND in the putamen (blue/green).
178-1	40811-40814	CUD	_
178-2	40815-40823	relative	_
178-3	40824-40826	to	_
178-4	40827-40829	HC	_
178-5	40830-40839	exhibited	_
178-6	40840-40847	greater	_
178-7	40848-40852	BPND	_
178-8	40853-40855	in	_
178-9	40856-40864	midbrain	_
178-10	40865-40872	regions	_
178-11	40873-40874	(	_
178-12	40874-40877	red	_
178-13	40877-40878	/	_
178-14	40878-40884	yellow	_
178-15	40884-40885	)	_
178-16	40886-40889	and	_
178-17	40890-40897	reduced	_
178-18	40898-40902	BPND	_
178-19	40903-40905	in	_
178-20	40906-40909	the	_
178-21	40910-40917	putamen	_
178-22	40918-40919	(	_
178-23	40919-40923	blue	_
178-24	40923-40924	/	_
178-25	40924-40929	green	_
178-26	40929-40930	)	_
178-27	40930-40931	.	_

#Text=Axial slices displayed at p<0.005, k>20 on MNI152.
179-1	40932-40937	Axial	_
179-2	40938-40944	slices	_
179-3	40945-40954	displayed	_
179-4	40955-40957	at	_
179-5	40958-40959	p	_
179-6	40959-40960	<	_
179-7	40960-40965	0.005	_
179-8	40965-40966	,	_
179-9	40967-40968	k	_
179-10	40968-40969	>	_
179-11	40969-40971	20	_
179-12	40972-40974	on	_
179-13	40975-40981	MNI152	_
179-14	40981-40982	.	_

#Text=Abbreviations: DCA, dorsal caudate; DPU, dorsal putamen; GP, globus pallidus; HY, hypothalamus; SN, substantia nigra; VP, ventral pallidum; VS, ventral striatum.
180-1	40983-40996	Abbreviations	_
180-2	40996-40997	:	_
180-3	40998-41001	DCA	_
180-4	41001-41002	,	_
180-5	41003-41009	dorsal	_
180-6	41010-41017	caudate	_
180-7	41017-41018	;	_
180-8	41019-41022	DPU	_
180-9	41022-41023	,	_
180-10	41024-41030	dorsal	_
180-11	41031-41038	putamen	_
180-12	41038-41039	;	_
180-13	41040-41042	GP	_
180-14	41042-41043	,	_
180-15	41044-41050	globus	_
180-16	41051-41059	pallidus	_
180-17	41059-41060	;	_
180-18	41061-41063	HY	_
180-19	41063-41064	,	_
180-20	41065-41077	hypothalamus	_
180-21	41077-41078	;	_
180-22	41079-41081	SN	_
180-23	41081-41082	,	_
180-24	41083-41093	substantia	_
180-25	41094-41099	nigra	_
180-26	41099-41100	;	_
180-27	41101-41103	VP	_
180-28	41103-41104	,	_
180-29	41105-41112	ventral	_
180-30	41113-41121	pallidum	_
180-31	41121-41122	;	_
180-32	41123-41125	VS	_
180-33	41125-41126	,	_
180-34	41127-41134	ventral	_
180-35	41135-41143	striatum	_
180-36	41143-41144	.	_

#Text=ICA-identified sources of [11C]-(+)-PHNO BPND displayed at B̃PM ≥0.5 on different intensity scales as denoted in the color bars.
181-1	41145-41159	ICA-identified	_
181-2	41160-41167	sources	_
181-3	41168-41170	of	_
181-4	41171-41172	[	_
181-5	41172-41175	11C	_
181-6	41175-41176	]	_
181-7	41176-41177	-	_
181-8	41177-41178	(	_
181-9	41178-41179	+	_
181-10	41179-41180	)	_
181-11	41180-41181	-	_
181-12	41181-41185	PHNO	_
181-13	41186-41190	BPND	_
181-14	41191-41200	displayed	_
181-15	41201-41203	at	_
181-16	41204-41208	B̃PM	_
181-17	41209-41210	≥	_
181-18	41210-41213	0.5	_
181-19	41214-41216	on	_
181-20	41217-41226	different	_
181-21	41227-41236	intensity	_
181-22	41237-41243	scales	_
181-23	41244-41246	as	_
181-24	41247-41254	denoted	_
181-25	41255-41257	in	_
181-26	41258-41261	the	_
181-27	41262-41267	color	_
181-28	41268-41272	bars	_
181-29	41272-41273	.	_

#Text=Source associations with estimated regional D2R-related and D3R-related BPND proportions, group intensity differences and correlation with years of cocaine use for the (a) striatopallidal and (b) pallidonigral sources.
182-1	41274-41280	Source	_
182-2	41281-41293	associations	_
182-3	41294-41298	with	_
182-4	41299-41308	estimated	_
182-5	41309-41317	regional	_
182-6	41318-41329	D2R-related	_
182-7	41330-41333	and	_
182-8	41334-41345	D3R-related	_
182-9	41346-41350	BPND	_
182-10	41351-41362	proportions	_
182-11	41362-41363	,	_
182-12	41364-41369	group	_
182-13	41370-41379	intensity	_
182-14	41380-41391	differences	_
182-15	41392-41395	and	_
182-16	41396-41407	correlation	_
182-17	41408-41412	with	_
182-18	41413-41418	years	_
182-19	41419-41421	of	_
182-20	41422-41429	cocaine	_
182-21	41430-41433	use	_
182-22	41434-41437	for	_
182-23	41438-41441	the	_
182-24	41442-41443	(	_
182-25	41443-41444	a	_
182-26	41444-41445	)	_
182-27	41446-41461	striatopallidal	_
182-28	41462-41465	and	_
182-29	41466-41467	(	_
182-30	41467-41468	b	_
182-31	41468-41469	)	_
182-32	41470-41483	pallidonigral	_
182-33	41484-41491	sources	_
182-34	41491-41492	.	_

#Text=Regional estimates of D2R-related and D3R-related BPND were calculated using reported fractions of [11C]-(+)-PHNO BPND (see Section 2.5).
183-1	41493-41501	Regional	_
183-2	41502-41511	estimates	_
183-3	41512-41514	of	_
183-4	41515-41526	D2R-related	_
183-5	41527-41530	and	_
183-6	41531-41542	D3R-related	_
183-7	41543-41547	BPND	_
183-8	41548-41552	were	_
183-9	41553-41563	calculated	_
183-10	41564-41569	using	_
183-11	41570-41578	reported	_
183-12	41579-41588	fractions	_
183-13	41589-41591	of	_
183-14	41592-41593	[	_
183-15	41593-41596	11C	_
183-16	41596-41597	]	_
183-17	41597-41598	-	_
183-18	41598-41599	(	_
183-19	41599-41600	+	_
183-20	41600-41601	)	_
183-21	41601-41602	-	_
183-22	41602-41606	PHNO	_
183-23	41607-41611	BPND	_
183-24	41612-41613	(	_
183-25	41613-41616	see	_
183-26	41617-41624	Section	_
183-27	41625-41628	2.5	_
183-28	41628-41629	)	_
183-29	41629-41630	.	_

#Text=Subject ICA-loadings refer to the mixing parameter representing source intensity, or how strongly each source contributed to the aggregate BPND signal.
184-1	41631-41638	Subject	_
184-2	41639-41651	ICA-loadings	_
184-3	41652-41657	refer	_
184-4	41658-41660	to	_
184-5	41661-41664	the	_
184-6	41665-41671	mixing	_
184-7	41672-41681	parameter	_
184-8	41682-41694	representing	_
184-9	41695-41701	source	_
184-10	41702-41711	intensity	_
184-11	41711-41712	,	_
184-12	41713-41715	or	_
184-13	41716-41719	how	_
184-14	41720-41728	strongly	_
184-15	41729-41733	each	_
184-16	41734-41740	source	_
184-17	41741-41752	contributed	_
184-18	41753-41755	to	_
184-19	41756-41759	the	_
184-20	41760-41769	aggregate	_
184-21	41770-41774	BPND	_
184-22	41775-41781	signal	_
184-23	41781-41782	.	_

#Text=Error bars indicate SD.
185-1	41783-41788	Error	_
185-2	41789-41793	bars	_
185-3	41794-41802	indicate	_
185-4	41803-41805	SD	_
185-5	41805-41806	.	_

#Text=*p<0.05.
186-1	41807-41808	*	_
186-2	41808-41809	p	_
186-3	41809-41810	<	_
186-4	41810-41814	0.05	_
186-5	41814-41815	.	_

#Text=Sample characteristics and injection data.
187-1	41816-41822	Sample	_
187-2	41823-41838	characteristics	_
187-3	41839-41842	and	_
187-4	41843-41852	injection	_
187-5	41853-41857	data	_
187-6	41857-41858	.	_

#Text=Variable\tHC (N=26)\tCUD (N=26)\tp-value\t \tAge, years (SD)\t41.3 (6.9)\t42.7 (6.4)\t0.46\t \tGender, F (%)\t5 (19.2)\t5 (19.2)\t1.00\t \tBody-mass, BMI (SD)\t28.7 (6.0)\t29.9 (6.5)\t0.47\t \tDaily tobacco user, N (%)\t1 (3.8)\t22 (84.6)\t<0.001\t \tDaily tobacco use, cigarettes (SD)\t0.4 (2.0)\t9.2 (6.4)\t<0.001\t \tWeekly alcohol use, drinks (SD)\t1.4 (2.2)\t6.8 (14.6)\t0.75\t \tAmount of cocaine per use, $ (SD)\t-\t112.7 (148.5)\t-\t \tFrequency of use, days/month (SD)\t-\t19.0 (7.7)\t-\t \tLast cocaine use before PET, days (SD)\t-\t7.8 (4.9)\t-\t \tCUD chronicity, years (SD)\t-\t19.3 (6.3)\t-\t \tRadioactive dose, MBq (SD)\t398 (155)\t370 (146)\t0.51\t \tInjected mass, µg/kg (SD)\t0.024 (0.007)\t0.025 (0.006)\t0.63\t \tSpecific activity, MBq/nmol (SD)\t56.7 (30.3)\t46.9 (19.5)\t0.17\t \t
#Text=Regional composition of sources of [11C]-(+)-PHNO BPND.
188-1	41859-41867	Variable	_
188-2	41868-41870	HC	_
188-3	41871-41872	(	_
188-4	41872-41873	N	_
188-5	41873-41874	=	_
188-6	41874-41876	26	_
188-7	41876-41877	)	_
188-8	41878-41881	CUD	_
188-9	41882-41883	(	_
188-10	41883-41884	N	_
188-11	41884-41885	=	_
188-12	41885-41887	26	_
188-13	41887-41888	)	_
188-14	41889-41896	p-value	_
188-15	41899-41902	Age	_
188-16	41902-41903	,	_
188-17	41904-41909	years	_
188-18	41910-41911	(	_
188-19	41911-41913	SD	_
188-20	41913-41914	)	_
188-21	41915-41919	41.3	_
188-22	41920-41921	(	_
188-23	41921-41924	6.9	_
188-24	41924-41925	)	_
188-25	41926-41930	42.7	_
188-26	41931-41932	(	_
188-27	41932-41935	6.4	_
188-28	41935-41936	)	_
188-29	41937-41941	0.46	_
188-30	41944-41950	Gender	_
188-31	41950-41951	,	_
188-32	41952-41953	F	_
188-33	41954-41955	(	_
188-34	41955-41956	%	_
188-35	41956-41957	)	_
188-36	41958-41959	5	_
188-37	41960-41961	(	_
188-38	41961-41965	19.2	_
188-39	41965-41966	)	_
188-40	41967-41968	5	_
188-41	41969-41970	(	_
188-42	41970-41974	19.2	_
188-43	41974-41975	)	_
188-44	41976-41980	1.00	_
188-45	41983-41992	Body-mass	_
188-46	41992-41993	,	_
188-47	41994-41997	BMI	_
188-48	41998-41999	(	_
188-49	41999-42001	SD	_
188-50	42001-42002	)	_
188-51	42003-42007	28.7	_
188-52	42008-42009	(	_
188-53	42009-42012	6.0	_
188-54	42012-42013	)	_
188-55	42014-42018	29.9	_
188-56	42019-42020	(	_
188-57	42020-42023	6.5	_
188-58	42023-42024	)	_
188-59	42025-42029	0.47	_
188-60	42032-42037	Daily	_
188-61	42038-42045	tobacco	_
188-62	42046-42050	user	_
188-63	42050-42051	,	_
188-64	42052-42053	N	_
188-65	42054-42055	(	_
188-66	42055-42056	%	_
188-67	42056-42057	)	_
188-68	42058-42059	1	_
188-69	42060-42061	(	_
188-70	42061-42064	3.8	_
188-71	42064-42065	)	_
188-72	42066-42068	22	_
188-73	42069-42070	(	_
188-74	42070-42074	84.6	_
188-75	42074-42075	)	_
188-76	42076-42077	<	_
188-77	42077-42082	0.001	_
188-78	42085-42090	Daily	_
188-79	42091-42098	tobacco	_
188-80	42099-42102	use	_
188-81	42102-42103	,	_
188-82	42104-42114	cigarettes	_
188-83	42115-42116	(	_
188-84	42116-42118	SD	_
188-85	42118-42119	)	_
188-86	42120-42123	0.4	_
188-87	42124-42125	(	_
188-88	42125-42128	2.0	_
188-89	42128-42129	)	_
188-90	42130-42133	9.2	_
188-91	42134-42135	(	_
188-92	42135-42138	6.4	_
188-93	42138-42139	)	_
188-94	42140-42141	<	_
188-95	42141-42146	0.001	_
188-96	42149-42155	Weekly	_
188-97	42156-42163	alcohol	_
188-98	42164-42167	use	_
188-99	42167-42168	,	_
188-100	42169-42175	drinks	_
188-101	42176-42177	(	_
188-102	42177-42179	SD	_
188-103	42179-42180	)	_
188-104	42181-42184	1.4	_
188-105	42185-42186	(	_
188-106	42186-42189	2.2	_
188-107	42189-42190	)	_
188-108	42191-42194	6.8	_
188-109	42195-42196	(	_
188-110	42196-42200	14.6	_
188-111	42200-42201	)	_
188-112	42202-42206	0.75	_
188-113	42209-42215	Amount	_
188-114	42216-42218	of	_
188-115	42219-42226	cocaine	_
188-116	42227-42230	per	_
188-117	42231-42234	use	_
188-118	42234-42235	,	_
188-119	42236-42237	$	_
188-120	42238-42239	(	_
188-121	42239-42241	SD	_
188-122	42241-42242	)	_
188-123	42243-42244	-	_
188-124	42245-42250	112.7	_
188-125	42251-42252	(	_
188-126	42252-42257	148.5	_
188-127	42257-42258	)	_
188-128	42259-42260	-	_
188-129	42263-42272	Frequency	_
188-130	42273-42275	of	_
188-131	42276-42279	use	_
188-132	42279-42280	,	_
188-133	42281-42285	days	_
188-134	42285-42286	/	_
188-135	42286-42291	month	_
188-136	42292-42293	(	_
188-137	42293-42295	SD	_
188-138	42295-42296	)	_
188-139	42297-42298	-	_
188-140	42299-42303	19.0	_
188-141	42304-42305	(	_
188-142	42305-42308	7.7	_
188-143	42308-42309	)	_
188-144	42310-42311	-	_
188-145	42314-42318	Last	_
188-146	42319-42326	cocaine	_
188-147	42327-42330	use	_
188-148	42331-42337	before	_
188-149	42338-42341	PET	_
188-150	42341-42342	,	_
188-151	42343-42347	days	_
188-152	42348-42349	(	_
188-153	42349-42351	SD	_
188-154	42351-42352	)	_
188-155	42353-42354	-	_
188-156	42355-42358	7.8	_
188-157	42359-42360	(	_
188-158	42360-42363	4.9	_
188-159	42363-42364	)	_
188-160	42365-42366	-	_
188-161	42369-42372	CUD	_
188-162	42373-42383	chronicity	_
188-163	42383-42384	,	_
188-164	42385-42390	years	_
188-165	42391-42392	(	_
188-166	42392-42394	SD	_
188-167	42394-42395	)	_
188-168	42396-42397	-	_
188-169	42398-42402	19.3	_
188-170	42403-42404	(	_
188-171	42404-42407	6.3	_
188-172	42407-42408	)	_
188-173	42409-42410	-	_
188-174	42413-42424	Radioactive	_
188-175	42425-42429	dose	_
188-176	42429-42430	,	_
188-177	42431-42434	MBq	_
188-178	42435-42436	(	_
188-179	42436-42438	SD	_
188-180	42438-42439	)	_
188-181	42440-42443	398	_
188-182	42444-42445	(	_
188-183	42445-42448	155	_
188-184	42448-42449	)	_
188-185	42450-42453	370	_
188-186	42454-42455	(	_
188-187	42455-42458	146	_
188-188	42458-42459	)	_
188-189	42460-42464	0.51	_
188-190	42467-42475	Injected	_
188-191	42476-42480	mass	_
188-192	42480-42481	,	_
188-193	42482-42484	µg	_
188-194	42484-42485	/	_
188-195	42485-42487	kg	_
188-196	42488-42489	(	_
188-197	42489-42491	SD	_
188-198	42491-42492	)	_
188-199	42493-42498	0.024	_
188-200	42499-42500	(	_
188-201	42500-42505	0.007	_
188-202	42505-42506	)	_
188-203	42507-42512	0.025	_
188-204	42513-42514	(	_
188-205	42514-42519	0.006	_
188-206	42519-42520	)	_
188-207	42521-42525	0.63	_
188-208	42528-42536	Specific	_
188-209	42537-42545	activity	_
188-210	42545-42546	,	_
188-211	42547-42550	MBq	_
188-212	42550-42551	/	_
188-213	42551-42555	nmol	_
188-214	42556-42557	(	_
188-215	42557-42559	SD	_
188-216	42559-42560	)	_
188-217	42561-42565	56.7	_
188-218	42566-42567	(	_
188-219	42567-42571	30.3	_
188-220	42571-42572	)	_
188-221	42573-42577	46.9	_
188-222	42578-42579	(	_
188-223	42579-42583	19.5	_
188-224	42583-42584	)	_
188-225	42585-42589	0.17	_
188-226	42593-42601	Regional	_
188-227	42602-42613	composition	_
188-228	42614-42616	of	_
188-229	42617-42624	sources	_
188-230	42625-42627	of	_
188-231	42628-42629	[	_
188-232	42629-42632	11C	_
188-233	42632-42633	]	_
188-234	42633-42634	-	_
188-235	42634-42635	(	_
188-236	42635-42636	+	_
188-237	42636-42637	)	_
188-238	42637-42638	-	_
188-239	42638-42642	PHNO	_
188-240	42643-42647	BPND	_
188-241	42647-42648	.	_

#Text=Component/region\tk\tx\ty\tz\tpeak B̃PMM\t \ta.
189-1	42649-42658	Component	_
189-2	42658-42659	/	_
189-3	42659-42665	region	_
189-4	42666-42667	k	_
189-5	42668-42669	x	_
189-6	42670-42671	y	_
189-7	42672-42673	z	_
189-8	42674-42678	peak	_
189-9	42679-42684	B̃PMM	_
189-10	42687-42688	a	_
189-11	42688-42689	.	_

#Text=Striatopallidal\t\t\t\t\t\t \t  L DPU, DCA, GP, VP, VS\t1467\t−10\t8\t−8\t3.20\t \t  R DPU, DCA, GP, VP, VS\t1416\t14\t6\t−4\t3.06\t \tb.
190-1	42690-42705	Striatopallidal	_
190-2	42713-42715	  	_
190-3	42715-42716	L	_
190-4	42717-42720	DPU	_
190-5	42720-42721	,	_
190-6	42722-42725	DCA	_
190-7	42725-42726	,	_
190-8	42727-42729	GP	_
190-9	42729-42730	,	_
190-10	42731-42733	VP	_
190-11	42733-42734	,	_
190-12	42735-42737	VS	_
190-13	42738-42742	1467	_
190-14	42743-42744	−	_
190-15	42744-42746	10	_
190-16	42747-42748	8	_
190-17	42749-42750	−	_
190-18	42750-42751	8	_
190-19	42752-42756	3.20	_
190-20	42759-42761	  	_
190-21	42761-42762	R	_
190-22	42763-42766	DPU	_
190-23	42766-42767	,	_
190-24	42768-42771	DCA	_
190-25	42771-42772	,	_
190-26	42773-42775	GP	_
190-27	42775-42776	,	_
190-28	42777-42779	VP	_
190-29	42779-42780	,	_
190-30	42781-42783	VS	_
190-31	42784-42788	1416	_
190-32	42789-42791	14	_
190-33	42792-42793	6	_
190-34	42794-42795	−	_
190-35	42795-42796	4	_
190-36	42797-42801	3.06	_
190-37	42804-42805	b	_
190-38	42805-42806	.	_

#Text=Pallidonigral\t\t\t\t\t\t \t  R GP, HY, SN, VP\t457\t12\t2\t−10\t1.60\t \t  L GP, HY, SN, VP\t579\t−14\t−2\t−8\t1.97\t \tc.
191-1	42807-42820	Pallidonigral	_
191-2	42828-42830	  	_
191-3	42830-42831	R	_
191-4	42832-42834	GP	_
191-5	42834-42835	,	_
191-6	42836-42838	HY	_
191-7	42838-42839	,	_
191-8	42840-42842	SN	_
191-9	42842-42843	,	_
191-10	42844-42846	VP	_
191-11	42847-42850	457	_
191-12	42851-42853	12	_
191-13	42854-42855	2	_
191-14	42856-42857	−	_
191-15	42857-42859	10	_
191-16	42860-42864	1.60	_
191-17	42867-42869	  	_
191-18	42869-42870	L	_
191-19	42871-42873	GP	_
191-20	42873-42874	,	_
191-21	42875-42877	HY	_
191-22	42877-42878	,	_
191-23	42879-42881	SN	_
191-24	42881-42882	,	_
191-25	42883-42885	VP	_
191-26	42886-42889	579	_
191-27	42890-42891	−	_
191-28	42891-42893	14	_
191-29	42894-42895	−	_
191-30	42895-42896	2	_
191-31	42897-42898	−	_
191-32	42898-42899	8	_
191-33	42900-42904	1.97	_
191-34	42907-42908	c	_
191-35	42908-42909	.	_

#Text=Mesoaccumbens\t\t\t\t\t\t \t  R SN\t5\t10\t−14\t−16\t0.59\t \t  L SN\t6\t−6\t−12\t−16\t0.62\t \t  R HY, VP, VS\t243\t10\t10\t−12\t1.23\t \t  L HY, VP, VS\t259\t−8\t8\t−14\t1.39\t \t
#Text=Regional composition of ICA-identified sources at the threshold of ICA-estimated BPND contribution (B̃PM) ≥0.5.
192-1	42910-42923	Mesoaccumbens	_
192-2	42931-42933	  	_
192-3	42933-42934	R	_
192-4	42935-42937	SN	_
192-5	42938-42939	5	_
192-6	42940-42942	10	_
192-7	42943-42944	−	_
192-8	42944-42946	14	_
192-9	42947-42948	−	_
192-10	42948-42950	16	_
192-11	42951-42955	0.59	_
192-12	42958-42960	  	_
192-13	42960-42961	L	_
192-14	42962-42964	SN	_
192-15	42965-42966	6	_
192-16	42967-42968	−	_
192-17	42968-42969	6	_
192-18	42970-42971	−	_
192-19	42971-42973	12	_
192-20	42974-42975	−	_
192-21	42975-42977	16	_
192-22	42978-42982	0.62	_
192-23	42985-42987	  	_
192-24	42987-42988	R	_
192-25	42989-42991	HY	_
192-26	42991-42992	,	_
192-27	42993-42995	VP	_
192-28	42995-42996	,	_
192-29	42997-42999	VS	_
192-30	43000-43003	243	_
192-31	43004-43006	10	_
192-32	43007-43009	10	_
192-33	43010-43011	−	_
192-34	43011-43013	12	_
192-35	43014-43018	1.23	_
192-36	43021-43023	  	_
192-37	43023-43024	L	_
192-38	43025-43027	HY	_
192-39	43027-43028	,	_
192-40	43029-43031	VP	_
192-41	43031-43032	,	_
192-42	43033-43035	VS	_
192-43	43036-43039	259	_
192-44	43040-43041	−	_
192-45	43041-43042	8	_
192-46	43043-43044	8	_
192-47	43045-43046	−	_
192-48	43046-43048	14	_
192-49	43049-43053	1.39	_
192-50	43057-43065	Regional	_
192-51	43066-43077	composition	_
192-52	43078-43080	of	_
192-53	43081-43095	ICA-identified	_
192-54	43096-43103	sources	_
192-55	43104-43106	at	_
192-56	43107-43110	the	_
192-57	43111-43120	threshold	_
192-58	43121-43123	of	_
192-59	43124-43137	ICA-estimated	_
192-60	43138-43142	BPND	_
192-61	43143-43155	contribution	_
192-62	43156-43157	(	_
192-63	43157-43161	B̃PM	_
192-64	43161-43162	)	_
192-65	43163-43164	≥	_
192-66	43164-43167	0.5	_
192-67	43167-43168	.	_

#Text=Cluster information includes spatial extent (k, in voxels), peak location (x, y, z) in MNI152 space and peak B̃PM.
193-1	43169-43176	Cluster	_
193-2	43177-43188	information	_
193-3	43189-43197	includes	_
193-4	43198-43205	spatial	_
193-5	43206-43212	extent	_
193-6	43213-43214	(	_
193-7	43214-43215	k	_
193-8	43215-43216	,	_
193-9	43217-43219	in	_
193-10	43220-43226	voxels	_
193-11	43226-43227	)	_
193-12	43227-43228	,	_
193-13	43229-43233	peak	_
193-14	43234-43242	location	_
193-15	43243-43244	(	_
193-16	43244-43245	x	_
193-17	43245-43246	,	_
193-18	43247-43248	y	_
193-19	43248-43249	,	_
193-20	43250-43251	z	_
193-21	43251-43252	)	_
193-22	43253-43255	in	_
193-23	43256-43262	MNI152	_
193-24	43263-43268	space	_
193-25	43269-43272	and	_
193-26	43273-43277	peak	_
193-27	43278-43282	B̃PM	_
193-28	43282-43283	.	_

#Text=Abbreviations: DCA, dorsal caudate; DPU, dorsal putamen; GP, globus pallidus; HY, hypothalamus; SN, substantia nigra; VP, ventral pallidum; VS, ventral striatum; R/L, right/left hemisphere.
194-1	43284-43297	Abbreviations	_
194-2	43297-43298	:	_
194-3	43299-43302	DCA	_
194-4	43302-43303	,	_
194-5	43304-43310	dorsal	_
194-6	43311-43318	caudate	_
194-7	43318-43319	;	_
194-8	43320-43323	DPU	_
194-9	43323-43324	,	_
194-10	43325-43331	dorsal	_
194-11	43332-43339	putamen	_
194-12	43339-43340	;	_
194-13	43341-43343	GP	_
194-14	43343-43344	,	_
194-15	43345-43351	globus	_
194-16	43352-43360	pallidus	_
194-17	43360-43361	;	_
194-18	43362-43364	HY	_
194-19	43364-43365	,	_
194-20	43366-43378	hypothalamus	_
194-21	43378-43379	;	_
194-22	43380-43382	SN	_
194-23	43382-43383	,	_
194-24	43384-43394	substantia	_
194-25	43395-43400	nigra	_
194-26	43400-43401	;	_
194-27	43402-43404	VP	_
194-28	43404-43405	,	_
194-29	43406-43413	ventral	_
194-30	43414-43422	pallidum	_
194-31	43422-43423	;	_
194-32	43424-43426	VS	_
194-33	43426-43427	,	_
194-34	43428-43435	ventral	_
194-35	43436-43444	striatum	_
194-36	43444-43445	;	_
194-37	43446-43447	R	_
194-38	43447-43448	/	_
194-39	43448-43449	L	_
194-40	43449-43450	,	_
194-41	43451-43456	right	_
194-42	43456-43457	/	_
194-43	43457-43461	left	_
194-44	43462-43472	hemisphere	_
194-45	43472-43473	.	_

#Text=Highlights
#Text=[11C]-(+)-PHNO binding potential reflects the relative local availability of both D2 and D3 receptors
#Text=Regional analysis indicated alterations in D2R-rich and D3R-rich regions in cocaine-use disorder
#Text=ICA identified source-based patterns of receptor availability consistent with DA circuitry
#Text=Source intensities suggest CUD-related differences may also be present in D2R/D3R-mixed regions
195-1	43474-43484	Highlights	_
195-2	43485-43486	[	_
195-3	43486-43489	11C	_
195-4	43489-43490	]	_
195-5	43490-43491	-	_
195-6	43491-43492	(	_
195-7	43492-43493	+	_
195-8	43493-43494	)	_
195-9	43494-43495	-	_
195-10	43495-43499	PHNO	_
195-11	43500-43507	binding	_
195-12	43508-43517	potential	_
195-13	43518-43526	reflects	_
195-14	43527-43530	the	_
195-15	43531-43539	relative	_
195-16	43540-43545	local	_
195-17	43546-43558	availability	_
195-18	43559-43561	of	_
195-19	43562-43566	both	_
195-20	43567-43569	D2	_
195-21	43570-43573	and	_
195-22	43574-43576	D3	_
195-23	43577-43586	receptors	_
195-24	43587-43595	Regional	_
195-25	43596-43604	analysis	_
195-26	43605-43614	indicated	_
195-27	43615-43626	alterations	_
195-28	43627-43629	in	_
195-29	43630-43638	D2R-rich	_
195-30	43639-43642	and	_
195-31	43643-43651	D3R-rich	_
195-32	43652-43659	regions	_
195-33	43660-43662	in	_
195-34	43663-43674	cocaine-use	_
195-35	43675-43683	disorder	_
195-36	43684-43687	ICA	_
195-37	43688-43698	identified	_
195-38	43699-43711	source-based	_
195-39	43712-43720	patterns	_
195-40	43721-43723	of	_
195-41	43724-43732	receptor	_
195-42	43733-43745	availability	_
195-43	43746-43756	consistent	_
195-44	43757-43761	with	_
195-45	43762-43764	DA	_
195-46	43765-43774	circuitry	_
195-47	43775-43781	Source	_
195-48	43782-43793	intensities	_
195-49	43794-43801	suggest	_
195-50	43802-43813	CUD-related	_
195-51	43814-43825	differences	_
195-52	43826-43829	may	_
195-53	43830-43834	also	_
195-54	43835-43837	be	_
195-55	43838-43845	present	_
195-56	43846-43848	in	_
195-57	43849-43852	D2R	_
195-58	43852-43853	/	_
195-59	43853-43862	D3R-mixed	_
195-60	43863-43870	regions	_
